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In everything I seek to grasp 
The fundamental: 
The daily choice, the daily task, 
The sentimental. 
To plumb the essence of the past, 
The first foundations, 
The crux, the roots, the inmost hearts, 
The explanations. 
And, puzzling out the weave of fate, 
Events observer, 
To live, feel, love and meditate 
And to discover. 
 
 
In ogni cosa ho voglia di arrivare 
sino alla sostanza. 
Nel lavoro, cercando la mia strada, 
nel tumulto del cuore. 
Sino all’essenza dei giorni passati, 
sino alla loro ragione, 
sino ai motivi, sino alle radici, 
sino al midollo. 
Eternamente aggrappandomi al filo 
dei destini, degli avvenimenti, 
sentire, amare, vivere, pensare 
effettuare scoperte. 
 
Boris L. Pasternak 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Index 
 
INDEX 
 
 
ABSTRACT ................................................................................................ I 
PRESENTAZIONE DEL LAVORO SVOLTO  .................................. III 
 
INTRODUCTION  ..................................................................................... 1 
 
CHAPTER 1 
RESEARCH STEPS................................................................................... 7 
1.1 Isolation procedure of new compounds  ............................................. 7 
1.2 Structural determination methods  .................................................... 11 
1.2.1 Mass spectrometry  ...................................................................... 11 
1.2.2 Nuclear Magnetic Resonance Spectroscopy ............................ 13 
1.3 Determination of stereochestry  ......................................................... 15 
1.3.1 Scalar and spatial NMR couplings  ........................................... 15 
1.3.2 Murata’s method  ......................................................................... 17 
1.3.3 Marfey’s method  ......................................................................... 23 
 
CHAPTER 2 
PORIFERA  ............................................................................................... 29 
2.1 Metabolites isolated from sponges  ................................................... 34 
2.1.1 Macrolides  ................................................................................... 35 
2.1.2 Terpenes  ....................................................................................... 37 
2.1.3 Sterols  ........................................................................................... 38 
2.1.4 Cyclic peptides  ............................................................................ 41 
 
CHAPTER 3 
COSCINODERMA MATHEWSI  ......................................................... 45 
3.1 Isolation of Coscinolactams A and B  ............................................... 47 
3.2 Structure determination of Coscinolactam A  .................................. 48 
3.3 Structure determination of Coscinolactam B  .................................. 50 
3.4 Pharmacological activity  .................................................................... 52 
 
Index 
 
CHAPTER 4 
THEONELLA SWINHOEI  ................................................................... 57 
4.1 Isolation and purification  ................................................................... 59 
4.2 Solomonsterols  .................................................................................... 60 
4.2.1 Solomonsterol A  ......................................................................... 61 
4.2.2 Solomonsterol B  .......................................................................... 63 
4.2.3 Pharmacological activity  ............................................................ 64 
4.2.4 PXR agonism  ............................................................................... 66 
4.2.5 Docking studies  ........................................................................... 68 
4.3 The family of perthamides  ................................................................ 71 
4.3.1 Perthamide C  ............................................................................... 71 
4.3.2 Perthamide D  ............................................................................... 81 
4.3.3 Perthamide E and its analogue, Perthamide F  ......................... 82 
4.3.4 Perthamide G  ............................................................................... 84 
4.3.5 Perthamides H and I  ................................................................... 86 
4.3.6 Perthamides J and K  ................................................................... 87 
4.3.7 Pharmacological activity of Perthamide C  .............................. 89 
4.4 Solomonamides  ................................................................................... 94 
4.4.1 Solomonamide A  ........................................................................ 94 
4.4.2 Solomonamide B .......................................................................... 99 
4.4.3 Pharmacological activity of Solomonamide A  ..................... 100 
4.5 Macrolides from Theonella swinhoei  ............................................. 103 
 
CHAPTER 5 
PLANTS AS PHARMACY  ................................................................... 107 
 
CHAPTER 6 
CUCUMIS MELO  ................................................................................. 109 
6.1 Extraction and isolation  ................................................................... 111 
6.2 Structural characterization of Compound 20 ................................. 111 
6.3 Structural characterization of Compound 21 ................................. 114 
6.4 Other metabolites isolated  ............................................................... 115 
 
 
Index 
 
CHAPTER 7 
BORRAGO OFFICINALIS  ................................................................. 107 
7.1 Extraction and isolation  ................................................................... 120 
7.2 Structural elucidation of Compound 24  ......................................... 120 
 
CHAPTER 8 
RUSCUS ACULEATUS  ....................................................................... 125 
8.1 Extraction and isolation  ................................................................... 127 
8.2 Saponins  ............................................................................................. 127 
8.3 Structural characterization of Compound 25 ................................. 128 
8.4 Structural characterization of Compound 26  ................................ 132 
8.5 Structural characterization of Compound 27  ................................ 134 
 
CONCLUSIONS ............................................................................................ 139 
 
EXPERIMENTAL SECTION 
I.   General experimental procedures  .................................................... 141 
II.  Experimental section of Coscinoderma mathewsi  ........................ 142 
III. Experimental section of Theonella swinhoei  ................................ 151 
IV. Experimental section of Cucumis melo  ......................................... 190 
V.  Experimental section of Borrago officinalis  ................................. 195 
VI. Experimental section of Ruscus aculeatus  .................................... 198 
 
REFERENCES .............................................................................................. 209 
 
ACKNOWLEDGEMENTS ........................................................................ 227 
  
 
Abstract 
 I 
ABSTRACT 
 
Natural products have long been a source of bioactive metabolites utilized for the 
treatment of human disease. In spite the impressive progress of new competing 
methodologies, as for example, combinatorial chemistry and high-throughput 
screening or genetic engineering, natural products remain a valuable source of 
bioactive compounds with therapeutic potential.  
In recent years, the marine environment has been seen as a vast resource for the 
discovery of structurally unique bioactive secondary metabolites, some belonging 
to totally novel chemical classes. In particular the Porifera have developed an 
arsenal of new compounds.  
Part of my research work is collocated within this area and concerns the 
investigation of the natural products deriving from marine sponges. In the frame 
of the project C.R.I.S.P. (Coral Reef Initiative of South Pacific), directed to the 
chemical investigation and valorisation of the marine invertebrates of South 
Pacific, particular attention was paid to two sponges: Theonella swinhoei and 
Coscinoderma mathewsi.  
From these sponges, several structurally interesting bioactive molecules have been 
isolated with promising biological activities. Worthy of note are perthamides, a 
family of cyclic octapeptides, encompassing majority of non-proteogenic amino 
acids, and solomonamides which represent a new class of cyclic peptides, 
featuring a potent in vivo anti-inflammatory activity. Solomonsterols have been 
demonstrated the first examples of sulfated sterols with a truncated side chain 
from a marine source endowed with a PXR agonistic activity.  
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The structure elucidation of these new molecules was performed using the most 
modern sophisticated spectroscopic techniques (2D-NMR and MS).  
The main interest in these compounds is related to their strong biological activity, 
that had led to pharmacological investigations on biomolecular target, the 
mechanism of action and the pharmacophore useful in the identification of new 
leads for developing a new generation of drugs. The detailed pharmacological 
investigation has in some cases required the access to adeguate amount of natural 
products or of semisynthetic derivatives through chemical synthesis, an issue 
addressed in a research parallel to the present work.  
The stereochemical novelty and complexity of some amino acid units of 
cyclopeptides have required a tailored integrated approach which combined NMR 
methods, stereoselective synthesis and LC/MS  
The second part of my research has been employed and addressed on the analysis 
of plants of Mediterranean area and used as foodstuff and as drugs in the folk 
medicine, to isolate the active principles with biological activity and nutraceutical 
property. In this respect, my research objectives have been to identify the 
chemical constituents from three plants Cucumis melo, Borrago officialis and 
Ruscus aculeatus.  
It is clear that Nature continues to be a major source not only of potential 
chemotherapeutic agents but also of lead compounds that have provided the basis 
and inspiration for the semisynthesis or total synthesis of effective new drugs; 
natural product chemistry has enriched both organic chemistry and medicine in a 
myriad of different ways.  
 
Presentazione del lavoro svolto 
 III 
PRESENTAZIONE DEL LAVORO SVOLTO 
 
La maggioranza degli agenti terapeutici attualmente in commercio deriva 
direttamente oppure indirettamente da molecole organiche naturali provenienti da 
organismi sia terrestri che marini. L’interesse della ricerca verso la chimica delle 
sostanze naturali è, quindi, collegato in particolare alla grande opportunità di 
scoprire molecole da usare come lead compound per lo sviluppo di nuove classi di 
farmaci. La diversità chimica che caratterizza le molecole naturali rende 
l’esplorazione delle loro caratteristiche biologiche, non solo una delle principali 
fonti di nuovi composti potenzialmente utilizzabili per la realizzazione di nuovi 
farmaci, ma anche un utile strumento per la scoperta di nuovi meccanismi 
d’azione. 
E’ per tale motivo che le piante hanno da sempre suscitato l’interesse per i chimici 
delle sostanze naturali. Negli ultimi decenni, invece, il progresso di alcune 
tecnologie ha reso possibile l’estensione della ricerca anche agli organismi marini 
e ciò ha portato all’isolamento di migliaia di nuove molecole con strutture del 
tutto inusuali mai trovate nel mondo terrestre e dotate di una vasta gamma di 
attività farmacologiche. In particolare, i Poriferi, più comunemente noti come 
spugne, rappresentano una fonte inesauribile di nuovi composti.  
All’interno di questo ambito si colloca il mio dottorato che si è focalizzato su due 
linee di ricerca, finalizzate allo studio di metaboliti secondari farmacologicamente 
attivi isolati da poriferi e da piante dell’area mediterranea. Tutte le strutture sono 
state caratterizzate con l’ausilio di tecniche spettroscopiche, in particolare la 
spettroscopia di risonanza magnetica nucleare e la spettrometria di massa. 
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La prima linea di ricerca rientra nell’ambito del progetto C.R.I.S.P. (Coral Reef 
Initiative of South Pacific) ed ha riguardato lo studio di spugne provenienti dal 
Sud Pacifico. Tale lavoro ha condotto all’isolamento di numerosi metaboliti 
caratterizzati da insolite strutture e significative attività biologiche.  
Lo scopo del progetto di ricerca non è tanto volto all’utilizzo terapeutico dei 
composti naturali in quanto tali, ma è per lo più indirizzato verso un loro impiego 
come composti modello (lead compounds) per la progettazione di nuovi farmaci. 
Tale ricerca prevede un approfondito studio sulla natura delle interazioni 
molecolari fra la sostanza bioattiva ed il target biologico, al fine di ottenere 
indicazioni sulla porzione della molecola responsabile dell'attività; ciò ha richiesto 
la messa a punto di strategie sintetiche o semisintetiche, condotte in un lavoro di 
ricerca parallelo a quello descritto in questa tesi. 
Lo studio della spugna Coscinoderma mathewsi ha portato all’isolamento di due 
nuovi sesterterpeni con lo scheletro del cheilantano, il coscinolattame A e B, e di 
un composto già noto, la suvanina. Questi tre composti, assieme a due derivati 
semisintetici della suvanina, hanno mostrato una moderata attività 
antinfiammatoria, inibendo la produzione di PGE2 e NO.  
La seconda spugna studiata è stata la Theonella swinhoei, dalla quale sono stati 
isolati nuovi metaboliti secondari, appartenenti a diverse classi biogenetiche, 
confermando la ricchezza biologica di tale spugna. 
L’estratto butanolico ha portato all’isolamento di una famiglia di ottapeptidi 
ciclici, denominati pertammidi C-K caratterizzati dalla presenza di diversi residui 
amminoacidici non proteogenici; tra tali peptidi la pertammide C è risultata essere 
il principale metabolita. 
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La caratterizzazione della struttura primaria di questi nuovi ciclopeptidi è 
avvenuta grazie all’utilizzo di tecniche spettroscopiche, quali la risonanza 
magnetica nucleare, nei suoi esperimenti mono e bidimensionali, e la 
spettrometria di massa. Un ulteriore sforzo è stato effettuato per la definizione 
della stereochimica dei residui amminoacidici presenti, che ha previsto l’uso 
combinato di tecniche NMR, sintesi stereoselettiva delle unità non ribosomiali, 
degradazione chimica  e l’applicazione del metodo di Marfey combinato ad analisi 
LC/MS. 
La pertammide C ha mostrato un’interessante attività antinfiammatoria in vivo,  
riducendo significativamente l’edema della zampa di topo indotto da carragenina. 
Peptidi ciclici di origine marina dotati di attività antiinfiammatoria sono molto 
poco comuni, per cui l’attività mostrata dalla pertammide C risulta molto 
singolare e sicuramente meritevole di ulteriori indagini sulle origini di tale attività 
e sull’identificazione del target biologico su cui agisce. L’isolamento di una 
piccola library di analoghi strutturali della pertammide C, insieme alla natura 
modulare di tale peptide ed il facile accesso chimico, consentirà di effettuare 
dettagliati studi al fine di stabilire le porzioni farmacoforiche utili 
nell’individuazione di nuovi lead per lo sviluppo di una nuova classe di farmaci 
antinfiammatori. 
Dalla stessa spugna sono stati isolati anche altri due nuovi peptidi ciclici, 
strutturalmente non correlati alla pertammide C, denominati solomonammide A e 
B, caratterizzati dalla presenza di un’unità non amminoacidica senza precedenti e 
dotati anche essi di attività antinfiammatoria in vivo. 
Dagli estratti più polari della stessa spugna sono stati isolati due steroli solfatati, 
denominati solomonsterolo A e B, che non sono relazionati agli steroli 
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precedentemente isolati dal genere Theonella. Questi rappresentano il primo 
esempio di steroli con nucleo 5α-colano e 24-nor-5α-colano da organismi marini, 
in grado di legare e attivare i recettori nucleari PXR. L’attivazione dei recettori X 
del Pregnano è responsabile dell’attività immunomodulante di entrambi i 
composti, attraverso l’inibizione dell’accumulo di Interleuchina-1β.  
Infine, l’analisi dell’estratto cloroformico della Theonella swinhoei ha portato 
all’isolamento di un nuovo macrolide, correlato strutturalmente allo swinolide A; 
quest’ultimo è noto per la sua capacità di legarsi specificamente al sistema 
dell’actina intracellulare. 
La seconda linea di studio si è inserita in un più ampio progetto di ricerca volto 
all’isolamento di metaboliti da piante dell’area mediterranea utilizzate a scopo 
alimentare e nella medicina tradizionale. Tale linea di ricerca è in atto già da 
diversi anni presso il gruppo in cui ho svolto il lavoro di dottorato, ed è volta 
all’isolamento di metaboliti secondari di interesse nutraceutico e farmacologico. 
In questo ambito la mia attenzione si è focalizzata sullo studio di tre piante tipiche 
del bacino mediterraneo: il Cucumis melo, la Borrago officinalis e il Ruscus 
aculeatus. In seguito allo studio di queste piante sono stati isolati vari metaboliti 
secondari.  
Dal Cucumis melo è stato isolato, assieme ad altri composti già noti ma mai isolati 
in tale pianta, un nuovo glicoside, formato da una catena disaccaridica, costituita 
da un’unità di glucosio ed una di apiosio unite mediante un legame 
interglicosidico β-(1’’→2’) e da un aglicone  costituito dall’alcol (E)-4-
idrossicinnamilico.  
Lo studio della Borrago officinalis ha portato all’isolamento di un nuovo 
benzilglucoside, che è risultato particolarmente interessante in quanto presenta 
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l’ossidrile in 6’ dell’unità di glucosio esterificato con l’acido 3-idrossi-3-
metilglutarico (HMGA).  
Infine, lo studio dell’estratto polare dei rizomi del Ruscus aculeatus ha portato 
all’isolamento di tre nuove saponine furostaniche. Particolarmente interessanti 
risultano due saponine caratterizzate dalla presenza di un gruppo solfato legato al 
C-1. Infatti, saponine contenenti unità monosaccaridiche solfatate di solito sono 
abbastanza frequenti nelle piante, mentre risulta poco comune l’esterificazione 
con un gruppo solfato nella porzione agliconica. 
In conclusione, la Natura è, e continua ad essere, la maggiore fonte di ispirazione 
di nuovi classi di farmaci, da utilizzare come lead per la progettazione di nuovi 
composti ottenibili per via sintetica.  
Dunque, la chimica delle sostanze naturali offre ancora entusiasmanti prospettive. 
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INTRODUCTION 
Drug discovery and development has a long history and dates back to the early 
days of human civilization. In those ancient times, drugs were entirely of natural 
origin and composed of herbs, animal products and inorganic materials. However, 
through trial and error, humans have discovered that some plants or parts of these 
(seeds, leaves, flowers, roots...) can have medical effects and humans have learnt 
to use them to reduce pain and suffering.  
Those treatments, that were effective, were subsequently recorded and 
documented, leading to the early Herbals. The development of pharmacognosy 
provided a disciplined and scientific description of natural products destined in 
medicine use. As chemical techniques improved, more and more drugs, isolated 
from natural sources, were discovered, structurally characterized, tested and, in 
due course, many were synthesized in the laboratory. Nowadays, many of today's 
medicines are obtained directly or indirectly from natural sources. These 
compounds, pharmacologically active, are known as secondary metabolites. 
In contrast to primary metabolic pathways, which synthesize, degrade, and 
generally interconvert compounds commonly encountered in all organisms, 
secondary metabolites have a much more limited distribution in nature, which are 
characteristic of specific species or specific taxa and they are not necessarily 
produced under all condition. For years, these compounds have been considered 
waste or products of primary overflow, but now it is well recognized that they 
play some vital role for the well-being of the producer, although the vast majority 
of cases the function of these compounds and their benefit to the organism is not 
yet known. Some are undoubtedly produced for easily appreciated reason, e.g. as 
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toxic materials providing defence against predators and the growth of neighboring 
species (allelopathy), as volatile attractants towards the same or other species, as 
coloring agents to attract or warn other species, or as photoprotective agents for 
the protection from ultraviolet radiation. In practice, the secondary metabolites are 
involved in the interactions within or between species and environment and they 
are produced to preserve and improve the life of the producing organism. 
These secondary metabolites has evolved in nature in response to needs and 
challenges of the natural environment. The diversity of secondary compounds 
reflects that Nature apparently optimizes certain compounds through many 
centuries of evolution and Nature has been continually carrying out its own 
version of combinatorial chemistry for the over 3 billion years. During that time, 
there has been an evolutionary process going on in which producers of secondary 
metabolites evolved according to their local environments. Combinatorial 
chemistry practiced by Nature is much more sophisticated than that in the 
laboratory, yielding elaborate structures rich in stereochemistry, concatenated 
rings and reactive functional groups. As a result, an amazing number of products 
have been found in nature, with peculiar structures and biological activities. 
Nowadays, although the increasing of synthesized drugs, it is estimated that over 
40% of medicines have their origins in these secondary metabolites, used as lead 
compounds. These molecules provide the source or inspiration for the majority of 
FDA-approved agents and continue to be one of the major sources of inspiration 
for drug discovery, presenting important structural motifs and pharcophores. They 
can be used as drugs in themselves, or they can be optimize via semi-synthesis or 
by total synthesis of analogues of the active principles, to yield drugs with 
improved properties. In the last decades, the natural products chemistry is grown, 
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not only to find new compounds to use as drugs but also to understand their 
mechanism of action. 
In 2009, Newman and Cragg published1 an analysis of the sources of drugs, 
covering the period from 01/1981 to the middle of October 2008 and 1024 small 
molecule drugs (Figure 1). The analysis demonstrated the continuing and valuable 
contributions of Nature as a source not only of potential chemotherapeutic agents 
but also of lead compounds that have provided the basis and inspiration for the 
semisynthesis or total synthesis of effective new drugs. In this analysis, the drugs 
were classified as N (an unmodified natural product); ND (a modified natural 
product); S (a synthetic compound with no natural product conception); S/NM (a 
synthetic compound showing competitive inhibition of the natural product 
substrate); S* (a synthetic compound with a natural product pharmacophore); and 
S*/NM (a synthetic compound with a natural product pharmacophore showing 
competitive inhibition of the natural product substrate). 
 
 
 
 
 
 
 
This analysis underlined that the proportion of truly synthetic (i.e., devoid of 
natural product inspiration and coded as S) is at 37% and 68.3% of compounds  
were classified as naturally derived or inspired. 
Figure 1.  Analysis of the source of drugs carried out by Newman and Cragg in 2009.1 
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Plants, in particular, have played a dominant role in the development of 
sophisticated traditional medicine systems, and for centuries they have been the 
only source of drugs known by humans. Among the innumerable examples of 
drugs, which have been developed from natural compounds, we can remember 
anti-inflammatory compounds (salicylic acid), decongestant drugs (ephedrine), 
analgesic agents (morphine), anesthetic compounds (cocaine), and so on. 
Clinically useful drugs which have been recently isolated from plants include the 
anticancer agent paclitaxel (Taxol) from the yew tree, and the antimalarial agent 
artemisinin from Artemisia annua.  
In recent years, there has been a great interest in finding new lead compounds 
from marine sources. The progress in some technologies and the wider availability 
of diving equipment made it possible to extend this research to marine organisms 
for the study of natural products chemistry. 
The greater part of earth surface is covered by seas and oceans which contains a 
larger number of organisms and less genetic homogeneity between separate 
populations of the same species than the terrestrial environment. There are over 
200,000 invertebrate and algal species. Other types of marine organisms include 
sponges (Porifera), cnidarians or coelenterates (corals, octocorals, hydroids and 
sea anemones), nemerteans (worms), ascidians (including sea squirts), mollusks 
(sea snails and sea slugs) and echinoderms (brittlestars, sea urchins, starfish and 
sea cucumbers). The molecular variety associated with this biodiversity represents 
a challenge for drug discovery. 
The study of marine organism as a source of biologically active compounds is 
considered a very promising field for the discovery of pharmacological tools and 
new medicines. In fact, since the natural products chemists diverted their attention 
Introduction 
 5 
to exploit the vast researches of marine flora and animal world, numerous novel 
compounds have been isolated from these marine organisms during the second 
half of 20th century and many of these compounds have shown very promising 
biological activities and are already at advanced stages of clinical trials, mostly for 
the treatment of cancer, or have been selected as promising candidates for 
extended preclinical evaluation. 
Among marine organisms, the chance of finding bioactive compounds is 
remarkably higher in some invertebrates, like corals, tunicates, and porifera. 
Presently, more than 35% of useful medical compounds from the sea are isolated 
from porifera, well known as sponges.  
The harsh marine environment which they inhabit, together with their lack of 
physical defences has required these organisms to develop chemical deterrents in 
order to survive. For these reason these metabolites show often antiviral, 
antifungal, antimicrobial, anti-inflammatory, antitumor, cytotoxic properties. 
Recent findings have proved that much of the unique chemistry isolated from 
marine invertebrates, such as sponges and tunicates, is also of bacterial origins. 
The symbiotic microorganisms constitute up to 40% of the biomass of some 
sponges and they are sources of various natural products; in fact metabolites 
previously ascribed to sponges have recently been demonstrated to be 
biosynthesized by symbionts. So, on one hand sponges offer nourishment and a 
safe habitat to their symbionts; on the other hand, symbiotic microorganisms help 
in the nutritional process, and participate in the host's chemical defense system 
against predators, producing secondary metabolites. 
Although natural compounds isolated from marine organism show interesting and 
specific pharmacological activities, they rarely raise the interest of 
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pharmaceuticals companies, because they are difficult to obtain in sufficient 
amounts for clinical use. Such compounds can only be harvested from their 
natural source: a process which can be tedious, time consuming, and expensive, as 
well as being wasteful on the natural resource. Total synthesis is a possible way to 
overcome this problem, but this is usually prevented by the complex structure of 
most natural products, often including many chiral centers, which makes this 
option economically unfeasible. Alternative approaches have therefore been 
proposed, such as the cultivation of the organism of interest under controlled 
conditions (aquaculture), and the laboratory production of metabolites in 
bioreactors from cell cultures. A more recent approach is the study of the 
metabolic processes leading to the synthesis of secondary metabolites. With the 
advent of genetic techniques that permit the isolation and expression of 
biosynthetic cassettes, microbes and their marine invertebrate hosts may be the 
new frontier for natural products lead discovery. 
In conclusion, it is clear that Nature will continue to be a major source of new 
drug leads. For these reasons effective utilization of these resources will require 
advances in technologies and the opening of new frontiers in science, 
understanding the importance of multidisciplinary teamwork, embracing natural 
product lead discovery and optimization through the application of total and semi 
synthesis and biochemistry, combined with good biology.  
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CHAPTER 1 
RESEARCH STEPS 
For the discovery of new compounds from natural source it is important a 
constant need to separate both large and small quantities of mixture efficiently and 
then it is necessary to characterize these new compound in a non-destructive way, 
with submilligram samples.  
The study of natural compounds consists on some steps: 
1. Isolation and purification of new compounds from biologic material; 
2. Structural determination of new compounds isolated; 
3. Determination of absolute and relative stereochemistry of new compounds. 
 
1.1 ISOLATION PROCEDURE OF NEW COMPOUNDS 
The isolation of natural products from natural sources poses numerous problems, 
because these compounds may only be present in infinitesimal quantities. When 
one considers, for example, that plants may have thousands of constituents, the 
difficulties in separating out one particular component can be appreciated. 
The nature of the separation problem varies considerably, from the isolation of 
small quantities (milligrams or less) for structure determination purposes to the 
isolation of very much larger amounts (hundred milligram to gram quantities) for 
comprehensive biological testing, for semi-synthetic work or even for production 
of therapeutic agents. For these purposes, a good selection of different techniques 
and approaches is essential. The problem of separation and isolation of new 
metabolites from natural sources was solved with the development of refined 
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techniques, such as the various analytical and preparative chromatographic 
methods. We have successfully performed a procedure of purification. 
First of all, the biological materials is extracted with an organic solvent, such as 
methanol. Then the crude extract is partitioned, utilizing modified Kupchan’s 
partitioning methodology,2 in which the composition of aqueous phase is adjusted 
sequentially as follows (Scheme 1).  
? The methanol extract is dissolved in a mixture of 10% H2O/MeOH and 
partitioned against n-hexane; the so obtained hexane extract is rich in 
lipophilic compounds.  
? The water content (% v/v) of the MeOH extract is adjusted to 30% and 
partitioned against CHCl3; in this extract compounds with medium polarity 
(peptides, macrolides, polyfuntionalized sterols, and so on) were usually 
found. 
? The aqueous phase is concentrated to remove MeOH and then extracted with 
n-BuOH; this extract contains polar compounds and salts.  
The so obtained four extracts (n-hexane, CHCl3, n-BuOH and H2O extracts) are 
tested trough preliminary bioassay to establish a potentially interesting activity. 
The most promising crude extracts are further fractioned trough sequential 
chromatographic techniques. The initial stages of a separation procedure involve 
methods with a high loading capacity and cheap stationary phases - these have 
traditionally been column chromatography with silica gel or liquid-liquid 
methods. Subsequent steps employ techniques which require smaller samples - 
HPLC, for example.  
 
 
Chapter 1 – RESEARCH STEPS 
 9 
 
 
 
 
 
 
 
 
 
 
DCCC (droplet countercurrent chromatography) is a preparative method usually 
used in our laboratories. In spite of a number of advantage (such as total recovery 
of the introduced sample, no irreversible adsorption,  and so on), this method 
doesn’t have a large development, but in my work it represents an useful tool for 
the separation of mixture of compounds. It is a liquid-liquid separation method 
which does not require a sorbent; it relies on the passage of droplets of a mobile 
phase through an immiscible stationary liquid phase for the continuous partition 
of a solute between the two phases. A typical DCCC instrument consists of 200-
600 vertical glass columns interconnected in series by capillary Teflon tubes.3 
These columns are first filled with the stationary phase of biphasic solvent system 
and the sample is injected. The mobile phase is then pumped into the first of the 
columns, forming a stream of droplets in the immiscible stationary phase. 
Depending on the choice of solvents for the mobile and stationary phases, droplets 
are made either to ascend (“ascending mode”) or descend (“descending mode”) 
through the columns (Figure 2). The choice of a two-phase solvent system is 
Scheme 1. Modified Kupchan’s partitioning methodology. 
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crucial to the success of DCCC separations. Binary systems are impractical for the 
formation of suitable droplets because of the large difference in polarity between 
the two components, and ternary (or quaternary) systems are required, such that 
the addition of the third (or fourth) component, miscible with the other 
components, diminishes the difference in polarity between the two phases. The 
selectivity of the system is thus increased, allowing the separation of closely 
related substances. In my work I usually used the ternary biphasic n-
BuOH/Me2CO/H2O (3:1:5) in the descending mode or CHCl3/MeOH/H2O 
(7:13:8) in the ascending mode. 
The fractions, collected, are combined on the basis of their similar TLC retention 
factors.  
 
 
 
 
 
 
 
Another preparative chromatographic technique used in my work is the MPLC 
(Medium Pressure Liquid chromatography). It is a liquid-solid chromatography, 
in which the liquid mobile phase is forced through the solid stationary phase at 
medium pressure. MPLC is more efficient in resolution than the open-column and 
flash chromatography methods and the separation involves a considerable gain in 
time. The solid stationary phase can be a normal phase, like silica gel (used in my 
work), or bonded phase (RP-8, RP-18). The technique makes use of pressures of 
Figure 2. The principle of DCCC. 
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ca. 5-40 bar and can easily accommodate much larger sample loads (100 mg-100 
g) than are generally applied in other separations. As far as separating power is 
concerned, MPLC lies somewhere between flash chromatography and semi-
preparative HPLC. 
High Performance (or High Pressure) Liquid Chromatography (HPLC) , both 
normal-phase and reverse-phase, is the most widely used chromatographic 
method, and finds application in the preparative separation of samples to “pilot” 
the preparative isolation of natural products (optimization of the experimental 
conditions, checking of the different fractions throughout the separation). On the 
whole, however, HPLC is commonly applied as the last step in purification 
processes affording pure compounds in high yields, and, in this respect, the 
quantities involved tend to be at the lower end of the scale.  
Finally the compounds, so isolated, are structurally characterized and are 
submitted to pharmacological assays. 
 
1.2 STRUCTURAL DETERMINATION METHODS 
Structural characterization of new compounds surely is the most interesting work 
of the natural products chemist. It is possible to determine complex organic 
structures completely in a non-destructive way, with submilligram samples 
through the combined use of all spectroscopic techniques. Structural 
determination described in this thesis is largely based on mostly mass 
spectrometry (MS) and nuclear magnetic resonance (NMR). 
1.2.1 Mass Spectrometry 
Mass spectrometry is an analytical technique that is used to determine the 
molecular mass of a compound on the basis of the mass-to-charge ratio (m/z ratio) 
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of ions produced from the molecules. A very accurate measurement of the 
molecular mass (high resolution mass spectrometry) can also provide the 
molecular formula of the molecule under study.  
A mass spectrometer converts sample molecules into ions in the gas phase 
(source), separates them according to their mass to charge ratio m/z (analyzer) and 
sequentially records the individual ion current intensities at each mass (detector), 
giving the mass spectrum. There are many different types of sources, as well as of 
analyzers. 
More information on the structure of the molecule under examination are given by 
the fragmentation of the ion produced in source. The ions may fragment by 
themselves, or they may be induced to fragment by letting them collide with gas 
molecules. In this case, a second analyzer is used to measure the mass of the 
fragments. This is known as tandem mass spectrometry or MS/MS. 
Most of compounds described in the following sections were analyzed by ESI 
mass spectrometry. The ESI source is especially useful in producing ions from 
polar compounds or macromolecules. The sample is dissolved in a volatile solvent 
like H2O, MeOH, and CH3CN; volatile acids, bases or buffers are often added to 
the solution.  
This solution passes through the electrospray 
needle that has a high potential difference applied 
to it (Figure 3). This forces the spraying of 
charged droplets from the needle with a surface 
charge of the same polarity to the charge on the 
needle. The droplets are repelled from the needle 
towards the source sampling cone on the counter electrode. As the solvent 
Figure 3. Source electrospray 
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evaporation occurs, the droplet shrinks until it reaches the point that the surface 
tension can no longer sustain the charge (the Rayleigh limit) at which point a 
"Coulombic explosion" occurs and the droplet is ripped apart. This produces 
smaller droplets that can repeat the process until the ionized analyte molecules can 
escape from the droplet by electrostatic repulsion. For molecules with a high 
molecular weight, the ions may take more than one proton (up to some tens), and 
therefore may have multiple charge. Formation of multiply charged ions allows 
the analysis of high molecular weight molecules such as proteins, because it 
reduces the m/z ratio of the ions, which is therefore easier to measure. 
This is a very soft method of ionization as very little residual energy is retained by 
the analyte upon ionization. The major disadvantage of the technique is that very 
little (usually no) fragmentation is produced. For structural elucidation studies, 
this leads to the requirement for tandem mass spectrometry where the analyte 
molecules can be fragmented. 
1.2.2 Nuclear Magnetic Resonance spectroscopy 
Nuclear magnetic resonance spectroscopy, most commonly known as NMR 
spectroscopy, is the most important spectroscopic technique used for structure 
elucidation of the isolated secondary metabolites. This technique is not destructive 
compared to mass spectrometry. In addition to standard 1H and 13C NMR spectra, 
a large use of 2D NMR experiments was made, resolving overlapping multiplet 
patterns and allowing interpretation of more first-order-like spectra. 
COSY (COrrelated SpectroscopY) is an homonuclear 2D experiment. It allows to 
determinate the connectivity of a molecule by identifying which protons are 
scalarly coupled. This method is very useful when the multiplets overlap or when 
extensive second order coupling complicates the 1D spectrum. 
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TOCSY (TOtal Correlated SpectroscopY also known as HOHAHA– 
HOmonuclear HArtmann HAhn) is very useful in the analysis of molecules 
composed of many separate spin systems. It shows the correlations between all 
protons within a given spin system, not just between geminal or vicinal protons as 
in COSY. Correlations are seen between distant protons as long as there are 
couplings between every intervening proton. This is extremely useful for 
identifying protons on sugar rings in oligosaccharides or amino acids in peptides: 
all protons on a given sugar ring will have a correlation with all other protons on 
the same ring but not with protons on different rings. 
ROESY (Rotating frame Overhauser Effect SpectroscopY) is useful for 
determining which signals arise from protons that are close to each other in space 
even if they are not bonded, detecting ROEs (Rotating-frame Overhauser Effect). 
ROESY also detects chemical and conformational exchange. ROE is similar to 
NOE (Nuclear Overhauser Effect), being related to dipolar coupling between 
nuclei, and depending on the geometric distance between the nuclei. While NOE 
is positive for small molecules and negative for macromolecules, ROE is always 
positive. Therefore, the ROESY experiment is particularly useful for medium-size 
molecules, which would show a NOE close to zero. 
The HSQC (Heteronuclear Single Quantum Correlation) is a 2D NMR 
heteronuclear correlation experiment, in which only one-bond proton-carbon 
couplings (1JCH) are observed. Instead HMBC (Heteronuclear Multiple Bond 
Correlation) is an experiment that identifies proton nuclei with carbon nuclei that 
are separated by more than one bond (2,3JCH).  
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1.3 DETERMINATION OF STEREOCHEMISTRY 
The determination of absolute and relative stereochemistry is a key step for the 
characterization of natural products. The stereochemistry involves the study of the 
relative spatial arrangement of atoms within molecules, their three-dimentional 
disposition in the space. The stereochemistry of a molecule is a concept of 
fundamental importance and is inseparably linked with molecular recognition, in 
fact the biological activity of a molecule is strictly related not only to its planar 
structure, but also to its sterical arrangement. It is now widely recognized that 
enantiomeric drugs may give to different interactions in the human system, thus 
behaving very differently in their activity, toxicology, adsorption, metabolism, 
pharmacokinetics and bioavailability.4 So, the knowledge of the three-dimentional  
disposition of a molecule is important to understand the biological activity, the 
interaction drug-receptor, but also to synthesize the natural products or its 
improved analogues.  
The majority of natural products have one or more chiral centers. Usually, in a 
step-by-step structural elucidation, the first goal is the identification of relative 
stereochemistry of chiral centers. Then, after the elucidation of absolute 
stereochemistry even at a single stereogenic carbon, it will be possible to deduce 
the absolute configuration of the total structure. Unluckily, when the relative 
stereochemistry of different chiral centers cannot be correlated, the absolute 
configuration must be assigned independently. 
1.3.1 Scalar and spatial NMR couplings 
NMR spectroscopy gives a lot of information about molecular three-dimensional 
structure. Structural information from NMR experiments come primarily from the 
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chemical shift of a nucleus that is sensitive to the environment, from through- 
magnetization transfer between pairs of protons.  
J couplings between pairs of protons separated by three or fewer covalent bonds 
can be measured. The value of a three-bond J coupling constant contains 
information about the intervening torsion angle (θ). This is called the Karplus 
relationship5  and has the form: 
3J = A cos θ2+B cos θ + C 
where A, B, and C are empirically derived constants for each type of coupling 
constant. The magnitude of these couplings are generally smallest when the 
torsion angle is close to 90° (3JH-H ~0-1.5 Hz) and largest at angles of 0° and 180° 
(generally J180° >J0°). Thus, it is possible to discriminate easily an axial-axial 
relation between two protons within a six membered ring, 3Ja-a~7-9 Hz, and an 
axial- equatorial or equatorial-equatorial correlation, 3Ja-e~3Je-e~2,5 Hz. It is also 
possible to discriminate between cis and trans relationship of two double bond 
protons (3Jcis~6-12 Hz, 3Jtrans~14-20 Hz). 
The other major source of structural information comes from through space 
dipole-dipole coupling between two protons called the NOE (Nuclear 
Overahauser Effect).6 This effect can be observed upon irradiation, during the 
acquisition of the spectra, on a specific signal. In this way, the relaxation times of 
all the protons surrounding the irradiated proton (distance < 2.5 Å), even though 
not belonging to the same spin system, are influenced and thus, their height 
changes. The intensity of a NOE is proportional to the inverse of the sixth power 
of the distance separating the two protons. Thus the NOE is a sensitive probe of 
short intramolecular distances. 
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NOEs are categorized according to the location of the two protons involved in the 
interaction. Intraresidual NOEs are between protons within the same residue, 
whereas sequential, medium, and long range NOEs are between protons on 
residues sequentially adjacent, separated by 1, 2 or 3 residues, and separated by 
four or more residues in the polypeptide sequence.  
The NOE effect establishes a spatial relationship between substituents of fixed 
molecules, but this effect is dependent from the dimensions of the molecule. 
Indeed, NOE effects cannot be evidenced for large molecules. To overcome this 
limitation, a two-dimensional homonuclear experiment, the ROESY experiment 
(Rotating-frame Overhauser Effect SpettroscopY), can be used.7 
1.3.2 Murata’s method 
NMR is certainly one of the most powerful instrumental techniques for the 
analysis of the relative stereochemistry of organic compounds. Even more, the 
application of NMR techniques to the problem of determining the relative spatial 
orientation of substituents has became a routine task in modern organic chemistry 
laboratories.  
Cyclic compounds with small (three to six memberered) rings display a predicable 
conformation behavior that allows the knowledge of their configuration to be 
extracted from simple NMR parameters, such as proton-proton J-coupling values 
and NOE intensities. A much more challenging task is the assignment of relative 
(and absolute) configuration in the case of flexible system, such as open 
(polysubstituted) chain and/or macrocyclic compounds for which a clear-cut, 
definite stereochemical strategy is not yet available. 
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In acyclic system all coupling constants are observed as a weighted average of 
each conformer, and for this reason, the dihedral angles obtained from these data 
provide a much more reliable constraint information regarding the major 
conformer than NOE data. However, the use of the sole homonuclear coupling 
constants (3JH-H) for relative stereochemistry assignments in flexible system is not 
feasible since they don’t allow to distinguish between all the spatial arrangements 
of the substituents linked to a two-carbon fragments, as it would be needed for the 
identification of the rotamer with the correct configuration (Figure 4). 
 
 
In other words, even if we restrict our attention just to staggered conformations, in 
absence of additional information on the geometry of the system, one angular 
constraint for each C2 segment is not sufficient to solve the problem, since more 
solutions are consistent with the experimental data. The situation change 
dramatically, though, when additional angular information on a stereochemically 
undetermined C2 fragment is provided from heteronuclear coupling costant (2,3JC-
H). Along these lines, Murata et al.8 have lately reported a method for the 
assignment of the relative configuration of acyclic compounds based on the 
combined use of homonuclear proton-proton coupling constants 3JH-H, 
heteronuclear proton-carbon coupling constants 2,3JH-C and NOE data.  
Figure 4. Values of 3JHH coupling for the six staggered rotamers corresponding to two 
different diastereomers erythro and threo 
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This model is basically applicable to acyclic structures having stereogenic carbons 
bearing hydroxyl, alkoxy or methyl substituents. Every chiral molecule containing 
consecutive or alternate streochemical centers can be ideally divided in two-
carbon fragment. This simplification allows to determinate, for each single 
fragment, the predominant rotamer with the exact configuration, among the six 
possible staggered conformers through the use of the J-based NMR approach, see 
Scheme 2. For the sake of simplicity, let us compare every single couple of vicinal 
asymmetric carbons to those belonging to a 2,3-disubstituted butane system. The 
strategy followed for a 2,3-disubstituted butane can then be applied to a large 
variety of natural and synthetic products in which the substituents are methoxy, 
hydroxy and methyl groups. A 2,3-disubstituted butane can have two relative 
diastereomeric configurations, named syn (or threo) and anti (or erythro). Each of 
these two configurations can be arranged in three staggered rotamers, for a total of 
six possible conformers, as shown in Scheme 2 (A1, A2, A3, B1, B2, B3). Every 
single rotamer shows its own homonuclear and heteronuclear coupling constant 
pattern. Assuming that we have a sufficient number of experimental coupling 
constraints, these 3JH-H and 
2,3JC-H
 
will allow to univocally identify four of the six 
rotamers, namely A1, A3, B1, B3. The two rotamers A2 and B2, characterized by 
an anti position of the two vicinal protons, have to be distinguished on the basis of 
NOE (or ROE) data because they show the same coupling constant pattern. 
The first step in the determination of the relative configuration of two vicinal 
methines consists in the evaluation of the homonuclear proton-proton coupling 
constant of the C2 fragment of interest (Scheme 2), in order to assess whether or 
not it exists in a predominant conformation.  
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Small 3JH-H (0-4 Hz) will indicate a gauche arrangement of H2 and H3 protons. In 
this case the relative configuration can be safely obtained from three or four 
additional angular constraints deriving from the heteronuclear coupling constants 
values. These 2,3JC-H values, indeed, will allow to establish the arrangement 
(gauche or anti) of H2 with regard to substituent Y and C4 and the arrangement of 
H3 with regard to substituent X and C1 and will therefore allow to choose the 
correct gauche rotamer among A1, A3 (threo), B1 and B3 (erythro) (Schemes 2 
and 3).  
Large 3JH-H values (8-12 Hz) indicate anti disposition of the protons. Nevertheless 
the 2,3JC-H values are the same for both rotamers A2 (threo) and B2 (erythro) 
(Schemes 2 and 3) and so they don’t allow to distinguish them. In this case it is 
necessary to use NOE data regarding protons on carbons C1 and C4 and possibly 
protons on substituents Y and X. An NOE effect between protons on C1 and C4 
and/or an NOE effect between protons on Y and X suggest the rotamer A2 in 
Scheme 2. Identification of the single conformer with a correct configuration from the 
staggered rotamers with threo (syn) and erytro (anti) arrangements through the combined use 
of measured 3JHH and 2,3JCH values. 
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Scheme 2, while an NOE between protons on C1 and on Y and/or an NOE 
between protons on C4 and on X are suggestive of the rotamer B2. Intermediate 
values of 3JH-H (4-8 Hz) are usually indicative of an interconversion between two 
or more conformers that is fast on the NMR scale. In this case, it would be still 
possible to identify the alternating conformers on the basis of the homonuclear 
and heteronuclear coupling constant value and to assign the relative configuration, 
but the methodology is being pushed to the limit and therefore much more care 
has to be put in its application. In addition, the registration of NMR spectra at a 
low temperature can be of help in case of complex conformational equilibria, due 
to the population increase of the most stable conformer. 
 
 
For small molecules, the homonuclear 3JH-H can be easily determined through the 
analysis of a 1D proton spectrum. Nevertheless, the use of more sophisticated 2D 
NMR techniques, such as E.COSY9 or P.E.COSY10, is mandatory when the direct 
Scheme 3. General J-coupling procedure. 
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measurement of the J values in the proton spectra of medium and high molecular 
weight products is prevented by severe signal overcrowding. 
Heteronuclear long range 2,3JC-H values have become widely available after the 
introduction of inverse detection NMR techniques11 and the implementation of 
pulse-field-gradient (PFG) hardware in commercial NMR spectrometers. These 
values are determined, in the original method proposed by Murata, by 2D hetero 
half-filtered TOCSY (HETLOC),12-13 phase sensitive HMBC (PS-HMBC) 14-17 
experiments and, in a recent application of the methodology, HSQC-TOCSY 
spectra have also been used for this purpose. 
However, the extensive use of JC-H couplings in the analysis of the relative 
configuration has been hampered due to the difficulties arising from the need to 
make reliable judgments on the size (large, medium or small) of a given 
heteronuclear J coupling value in the absence of a desirable wealth of literature 
data and of efficient empirical rules, unlike the case of 1H-1H J values, and due to 
the impossibility to deal with cases in which the dominant conformation of the C2 
fragment under investigation is represented by an anti arrangement between 
protons. Indeed, in this particular instance, the sole pattern, however extensive, of 
homo- and heteronuclear J-couplings does not allow us to distinguish between the 
two possible relative configurations (erythro and threo). 
These limitations were overcame utilizing a recent method, performed by the 
research group of Riccio-Gomez-Bifulco-Bassarello, of University of Salerno.18  
This method represents a strategy for configurational analysis of flexible organic 
compounds, based on the use of QM calculations at DFT (density functional 
theory) level,19,20 to accurately predict J coupling values and to subsequently 
compare them against their corresponding experimental counterparts. Indeed, QM 
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methods21,22 have lately proved to be invaluable tools for computing faithfully a 
number of atomic and molecular properties, including relevant NMR parameters, 
such as chemical shifts and coupling constants. 23-25 
QM method calculates, quantitatively and not qualitatively (not more small, 
medium or large), homo- and heteronuclear coupling constant values for each of 
the six main staggered rotamers in which any given two-carbon (chiral) fragment 
can be ideally represented (Figure 4). It is based on the dissection of the full 
molecular system into a series of simplified fragments which, in most cases, are 
nothing else than suitable versions of each pair of stereocenters in which the 
molecule can be ideally divided.  
Once the simplified C2 fragments of the molecule under investigation have been 
selected, all six staggered rotamers of a given C2 fragment are first subjected to a 
high-level geometry optimization, and then J coupling values are computed for all 
optimized rotamers. The so-obtained data sets of J coupling values can then be 
analyzed against the experimental values, allowing to draw conclusions on the 
relative configuration of the examined C2 molecular fragment. Then, the same 
approach is repeated for all the other C2 fragments of the system. For only one of 
the six arrangements are the J values in agreement with the experimental ones. 
1.3.3 Marfey’s method 
Indirect methods, to determinate the absolute configuaration, involve the 
formation of covalent diastereomeric derivates by reacting the enantiomers with a 
chiral derivatizing agent (CDA). Thus the diastereomeric derivatives may be 
resolved by using conventional achiral columns in HPLC, both normal and 
reversed phase. 
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The most widely used method to determinate the absolute stereochemistry of 
ribosomial amino acids is the Marfey’s method.26 This method consists of the 
derivatization of amino acid residues, belonging to complete acid hydrolysis of 
peptide, with a chiral agent FDAA (1-fluoro-2,4-dinitrophenyl-L-alaninamide, 
Figure 5)  and then the comparison of retention times of these derivates from 
parent peptide with the retention time of appropriate standards D and L through 
HPLC. 
 
 
 
 
This method is enough easy for ribosomial amino acids, commercially available, 
and consist of four phases: 
1. Hydrolysis of parent peptide with HCl 6 N; 
2. Derivatization of the hydrolyzed  with L-FDAA; 
3. Derivatization of both standards, D and L, with L-FDAA. If the D-
standard isn’t commercially available or is too expensive, it is possible to 
derivatize L-amino acid with D-FDAA. 
4. Analysis through HPLC of retention times. 
However, it is difficult to apply this chromatographic method to a peptide 
containing unusual amino acids without having their standard samples. Another 
limitation is the possibility to make mistake valuing the tR of the derivates in 
HPLC. The last problem can be solved using LC-MS that allowed to identify the 
peak through the ratio m/z. 
Recently a new method was developed, known as advanced Marfey’s method.27  
F HN
O2N NO2
NH2
O
Figure 5. Structure of L-FDAA 
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It is useful to determinate the absolute stereochemistry of non conventional amino 
acid, not commercially available, and is based on the elution time of amino acids 
derivatized wih L-FDAA. This method was tested on a number of proteogenic or 
not amino acids and showed  the L-amino acid-L-FDAA derivate is eluted from 
the column before its corresponding D-isomer. 
Now it is well recognized, according to the NMR and UV measurement, that D 
and L-amino acid-L-FDAA derivatives can be resolved due to the difference in 
their hydrophobicity which is derived from the cis or trans type arrangement of 
two more hydrophobic substituents at both α-carbons of an introduced amino acid 
and L-FDAA. In fact the D-isomer (with a cis type arrangement) interacts more 
strongly with RP silica gel and has the longer retention time compared to the less 
hydrophobic L-amino acid-L-FDAA, which has a trans type arrangement (Figure 
6).  
 
 
 
 
The advanced Marfey’s method is an useful tool to determinate the absolute 
configuration of non ribosomial amino acids. It consists of four steps: 
1. The amino acid obtained from hydrolysis of the peptide is divided into 
two portions; 
2. Derivatization of amino acid with L-FDAA; 
3. Derivatization of amino acid with D-FDAA; 
Figure 6. Structures of  D and L amino acids-L-FDAA derivatives 
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4. Analysis of tR through LC-MS. 
The peaks of any amino acids in peptides are identified without a standard sample 
using mass spectrometry, and the absolute configuration of a desired amino acid is 
deduced from its corresponding enantiomer.  
 This method is applicable to determinate the absolute configuration of the α 
chiral center of α-amino acid and to determine the absolute configuration of α-
amino acid with more chiral centers, only if the relative configuaration is known. 
The method cannot be used: 
a) for β or γ-amino acids ; 
b) for amino acids with more chiral centers, if it isn’t known the relative 
configuration. 
The advanced Marfey’s method is a nonempirical one, but it has some draw-
backs, since it relies on the eluition order of amino acid derivative with L-FDAA 
to determine its absolute configuration. It is clear that the nature of the amino acid 
side-chain is responsible for this behavior. So some amino acid don’t follow the 
eluition order in column and the isomer L-amino acid-L-FDAA has a longer 
ritention time compared to the D-amino acid-L-FDAA, or the two derivatives 
have tR too similar (see Table 1). The amino acids with ionizable side-chain, like 
Asp and Glu, have problem of derivatization. Amino acids like tyrosine and 
histidine or containing two amino groups such as ornithine and lysine can form 
both mono- and di-substituted Marfey’s derivatives thus doubling the number of 
peaks in a chromatogram for these amino acids. 
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Amino acid 
L-FDAA 
tR (min) 
D-FDAA 
tR (min) 
β-threo-hydrossiapartic acid 3.8 3.7 
β-erythro-hydrossiacpartic acid 6.9 6.1 
Ornithine (mono-α-FDAA) 9.4 8.5 
Ornithine (di-FDAA) 28.5 26.0 
Hystidine (mono-α-FDAA) 6.7 6.0 
Citruline 10.7 10.0 
N-Me aspartic acid 11.4 11.0 
Serine  9.2 9.3 
Glutamine  8.8 8.9 
Asparagine 6.7 7.3 
Lysine 10.6 10.8 
Table 1. Analysis of amino acid derivtized with L and D-FDAA. 
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CHAPTER 2 
PORIFERA 
Sponges, which constitute phylum Porifera, are the most primitive of the 
multicellular animals. Neither true tissues nor organs are present and the cells 
display a considerable degree of independence. All the members of the phylum 
are sessile and exhibit little detectable movement. This combination of 
characteristic convinced Aristotele, Pliny and other ancient naturalist that sponges 
were plants.  
They are aquatic sessile filter feeders and live permanently attached to a location 
in the water. Sponges can be found in nearly all aquatic environment (marine and 
fresh water; shallow and deep; tropical and Antarctic), wherever there are 
substrata for sponge attachment and growth. There are over 9000 presently known 
species of sponges and as many species not yet described.28 
They can show a variety of sizes, colors, and shapes, including arboresecent (tree-
like), flabellate (fan-shaped), caliculate (cup shaped), tubular (tube shaped) and 
amorphous (shapeless) (Figure 6).  
 
 
 
 
 
 
 
Figure 6. Some examples of Porifera. 
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The closest to a tissue in a sponge is the outer dermal membrane composed of two 
cell layers of specialized cells called pynacocytes, which digest food particles too 
large to enter the ostia. The body wall is approximately two cell layers thick with 
a gel like substance called the mesohyl, the gelatinous matrix within the sponge 
made of collagen. The body wall is perforated by many pores and channels (ostia), 
through which water enters the animal, passing into the spongocoel, and exiting it 
through a large opening, the osculum (Figure 7). The interior cells are called 
choanocytes and contain a central flagellum surrounded by a collar of microvilli 
which are connected by a thin membrane. By cooperatively moving their flagella, 
choanocytes generate a flow of water through the sponges pores, into the 
spongocoel, and out through the osculum. This improves both respiratory and 
digestive functions for the sponge, pulling in oxygen and nutrients and allowing a 
rapid expulsion of carbon dioxide and other waste products. 
 
 
 
 
 
 
Body plans range from simple through to complex, produced by 
varying degrees of infolding of the body wall and complexity of 
water canals throughout the sponge. The simplest body structure 
in sponges is a tube or vase shape known as asconoid. This 
refers to a sessile tubular structure. Water, along with particulate 
matter, flows through small pores. The ostia lead to flagellated coanoderm which 
Figure 7. A sponge body structure.  
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pick up particulate matter, while the water is pushed up and out of the tube at the 
osculum.  
Syncanoids also take on tubular structure but have an internal 
tissue which generates a much greater surface area for the 
absorption of nutrients. Folds in the internal tissue create a sort 
of zigzag pattern in which the internal openings are referred to 
as choanocyte chambers. The external openings are incurrent canals. However this 
is not a typical zigzag pattern as the internal and external chambers are connected 
by small canals called prosopyles. As such, the water flow enters the ostia, moves 
through the incurrent canals, through the prosopyle, into the coanoderm chamber, 
through the atrium and out the osculum. 
The most derived form of sponges takes on leucanoid design. 
Leucanoids differ from Syncanoids in that they have spherical 
choanocyte chambers and often several osculum. These 
sponges minimize the amount of water which is pumped 
through the body and maximize the number of choanocytes.  
The body of the sponges is reinforced by the skeleton, collagen fibers and spicules 
(Figure 8). Sponges use various materials to reinforce their mesohyl and in some 
cases to produce skeletons and this form the main basis for classifying sponges. 
Sponges produce spicules made of calcium carbonate.  
 
 
 
 
Figure 8. Spicules seen at microscope. 
Chapter 2 - PORIFERA 
 32 
Demosponges reinforce the mesohyl with fibers of a special form of collagen 
called spongin, most also produce spicules of silica, and a few secrete massive 
external frameworks of calcium carbonate. Although glass sponges also produce 
spicules made of silica, their bodies mainly consist of syncytia that in some ways 
behave like many cells sharing a single external membrane, and in others like 
individual cells with multiple nuclei.  
Probably because of their variety of construction methods, demosponges 
constitute about 90% of all known sponge species, including all freshwater ones, 
and have the widest range of habitats. Calcareous sponges are restricted to 
relatively shallow marine waters where production of calcium carbonate is easiest. 
The fragile Hexactinellida (glass sponges) are restricted to polar regions and the 
ocean depths where predators are rare, and their feeding systems very efficiently 
harvest what little food is available. 
Sponges, lacking any nervous, digestive, circulatory, muscular systems or any 
physical defence from their predators, produce secondary metabolites, involved in 
their chemical defence, which is essential for their survival. In fact many species 
contain toxic substances, probably to discourage predators. The chemicals also 
probably play a role in competition among sponges and other organisms, as they 
are released by sponges to insure themselves space in the marine ecosystem. Some 
of these chemicals have been found to have beneficial pharmaceutical effects for 
humans, including compounds with respiratory, cardiovascular, gastrointestinal, 
anti-inflammatory, antitumor, and antibiotic activities. 
Sponges also provide a home for a number of small marine plants, which live in 
and around their pore systems. Symbiotic relationships with bacteria and algae 
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have also been reported. It is well recognized that the symbiontic bacteria are the 
real producer of many secondary metabolites with biological activities.  
Sponges are very fertile host animals for diverse symbiotic microorganisms and 
various microorganisms have been found in sponges. They include a diverse range 
of archaea, heterotrophic bacteria, cyanobacteria, green algae, red algae, 
cryptophytes, dinoflagellates and diatoms. 
One host sponge can possess diverse symbionts. For example, sponge Theonella 
swinhoei supports unicellular heterotrophic bacteria, unicellular cyanobacteria and 
filamentous heterotrophic bacteria at the same time.29 
The symbionts locate both intra- and extra cellularly (Figure 9), and each 
symbiotic microorganism seems to have a specific habitat in the host sponge. 
Extracellular symbionts are present on the outer layers of sponges as 
exosymbionts, or in the mesohyl as endosymbionts. Intracellular or intranuclear 
symbionts permanently reside in host cells or nuclei. In the case of the sponge 
Theonella swinhoei, all populations of symbiotic bacteria are located 
extracellularly. 
 
 
 
 
 
 
The amount of symbiotic microorganisms residing in sponges varies between host 
species. While bacteria constitute up to 60% of the biomass of some sponges, 
others contain only a small number of bacteria inside their tissue. 
Figure 9. Schematic diagram of symbiotic relationships between sponges and microorganisms. 
A, extracellular exosymbiosis; B, extracellular endosymbiosis; C, intracellular symbiosis; and 
D, intranuclear symbiosis. 
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Then why do symbiotic microorganisms inhabit sponges? The surfaces or internal 
spaces of marine sponges are more nutrient-rich than seawater and sediments; 
therefore sponges offer nourishment and a safe habitat to their symbionts. On the 
other hand, symbiotic microorganisms help in the nutritional process, either by 
intracellular digestion or by translocation of metabolites including nitrogen 
fixation, nitrification and photosynthesis. Microorganisms also stabilize the 
sponge skeleton and participate in the host's chemical defense system against 
predators and biofouling. Bacteria collected from sponges have allowed isolation 
of antimicrobioal compounds, which suggests that these bacteria may play a role 
in the defence mechanism of these invertebrates. 
 
2.1 METABOLITES ISOLATED FROM SPONGES 
A number of promising compounds have been identified from marine sponges 
that possess pronounced biological activity and are already at advanced stages of 
clinical trials, mostly for the treatment of cancer, or have been selected as 
promising candidates for extended preclinical evaluation.30 The types of 
compounds characterized from marine organisms are diverse and represent many 
different classes, structurally complex with unique functionalities, including:  
• Macrolides are a group of compounds that stems from the presence of a 
macrolide ring, a large macrocyclic lactone ring to which one or more 
sugars may be attached. 
• Terpenes are a large and varied class of natural compounds, structurally 
different each other. They derive from C5 isoprene units linked together 
head to tail. Several modes of cyclization are conceivable and lead to 
various skeletons just like the cyclization of polyketide chains. The 
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terpenes are classified according to the number of C5 units: monoterpenes, 
C10; sesquiterpenes C15; diterpenes, C20; sesterterpenes, C25; triterpenes, 
C30; and tetraterpenes C40.   
• Steroids have a tetracyclic ring system and comprise a large number of 
ubiquitous compounds which are divided into subgroups, chiefly 
according to side chain functionality: sterols, sapogenins, cardiac 
aglycones, bile acids, adrenal steroids and sex hormones, all of vital 
importance for life. The most common sterol of animal origin is 
cholesterol. 
• Cyclic Peptides are polypeptide chains whose amino and carboxyl 
terminus are themselves linked together with a peptide bond that forms a 
circular chain. They are often characterized for the presence of unusual 
amino acids. 
2.1.1 Macrolides  
Marine macrolides provide a fascinating range of structural and functional 
diversity, which may find application as specific molecular probes for the 
investigation of the cytoskeleton and cell cycle events. In fact, many macrolides 
isolated from sponges disrupt the organization of microfilaments, interacting with 
actin in the cell cytoskeleton, and represent a promising mechanism of action for 
developing novel anticancer drugs. 
The latrunculins are 2-thiazolidinone-containing macrolides, 
isolated from the Red Sea sponge Latrunculia magnifica.31 
Latrunculin A is the most potent of the class and affects 
different components of the actin-based cytoskeleton.  
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The sphinxolides and reidispongiolides are 26-membered lactones isolated from 
two New Caledonian marine sponges Neosiphonia superstes and Reidispongia 
coerulea.32-36 They exhibit an extraordinary in vitro activity against various 
human tumor cell lines and a potent actin-depolimerizating activity. 
 
 
 
 
 
 
 
 
Other macrolides that are becoming important as molecular tools are the 
macrolide swinholide A37 and its analogue misakinolide,38 which bind specifically 
to the intracellular actin network and represent useful tools in investigations of 
actin organization, dynamics and function.  
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2.1.2 Terpenes 
Marine organisms produce a wide array of fascinating terpenoid structures 
distinguished by characteristic structural features. Especially striking is the 
frequent occurrence of sesterterpenes in marine organisms, and sponges must be 
considered as one of the prime sources of these C25 terpenoid compounds. In 
most cases however, these structural features are not strictly unique for marine 
natural products. The prominent biological activity of marine terpenes is evident 
in their ecological role in the marine environment, and makes them interesting as 
potential drugs. 
Examples are: curcuphenol, that is a sesquiterpene phenol isolated from different 
marine sponges belonging to the genus Didiscus, that inhibts growth of several 
cell lines and exhibits in vitro antimalarial activity;39 spongiadiol and 
epispongiadiol, furanoditerpenes with cytotoxic and antiviral activity, isolated 
from a Caribbean deep water marine sponge, Spongia sp.40  
 
 
 
 
A number of cytotoxic furanosesterterpenes have been obtained from a variety of 
sponges, such as palominin from a Caribbean Ircinia sp. and cacospongionolide 
from the marine sponge Cacospongia mollior.41,42  
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2.1.3 Sterols 
In the last 30 years many sterols with unprecedented structures have been isolated 
from marine sources. For many years the known carbon skeleton of sterols ranged 
from C27 to C29, and the carbon variation occurred exclusively in the side chain 
at C24.43 After the discovery of the C26-sterols, first detected in 1970 from the 
mollusk Placopecten magellanicus44 and later found widespread in marine 
invertebrates and also in a marine phytoplankton,45 a number of  
“nonconventional” sterols have been reported.  
Unconventional steroids often co-occur with conventional ones and are sometimes 
present in small amounts; however, many exceptions are reported for some 
sponges that are found with unusual structures as the predominant steroids rather 
than cholesterol or the conventional 3β-hydroxy sterols.46-48 It is, therefore, 
particularly interesting when a sponge contains unusual steroids in large 
quantities, as these very likely play a functional (rather than metabolic) role in 
maintaining the integrity of membranous structures. It has been hypothesized and, 
to some extent, documented that the uniqueness of sterols in cell membranes of 
sponges is related to the other membrane components, particularly the 
phospholipids. These latter compounds seem to have head groups and fatty acids 
very different from those of higher animals; therefore, the structural modifications 
exhibited by the sponge sterols may be a sort of structural adjustments for a better 
fit with other membrane components.49-52 
The sterols isolated from sponges are sometimes very complex mixtures of highly 
functionalized compounds, many of which have no terrestrial counterpart. These 
include sterols having side chains modified by the apparent loss of carbon atoms 
or by the addition of extra carbon atoms at biogenetically unprecedented positions 
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of a normal Cα side chain, as well sterols with unusual nuclei, containing a 
variety of oxygenated functionalities such as polyhydroxy, epoxide, epidioxy, and 
mono or polyenone systems. 
The highly functionalized steroids have attracted 
considerable attention because of their biological 
and pharmacological activities. Remarkable 
example is the 9,11-secosterol herbasterol, 
isolated from the sponge Dysidea herbacea, which is ichthyotoxic. 53 
Contignasterol represents the first marine steroid 
found to have a cis C/D ring junction as well as a 
cyclic hemiacetal functionality at C-29 in the 
side-chain and it is a potent inhibitor of histamine 
release from rat mast cells induced by anti-IgE.54  
Other examples of sterols with unconventional nuclei are theonellasterone and  
bistheonellasterone, isolated from the Okinawan Theonella swinhoei; the last one 
represents a dimeric steroid, considered to be biosynthesized through a Diels-
Alder cycloaddition of theonellasterone and its ∆4-isomer. 
 
 
 
 
 
 
Another unusual structural features of these sterols are associated with their side 
chains. Sterol side chains have been isolated with such unusual features as 
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quaternary alkyl groups, cyclopropane and cyclopropene rings, allenes, and 
acetylenes (Figure 10). Biosynthetic studies have been performed on mechanism 
and scope of sterol side-chain dealkylation in sponges 55, and a detailed review 
has been published as a comprehensive summary of biosynthesis of sterol side-
chain in marine organisms. 56  
 
 
 
 
 
 
Finally, the discovery of the interesting properties of sulfated polyhydroxysterols 
has increased interest in these compounds. Most of these natural products are 
characterized by the 2β,3α,6α-tri-O-sulfate functions together with additional 
alkylation in the side chain. These steroids are of interest not only because of their 
structures but also because of their physiological activities, which include an anti-
human immunodeficiency virus (HIV) effect and a high inhibitory action on some 
enzymes. 
Halistanol sulfate, present in Halichondriidae sponges and characterized by the 
2β,3α,6α-trisulfoxy functionalities, is the 
first example of sulfated sterol isolated from 
Porifera, with a potent anti-HIV activity.57 
Successively, several new sulfate sterols 
have been reported. 
 
Figure 10. Examples of nonconventional side chains of sponge monohydroxysterols. 
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2.1.4 Cyclic peptides 
Cyclic peptides are an unusual class of compounds in which a carboxyl function is 
linked with an amine group to form a ring. They represent the most interesting 
class of secondary metabolites isolated from sponges.  
The unusual properties of cyclic peptides are due both to their circular structure 
and their unusual mode of biosynthesis, which frequently incorporates uncommon 
amino acids. For instance, they can contain D amino acids, β-hydroxyamino acids, 
and N-alkylated amino acids. As result,  the presence of non-ribosomial amino 
acids produces pronounced effects on the pharmacological activities of these 
metabolites. For example, N-alkylation and the lack of N and C termini enhance 
the hydrophobicity, thus determining a more facile crossing of biological 
membranes and an improved stability to enzymatic degradation. In addition N-
alkyl residues exhibit reduced preferences to form the trans conformation of the 
amide bond leading to biologically important β-turns structures. Cyclization 
reduces peptide conformational flexibility that results in a higher receptor affinity 
and often offers the possibility to determine their three dimensional structures. All 
these features make cyclopeptides promising lead compounds in drug discovery; 
thus these compounds are undergoing very active investigation as potential new 
sources of drugs and antibiotics. They are much more resistant to proteases than a 
linear peptide chain. This resistance to proteolysis means that they tend to survive 
the human digestive process. They can also bind proteins in the cell where 
traditional drugs cannot.  
Cyclic depsipeptides are cyclic peptides in which one or more of the peptide 
(amide) bonds are replaced by other bonds. Other functional groups, different 
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from the usual amino and carboxyl group, are linked together, closing the 
polypeptide chain, including ester, lactone, thioester bonds. 
The biosynthesis of natural cyclic peptides is interesting to biologists, since it 
frequently involves non-ribosomal peptide synthetases. Most peptides are made 
by bacteria. Some microorganisms have large enzyme complexes composed of 
modules that they use to assemble the cyclic peptides and they do not use 
ribosomes or mRNA.  
Nonribosomal peptide synthetases (NRPSs) and polyketide synthases (PKSs) are 
multi-enzymatic, multi-domain megasynthases involved in the biosynthesis of 
nonribosomal peptides and polyketides.58-60  
Nonribosomal peptides are biosynthesized by sequential condensation of amino 
acid monomers, whereas polyketides are made from repetitive addition of carbon 
ketide units derived from thioesters of acetate or other short carboxylic acids. 
NRPSs and modular PKSs are comprised of so-called modules, which are sets of 
distinct active sites for catalysing each condensation and chain elongation step 
(Figure 11). Each module in an NRPS or PKS consists of certain obligatory or 
core domains for addition of each peptide or ketide unit and a variable number of 
optional domains responsible for modification of the peptide/ketide backbone. 
The minimal core module in the case of an NRPS consists of an adenylation (A) 
domain for selection and activation of amino acid monomers, a condensation (C) 
domain for catalysing the formation of peptide bonds and a thiolation or peptidyl 
carrier protein (T or PCP) domain with a swinging phosphopantetheine group for 
transferring the monomers/growing chain to various catalytic sites. During the 
biosynthesis, the growing chain remains covalently attached to the enzyme and 
upon reaching its full length, a thioesterase (TE) domain catalyses the release of 
the NRPS and PKS products, 
The number of modules in such PKSs or NRPSs correlates directly with the 
number of chain elongation steps during biosynthesis, and the domains present in 
each module dictate the chemical moiety which the given module would add to a 
growing chain. 
 
 
 
 
 
 
 
 
 
 
The first bioactive peptide isolated from sponges is the discodermin A, obtained 
from Discodermia kiiensis
the ability to inhibit the tumor grown, induced by 
 
 
 
 
Figure 11. Biosynthetic gene cluster of CYM and proposed biosynthesis of cyclomarin A (1) 
and cyclomarzaine A (5).
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cyclic products. 
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Interesting examples of cyclodepsipeptides are the family of callipeltins, which 
show a potent antiviral activity. The first compounds of this family is callipeltin 
A, isolated in the 1996 from the sponge Callipelta sp.62-64 
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CHAPTER 3 
COSCINODERMA MATHEWSI 
 
In the course of a project directed to the chemical investigation and evaluation of 
the marine invertebrates of South Pacific (C.R.I.S.P., Coral Reef Initiative Sud 
Pacific), I had the opportunity to study various marine sponges, analyzing their 
chemical composition and biological activities of the secondary metabolites.  
In the frame of this project, I had the opportunity to 
examine a specimen of Coscinoderma mathewsi, 
collected along the coasts of Solomon Island.  
The sponge Coscinoderma mathewsi Lendenfield 
belongs to the order of Dyctioceratida, family Spongiidae and has been a source 
of various terpenoid compounds,65-67 as have other members of this family.68-71 
Recently, many sulfated steroids were isolated from marine sponges of the 
Coscinoderma genus, often characterized by unusual biological effects.  
As examples halisulfates 172 and 773 were isolated from a Micronesia collection of 
the sponge. Halisulfate 7 is an inhibitor of the catalytic subunits of the mammalian 
Ser/Thr protein phosphatases calcineurin, PP-1, and PP-2A,74 whereas halisulfate 1 
is a potent isocitrate lyase inhibitor.75,76 
 
 
 
 
 
Coscinoderma mathewsi 
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Coscinosulfate, a sesquiterpene sulphate from the New Caledonian sponge 
Coscinoderma mathewsi, displays significant inhibitory activity towards CDC25A 
phosphatase. 77 
The tricyclic sesterterpene suvanine78,79 is a thrombin and trypsin inhibitor and 
shows moderate antimycobacterial activity. 80 
 
Investigation of the marine sponge Coscinoderma mathewsi led to the isolation of 
two novel nitrogen-containing cheilanthane sesterterpenoids, coscinolactams A and 
B, together with known suvanine.81 
 
Cheilanthanes represent a relatively new class of sesterterpenoids with the 
"triterpene-type" ring-closure. The name 
“cheilanthane” is derived from the name of the 
fern Cheilanthes farinose- the source of the first 
representative of this class of compounds, 
namely cheilanthatriol, isolated in 1971 by 
OSO3H
O
Suvanine
OSO3H
N
COOH
O
Coscinolactam A
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Indian researchers.82 Numerous cheilanthanic sesterterpenoids have been isolated 
later on from other plant sources, marine organisms and fossil sediments.  
Today, there are more than 50 known cheilanthanes. The interest in these 
compounds is first of all due to their strong biological activity. This aspect has 
also inspired synthetic chemists to develop several synthetic routes to 
cheilanthane sesterterpenoids. 
 
3.1 ISOLATION OF COSCINOLACTAMS A AND B  
Samples of Coscinoderma mathewsi Lendenfield (order Dictyoceratida, family 
Spongiidae) were collected on the barrier reef of Vangunu Island (Solomon 
Islands), immediately frozen and lyophilized. The crude ethanolic extract exhibited 
an anti-PLA2 activity (72% inhibition at 400 µg/mL).  
The specimens of lyophilized sponge were extracted three times with methanol at 
room temperature. The combined extracts were fractionated according to the 
Kupchan partitioning procedure, obtaining four extacts.2  
The bioactive chloroform extract was purified by DCCC (CHCl3:MeOH:H2O 
ascending mode), followed by reverse-phase HPLC (MeOH aqueous 65%) to give 
suvanine (3). 
The more polar coscinolactams A (1) and B (2) were obtained from the butanol 
extract chromatographed by DCCC (CHCl3:MeOH:H2O ascending mode) and 
reverse-phase HPLC (MeOH acqueous 45%).  
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3.2 STRUCTURE DETERMINATION OF COSCINOLACTAM A 
 
 
 
 
 
The molecular formula of coscinolactam A (1) was determined to be C27H41NO7S 
by HR-ESIMS (m/z 522.2547 [M – H]-). The gross structure was deduced from 
detailed analysis of the 1H and 13C NMR spectroscopic data (Table 2), aided by 2D 
NMR experiments (1H-1H COSY, TOCSY, HSQC and HMBC). 
The NMR spectroscopic data showed the signals for two acyl carbons at δC 176.3 
and 173.7, two trisubstituted double bonds [δC 125.2 (s), 140.5(s), 133.9 (d), 137.8 
(d); δH 6.89 (1H, s) and 6.36 (1H, s)], and two diasterotopic methylenes linked to a 
nitrogen atom [δH 4.00 (1H, d, J = 15.9 Hz)-4.12 (1H, d, J = 15.9 Hz), δC 52.8 and 
δH 3.89 (1H, d, J = 16.9 Hz)-4.15 (1H, d, J = 16.9 Hz), δC 46.8]. The remaining 
signals are at higher field and correspond to four methyls on quaternary carbons, 
nine methylenes, three methines and three quaternary carbons. Comparison with 
the NMR spectroscopic data of suvanine clearly indicated that coscinolactam A 
possesses the same tricyclic spongiane-like framework of suvanine. The enol 
sulphate functionality at C-13, characteristic of suvanine, was also present, as 
evidenced by 13C NMR spectroscopic data and by the presence of the diagnostic 
1H NMR signal at δH 6.36 relative to H-24.  
COSY and HMBC data revealed the linkage of the C-14 to the methylene at C-15 
(δH 1.47, 1.91, δC 23.6) and the allylic methylene C-16 (δH 2.22, 2.51, δC 25.9). 
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HMBC correlations of H-18 to C-17 (δC 140.5), C-19 (δC 52.8) and C-25 (δC 
173.7) and the chemical shift of C-19 (δC 52.8) revealed the presence of an α,β-
unsaturated γ-lactam ring. The linkage between C-16 and C-17 was inferred by key 
HMBC correlation H-18 to C-16, and H2-16 to C-25. The remaining set of 
resonances, a methylene (δH 3.89 and 4.15, δC 46.8) and an acyl carbonyl (δC 
176.3) was easily assigned to a glycine residue (C-1’ to C2’). The linkage of this 
latter unit to N-25 was evidenced by HMBC correlations H2-1’ to C-19 and C-25 
(Figure 12).  
 
 
 
 
 
The relative stereochemistry of the tricyclic system was determined by NOESY 
correlations. In particular, intense NOESY cross-peaks between CH3-22 and CH3-
21, H-12 and H-14 suggested a tricyclic system with a AB trans, BC cis 
stereochemistry (Figure 13). The stereochemistry of the exocyclic double bond was 
established as E on the basis of the observed NOE contact between H-24 (δH 6.36) 
and one of the protons belonging to diasterotopic methylene at C-15 (δH 1.47). The 
good match with the 1H and 13C NMR resonances of coscinolactam A with the 
corresponding resonances of the tricyclic portion of suvanine indirectly confirmed 
the proposed structure.  
 
Figure 12. Key HMBC cross peaks detected for coscinolactam A. 
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3.3 STRUCTURAL DETERMINATION OF COSCINOLACTAM B 
 
 
 
 
 
The mass spectrum of coscinolactam B (2) showed the same ion peak of 
coscinolactam A (m/z 522.2509 [M–H]-), suggesting that coscinolactam B was 
isomeric with coscinolactam A. Also 1H and 13C NMR spectra of coscinolactam B 
were very similar to those of coscinolactam A except for the signals relative to the 
α,β-unsaturated γ-lactam ring.  
In particular the upfield shift of the olefinic proton (δH 5.85 in coscinolactam B vs. 
6.89 in coscinolactam A) and the downfield shift of the γ-carbon (δC 56.3 in 
coscinolactam B vs. 52.8 in coscinolactam A) suggested the presence of a β-
substituted α,β-unsaturated γ-lactam ring. The linkage of the β-carbon of the 
lactam ring to C-16 was also confirmed by the diagnostic HMBC correlation 
between H2-16 and C-25 (Figure 14). 
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Figure 13. NOESY correlation of coscinolactam A. 
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Whereas lactam systems are quite unusual in natural products, a similar system 
consisting of a aminoacyl-derived unit fused with a terpenoid system was found in 
echinophyllins A and D clerodane diterpenoids from the brazilian medicinal plant 
Echinodorus macrophyllus.83,84 1H and 13C NMR spectroscopic data of 
coscinolactams A and B match very well with those of echinophyllins A and D 
relative to the isomeric γ-lactam ring subunits. A glycine-derived lactam system 
was found in spongolactam C, a diterpene derivative isolated from the Okinawan 
marine sponge Spongia sp.85 
Biogenetically the isomeric coscinolactams A and B may be derived from 
suvanine, through oxidation to isomeric γ-hydroxybutenolide derivatives, 
condensation with glycine and reduction to γ-lactam which has been chemically 
explored in the semisynthesis of spongolactam C from the corresponding 
furanoterpene (Scheme 4).85  
 
 
 
 
 
Figure 14. Key HMBC cross peaks detected for coscinolactm B. 
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3.4 PHARMACOLOGICAL ACTIVITY 
To investigate the role of the sulphate group on the pharmacological profile of 
these natural compounds, major suvanine was subjected to hydrolytic and 
reductive transformations, obtaining two semisynthetic derivates depicted in 
Scheme 5.  
Suvanine was desulfated with pyridine and dioxane, obtaining the aldehyde 
derivate (4); this one was reduced with NaBH4 to give the alcohol derivate (5).  
 
 
 
 
 
 
Scheme 5. a) dioxane-pyridine, 180 °C; b) NaBH4, MeOH, r.t. 
Scheme 4. Biogenesis of coscinlactams A and B.  
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Il coscinolactam A, suvanine and the derivatives  4 and 5 were tested against four 
different secretory PLA2 belonging to groups IA, IB, IIB and III) (Table 3). 
LY311727, a well known inhibitor of group IIA sPLA2, was used as a reference 
tool.86 Despite the good activity previously exhibited by the crude extract, only 
suvanine showed a moderate activity against human synovial sPLA2-IIA and bee 
venom sPLA2-III. In addition, all compounds were devoid of significant cytotoxic 
effects on RAW 264.7 at concentrations up to 10 mM, as assessed by the 
mitochondrial-dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to formazan (data not shown). Their ability 
to inhibit PGE2 and NO production on RAW 264.7 cells stimulated with LPS was 
also investigated (Table 4). Interestingly, the suvanine aldehyde derivative 4 
showed an improved capability to inhibit NO production and to a lesser extent 
PGE2, whereas the suvanine alcoholic derivative 5 was proved to be almost 
inactive in all experiments. Compound 4 inhibited dose-dependently the 
production of NO, showing an IC50 value of 7.3-2.3 mM. The NO reduction was 
the consequence of the inhibition of the expression of inducible NO synthase 
(Figure 14), exactly as the dexamethasone control drug did. This suvanine 
aldehyde derivative 4, which can mainly reduce NO and PGE2 production by 
affecting the expression of the inducible NO synthase enzyme, could be an 
interesting strategy to obtain promising anti-inflammatory agents. 
 
 
 
 
 
Figure 14. Effect of compound 4 on iNOS expression in LPS-stimulated RAW264.7 cells.  
The figure is representative of two similar experiments. B: normal cells. C: LPS-stimulated cells. 
Dx= Dexamethasone 
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Coscinolactam A (1) Coscinolactam B (2) 
  δHa δC HMBC δHa δC HMBC 
1 1.86 ovl, 0.87 dd 
(14.0, 7.4) 
43. 2  1.86 ovl, 0.87 43. 1  
2 1.63 ovl, 1.40 
ovl 
19.7  1.62 ovl, 1.40 
ovl 
19. 6  
3 1.40 ovl, 1.16 m 43.0  1.40 ovl, 1.16 
m 
43.0  
4 - 34. 3  - 34.0  
5 1.06 dd (9.0, 4.4) 54. 2 C1, C4, C6,  C10, 
C21,  
1.08 dd (11.2, 
4.6) 
54.1 C1, C4, C6, C21 
6 1.54 m, 1.33 ovl 19. 3  1.60 ovl, 1.34 
ovl 
19. 3  
7 1.90 ovl, 1.33 
ovl 
36. 3 C5, C6, C8, C9, 
C23 
1.90 ovl, 1.37 
ovl 
36. 1  
8 - 39. 9  - 39. 7  
9 0.91 t (7.6) 58. 6 C1, C8, C11, C12, 
C22, C23,  
0.92 t (6.0) 58. 3 C1, C8, C11, C12, 
C22, C23 
10 - 40. 2  - 40. 1  
11 1.70 m, 1.61 ovl 20. 9  1.71 m, 1.62 
ovl 
20. 9  
12 2.60 dt (15.9, 
6.1), 2.18 m 
25. 4 C9, C11, C13, C14, 
C24 
2.59 m, 2.18 dt 
(16.2, 8.5)  
25. 2 C9, C11, C13, 
C14, C24 
13 - 125. 2  - 124. 9  
14 2.35 d (10.4) 43. 9 C8, C13, C15, C16, 
C24, C23,  
2.33 d (10.4) 43. 9 C8, C13, C15, 
C16, C23, C24 
15 1.91 ovl, 1.47 m 23. 6  1.89 ovl, 1.57 
ovl 
23. 7  
16 2.51 m, 2.22 m 25. 9 C14, C15, C17, 
C18, C25 
2.62 m, 2.36 dt 
(16.1, 8.1) 
29. 1 C14, C15, C17, 
C18, C25 
17 - 140. 5  - 164. 2  
18 6.89 s 137.8 C16, C17, C19, 
C25 
5.85 s 121. 3 C16, C17, C19, 
C25 
19 4.12 d (15.9), 
4.00 d (15.9) 
52. 8 C17, C18 - 174.0  
20 0.86 s 33. 7 C3, C4, C5, C21 0.87 s 33. 8 C3, C4, C5, C21 
21 0.89 s 22. 2 C3, C4, C5, C20 0.89 s 22.1 C3, C4, C5, C20 
22 1.05 s 18. 5 C1, C5, C9, C10 1.05 s 18. 5 C1, C5, C9, C10 
23 0.84 s 26. 5 C7, C8, C9, C14 0.86 s 26. 5 C7, C8, C9, C14 
24 6.36 s 133. 9 C12, C13, C14 6.27 s 133. 3 C12, C13, C14 
25 - 173. 7  4.18 d (16.8) 56.3 C17, C18, C19,  
1’  4.15 d (16.9), 
3.89 d (16.9) 
46. 8 C19, C25, C2’ 3.82 d (17.1) 39.5 C19, C25 
2’  - 176.03.00   - n.o   
 
 
 
Table 2. 1H and 13C NMR spectroscopic data (700 MHz, CD3OD) for coscinolactams A and B. 
Ovl: overlapped. 
a Coupling constants are in parentheses and given in hertz. 1H and 13C assignments aided by 
COSY, TOCSY, HSQC and HMBC experiments. 
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Compound GroupIIA-sPLA2 GroupIA-sPLA2 GroupIB-sPLA2 GroupIII-sPLA2 
(10 µM) % I % I % I % I 
1 6.7 ± 1.6 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
3 32.8 ± 1.3** 0.0 ± 0.0 0.0 ± 0.0 29.4 ± 3.0** 
4 10.6 ± 5.3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
5 7.6 ± 4.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
LY311727 96.3 ± 1.7** 7.9 ± 5.6 36.9 ± 11.0** 2.4 ± 1.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  PGE2 NO 
Compound % Inhibition % Inhibition 
(10 µM)   
1 48.5 ± 3.0** 31.8 ± 4.0** 
3 41.6 ± 4.6** 21.0 ± 5.7 
4 49.2 ± 4.1** 60.0 ± 8.1** 
5 14.9 ± 2.1** 31.9 ± 2.8** 
Dexamethasone 78.7 ± 5.4** 96.6 ± 1.4** 
1 µM     
Table 4. Inhibitory activity of compounds 1 and 3–5 at 10 µM on the production of PGE2 and 
NO in LPS-stimulated RAW 264.7 cells 
Table 3. Inhibitory activity (% I) of compounds 1, 3-5 at 10 µM on different sPLA2 belonging to the 
groups IIA, IA (Naja naja venom), IB (porcine pancreatic enzyme), and III (bee venom enzyme). 
Results show mean_S.E.M. (n=6). Statistical significances: **p<0.01, with respect to the corresponding 
enzyme control group (IIA sPLA2=12,129±384 cpm; IA sPLA2=10,973±350 cpm; IB sPLA2¼8008_47 cpm; 
III sPLA2¼14,854_1054 cpm). Enzyme control group contains the vehicle (ethanol 1%). LY311727 used as 
control. 
Results show mean_SEM (n=6). Statistical significances: **p<0.01, with respect to the LPS-stimulated 
control group (contains the vehicle ethanol 1%). PGE2 (non stimulated cells=0.6±0.2 ng/mL; LPS-
stimulated cells=16.0±1.6 ng/mL). Nitrite (non-stimulated cells=48.8±3.6 ng/mL; LPS-stimulated 
cells=414.1±16.4 ng/mL). Dexamethasone used as control. 
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CHAPTER 4 
THEONELLA SWINHOEI 
 
Sponges of the order Lithistida are an evolutionary ancient 
lineage that is typically found in deeper waters and caves 
of tropical oceans. Lithistid sponges have a structurally 
massive, rigid or “rock-like” morphology. This 
polyphyletic order is grouped together because their skeletons consist of fused or 
interlocked spicules, colled desmas.  
Over half of the compounds reported for litisthid sponges were isolated from 
Theonella (family Theonellidae). Theonella species have been reported to contain 
a wide variety of diverse secondary metabolites with intriguing structures and 
promising biological activities, which have been calculated to represent more than 
nine biosynthetic classes.87 In particular, Theonella swinhoei represents one of the 
most prolific source of innovative and bioactive metabolites, which include 
complex polyketides as swinholide A and misakinolide A,37,38 that had shown a 
potent cytotoxic activity, disrupting the actine cytoskeleton; tetramic acid 
glycosides as antifungal aurantosides,88 innumerable sterols (theonellasterols, 
swinhosterols).89,90 Hovewer, among bioactive metabolites found from worldwide 
collections of Theonella swinhoei, surely the peptides represent the most 
significant group. The diverse array of Theonella derived peptides range from 
acyclic peptides such as polytheonamides,91-94 koshikamides A1 and A2;95,96 
cyclic peptides, exemplified by cyclotheonamides,97,98 kombamide,99 
orbiculamide,100 keramamides,101-105 cupolamide,106 oriamide;107 large-ring 
Theonella swinhoei 
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bicyclic peptides, such as theonellamides108; depsipetides headed by 
theonellapeptolides,109-111 koshikamides A and B,112,113 nagahamide;114 and 
glycopeptides.115,116 As for other peptides of marine origin, the most striking 
feature of these metabolites is the preponderance of non-ribosomial amino acids, 
including the D configured, N-methylated and alkylated.  
The exceptional chemical diversity found in the metabolites of Theonella sponges 
may in part be due to the biosynthetic capacity of bacteria that they host.117 This 
hypothesis has been convincingly supported in the case of swinholide A, 
omnamides and theopederins. In 2005, Gerwich118 reported the direct isolation of 
swinholide A and related derivatives from two different cyanobacteria, thus 
unequivocally demonstrating that marine cyanobacteria possess the metabolic 
capacity to produce this skeletal class. As concerning omnamides and 
theopederins, from the highly complex metagenome of Theonella swinhoei, was 
identified a prokaryotic gene cluster,119 likely responsible for the biosynthesis of 
these two metabolites. 120,121 
In the course of a search for novel metabolites from marine sponges belonging to 
Lithistida order, I had the opportunity to study the sponge Theonella swinhoei. 
The analysis of this sponge afforded to the isolation of new compounds, 
belonging to different chemical classes. The variety of compounds isolated 
reaffirms the biological richness of Theonella swinhoei, that may be considered a 
cornucopia of metabolites. 
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4.1 ISOLATION AND PURIFICATION 
A specimen of sponge Theonella swinhoei was collected on the barrier reef of 
Vangunu Island, Solomon Islands, in July 2004. 
The samples were frozen immediately after collection and lyophilized to yield 207 
g of dry mass. Taxonomic identification was performed by Prof. John Hooper of 
Queensland Museum, Brisbane, Australia, and reference specimens are on file 
(R3170) at the ORSTOM Centre of Noumea. 
The lyophilized material was extracted with methanol; and the crude methanolic 
extract was subjected to a modified Kupchan's partitioning procedure (Scheme 6).2 
The study of the polar extracts afforded the isolation of two new sulphated sterols, 
solomonsterols A and B, the first example of C-24 and C-23 sulfated sterols from 
a marine source endowed with a PXR agonistic activity; nine peptides named 
perthamides C-K, endowed with a potent anti-inflammatory and 
immunosuppressive activities; other two minor peptides, solomonamides A and B 
with an interesting anti-inflammatory activity and an unprecedented skeleton.  
The chloroform extract gave the cytotoxic macrolide swinholide A together with a 
minor new structural analogue. 
 
 
 
 
 
 
 
Scheme 6. Modified Kupchan’s partitioning methodology applied to the sponge Theonella swinhoei. 
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4.2 SOLOMONSTEROLS 
The purification of the most polar fractions of n-BuOH extract of the sponge 
afforded two new sulfated sterols with a 5-α-cholane and 24-nor-5-α-cholane 
skeleton, named solomonsterols A and B.  
Sulfated steroids are a family of secondary metabolites often found in sponges and 
echinoderms. Since the isolation of halistanol from Halichondriidae sponges,57 
several sulfated polyhydroxysterols have been isolated from sponges. Most of 
them are characterized by the 2β,3α,6α-tri-O-sulfate functions with different 
pattern of alkylation in the side chain, whereas some show unprecedented 
structural features.  
Recent examples are pregnane ptilosterols from Ptilocaulis spiculifer,122 
geodisterol sulfate123 and iodinated and chlorinated topsentiasterol sulfates124 from 
the sponge Topsentia, eurysterols125 from an unclassificated sponge of the genus 
Euryspongia. Steroidal sulphates are of interest not only due to their structures, 
but also because they often exhibited a variety of biological activities including 
anti-viral,126,127 antifungal,128 antifouling,129 and action on specific enzymatic 
targets.130-133 
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4.2.1 Solomonsterol A  
 
 
 
 
Solomonsterol A (6) was isolated as a colourless amorphous solid. The 1H NMR 
spectrum showed signals typical of a sterol: two upfield Me singlets at δH 0.69 
and δH 1.00 and one methyl doublet at δH 0.95 (J = 6.5 Hz). The negative ion HR 
ESIMS spectrum gave a predominant pseudomolecular ion at m/z 661.1415 [M-
Na+]- corresponding to a molecular formula of C24H39Na3O12S3. The ESI and 
MS/MS spectra showed pseudomolecular and fragment ions compatible with the 
presence of sulfate groups: 617 (M- in hydrogen form), 308.3 (double charged 
species), 559 [M - NaSO3]-, 541 [M -NaHSO4 - Na+]-, 439 [M - 2NaHSO4 - Na+]-. 
1H and 13C NMR spectra, together with mass data, evidenced the presence in the 
molecule of two secondary (δH 4.74, q, J = 2.9 Hz, δC 76.1, CH; δH 4.70, q, J = 
2.9 Hz, δC 75.8, CH) and one primary sulfoxy groups (δH 3.96, t, J = 6.6 Hz, δC 
69.3, CH2). The location of two secondary sulfoxy groups at C2 and C3 of the 
steroidal nucleus was determined by interpretation of 1H NMR, COSY, HSQC, 
and HMBC spectra (Figure 15). In fact, following the spin system -CH2-CH(O-)-
CH(O-)-CH2 the two solfoxy group had to be on C2 and C3. 
 
 
 
 Figure 15. Key skeletal connectivities for solomonsterol A (1), as deduced from COSY and 
HMBC spectra. 
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The 2β,3α-disulfoxy configuration was assigned on the basis of the coupling 
pattern of H-2 (q) and H-3 (q). Both signals were observed as “sharp” quartet with 
a  J= 2.0 Hz, suggesting the absence of any axial coupling costants (J= 10-15 Hz); 
therefore the H-2 and H-3 were equatorial, and because the rigidity of the 
steroidal skeleton, the two solfoxy group are axial, 2α,3β . 
The tetracyclic steroidal skeleton was considered to adopt an all-trans 
arrangement as evidenced by ROESY analysis (Figure 16). The ROESY 
correlations observed from H3-19 and H3-18 to H-8 and H-11β, from H-5 to H-9 
and from H-9 to H-14 indicated the relative configuration for each ring junction to 
be trans. The constitution and configuration of steroidal nucleus was also 
supported by 1H and 13C NMR data in agreement with those of all-trans 2β,3α-
disulfoxy steroids reported from sponges134 and ophiuroids.135  
 
 
 
 
 
 
The COSY spectrum revealed useful information concerning the side chain. 
Starting from the methine proton at δH 1.13 (H-17), COSY correlations could be 
observed to the methine proton at δH 1.43 (H-20), which in turn was coupled to 
both of the methyl protons at δH 0.95 (H3-21) and the methylene protons at δH 
1.10-1.54 (H2-22). These latter protons were coupled to the methylene protons at 
δH 1.55-1.75 (H2-23), which in turn were coupled to the methylene protons at δH 
3.96 (H2-24), suggesting a 24-sulfoxy-C24 side chain. 
Figure16.  ROE correlations supporting the relative configuration of solomonsterol A. 
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Hence, the new sulfated steroid, solomonsterol A, was established as 5α-cholan-
2β,3α,24-tryl-2,3,24-sodium sulphate. 
4.2.2 Solomonsterol B  
 
 
 
The molecular formula of the solomosterol B was established as C23H37Na3O12S3 
through NMR (Table 5) and HR ESIMS data. The analysis of ESIMS, 1H and 13C 
NMR data suggested a close analogy between solomonsterols A and B. In 
particular, the resonances relative to the steroid nucleus of solomonsterol B (7) 
were almost superimposable to those of solomonsterol A, indicating a common 
2β-3α disulfoxy substitution.  
A shortened side chain, also suggested by MS data, was easily determined by the 
interpretation of 2D NMR spectra. Two downfield signals relative to a 
diasterotopic carbinol methylene, at δH 4.00 and 4.05 observed in the 1H NMR 
spectrum were assigned to H2-23 on the basis of key HMBC correlations H2-
23/C20, H2-22/C23 and H2-22/C20 (Figure 17). Therefore the structure of new 
steroid sulfate solomonsterol B was defined as 24-nor-5α-cholan-2β,3α,24-tryl-
2,3,23-sodium sulfate. 
 
 
 
 
OSO3Na
NaO3SO
NaO3SO H
7
Figure 17. Key HMBC correlations of solomonsterol B. 
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The tetracyclic steroidal skeleton was considered to adopt an all-trans 
arrangement as evidenced by ROESY analysis, similarly to solomonsterol A. 
Few examples of steroidal derivatives with a truncated side chain have been so far 
reported from marine organisms. They include pregnane derivatives isolated from 
octocorals,136-139 and sponges;140-143 androstanes from a Cliona sponge,144 and 
ergostane geodisterol, again from a sponge.145 Whereas bile acid derivatives have 
been isolated from a bacterium associated to a sponge,146 in the literature the 
occurrence of C23 and C22 steroids is limited to 3β-hydroxy-24-norchol-5-en-23-
oic acid, isolated from Euryspongia n. sp.147 and to 23,24-dinor-5α-cholane from 
an Haliclona sponge.140  
4.2.3 Pharmcological activity 
Because there is evidence that sponge-derived steroids could be antiinflammatory 
and several compounds derived from exploitation of marine sponge chemistry are 
used to treat a variety of human diseases ranging from inflammation to cancer,148 
we have investigated whether solomonsterols A and B exert any effect on cells of 
innate immunity, the first line and the most ancient line of defence of mammalians 
against bacteria and viruses.149 For this purposes RAW264.7 cells, a murine 
macrophage cell line, were used. In these experiments, cells were incubated with 
solomonsterols A and B at the concentration of 10 and 50 ?M and expression of 
mRNA encoding for pro-inflammatory mediators measured by Real-Time (RT) 
polymerase chain reaction (PCR). As illustrated in Figure 18, solomonsterols A 
and B effectively inhibited induction of the expression of interleukin-(IL)-1β 
mRNA induced by challenging RAW264.7 cells with lipopolysaccharide (LPS) a 
tool like receptor (TLR)-4 ligand. At the concentration of 50 µM both compounds 
reduced the expression of IL-1β mRNA by 50% (Figure 18, panel A; N=4; P<0.05 
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versus LPS alone). In contrast with their effect on IL-1β, both compounds exerted 
no effect on expression of TNFα (tumor necrosis factor) mRNA (Figure 18, panel 
B). 
At the end of the experiment cell viability was valued using the trypan blue (a 
diazo dye used to selectively colour dead tissues or cells blue). In fact both 
compounds had no effect on cell viability measured by the trypan blue excluding 
test (viability was greater than 95%) excluding that inhibition of IL-1β production 
was due to a cytotoxic effect.  
 
 
The pharmacological screening demonstrated that both solomonsterols A and B 
are endowed with an immunomodulatory potential. Because IL-1β is a key 
cytokine and high in the hierarchy that drives innate immune response, these 
results highlight the potential for the use of solomonsterols in clinical conditions 
characterized by a dysregulation of innate immunity. 
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Figure 18. Relative mRNA expression of IL-1β and TNFα in RAW264.7 macrophages treated 
with LPS alone or with LPS in combination with 1 and 2. 
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4.2.4 PXR agonism 
In the search for a molecular target(s) and to 
identify the mechanism of action of solomonsterols 
A and B we speculated on the possibility that they 
could be potential ligands for nuclear receptors. The 
results of these studies demonstrated that while solomonsterols A and B do not 
activate the farnesoid-X-receptor (FXR, data not shown), both agents were 
effective ligands for PXR, an evolutionary conserved nuclear receptor. 
PXR (pregnane-X-receptor), also known as NR1I2 (nuclear receptor subfamily 1, 
group I, member 2), is a master gene orchestrating the expression of a wide family 
of genes involved in uptake, metabolism and disposal of a number of endo- and 
xeno-biotics, including drugs, bile acids, steroid hormones and metabolic 
intermediates in mammalian cells.149 Following ligand binding, PXR forms an 
heterodimer with the retinoid-X-receptor (RXR) that binds to specific PXR 
response elements (PXREs), located in the 5′-flanking regions of PXR target 
genes, resulting in their transcriptional activation.150 -152   
PXR is mainly associated with the cellular response to xenobiotics, including 
induction of enzymes involved in drug oxidation and conjugation, as well as 
induction of xenobiotic and endobiotic transporters. These include the phase I 
enzymes such as cytochrome P450, CYP2B6, CYP2B9, CYP2C8, CYP2C9, 
CYP3A4 and CYP3A7, the phase II enzymes such as the glutathione-S-
transferases (GSTs), UDP-glucuronosyltransferases (UGTs) and sulfotransferases 
(SULTs); and the transporters, such as multidrug resistance protein 1 (MDR1), 
MDR2, multidrug resistance-associated protein 2 (MRP2) and the organic anion 
transporter polypeptide 2 (OATP2).151  Rifaximin, a non absorbable antibiotic, is a 
Pregnane-X-receptor 
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human PXR agonist and has been known as an immunosuppressant modulating 
humoral and cellular immunological responses, and its immunosuppressive role 
has also been well-documented in humans.152  
A transactivation experiment was performed in HepG2 cells, a human 
hepatocarcinoma cell line. To investigate their PXR-activating properties, 
solomonsterols A and B were tested in a cell based luciferase assay. Since PXR 
functions as an heterodimer with the retinoid-X-receptor (RXR), HepG2 cells 
were transfected with a PXR and RXR expressing vectors (pSG5-PXR and pSG5-
RXR), with a reporter vector containing the PXR target gene promoter (CYP3A4 
gene promoter) cloned upstream of the luciferase gene (pCYP3A4promoter-
TKLuc) and with a β-galactosidase expressing vector as internal control of 
transfection efficiency (pCMV-β-gal). 24 hours post transfection the cells were 
stimulated 18 hours with the PXR ligand rifaximin 10 ?M (as positive internal 
control) and with 50 ?M of solomonsterols A and B. 5 ?L of cell lysate was 
incubated with a substrate of luciferase gene (luciferase assay substrate - 
Promega) and the Relative Luciferase Units (RLU) were measured with the 
Glomax 20/20 luminometer (Promega). Luciferase activities were normalized for 
transfection efficiencies by dividing the relative light units by β-galactosidase 
activity expressed from cotransfected pCMV-βgal plasmid (RLU/β-gal). 
As illustrated in Figure 19, both compounds were potent inducers of PXR 
transactivation boosting the receptor activity by 4-5 folds (n=4; P<0.05 versus 
untreated) and were at least as potent of rifaximin. In addition both agents 
effectively stimulated the expression of two PXR target genes, CYP3A4 and 
MDR1 in the same cell line (figure 19 B and C; n=4; P< 0.05).    
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These data indicate that solomonsterols A and B exert immune-modulatory 
activity and are ligands for the human PXR.  
Recent studies have shown that activation of PXR ameliorates inflammation in 
rodent models of inflammatory bowel disease via inhibition of the expression of 
NF-kB target gene and a recent report identified PXR as a gene strongly 
associated with the susceptibility to inflammatory bowel diseases in humans, 
highlighting a possible role of solomonsterols in counter-regulating dysregulated 
immunity in human diseases.153 
 
 
 
 
 
 
 
4.2.5 Docking studies 
 To have details for what concerns the binding mode of solomonsterols A and B to 
PXR at atomic level, molecular docking studies were performed on 1 with PXR 
using Autodock Vina 1.0.3 software.154 The docking results positioned 
solomonsterol A within the PXR binding pocket, and among the 9 docked 
conformations generated, the lowest binding energy displayed an affinity of -10.0 
Kcal/mol (Figure 20). In this model, the steroidal nucleus shows hydrophobic 
interactions with LEU206, LEU209, VAL211, ILE236, LEU239, LEU240, 
MET243, MET246, confirming the binding mode already reported for a set of 
analogous compounds.155 Moreover, the sulfate groups exert hydrogen bonds with 
Figure 19. Panel A. Transactivation of PXR by compounds 1 and 2 in HepG2 cells. Panel B and 
C. Compounds 1 and 2 effectively increased the expression of CYP3A4 and MDR1, two PXR 
regulated genes in HepG2 cells. Expression of target genes was measured by RT-PCR. 
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SER247 (3-O-sulfate), HIS407 (2-Osulfate), and LYS210 (24-O-sulfate, also 
protruding toward the solvent), providing the complex with an increased predicted 
stability fully compatible with the experimental biological assays. 
 
 
 
 
 
 
 
 
 
 
In conclusion, solomonsterols A and B are a novel class of PXR agonsts, isolated 
from Theonella swinhoei; such compounds could be potentially used for the 
treatment of human disorders characterized by dysregulation of innate immunity 
and with inflammation, and, in light of our molecular modelling results, they can 
inspire the synthesis of new compounds able to target PXR. Furthermore the 
discovery of solomonsterols provides insight into the mechanism of ligand 
recognition by PXR and reaffirms the utility of examining natural product 
libraries for identifying novel receptor ligands. 
 
 
 
Figure 20. Docked model of solomonterol A bound to PXR model (pdb code: 1M13, displayed as 
purple ribbon); solomonsterol A is displayed as sticks coloured by atom type, while HIS407, 
SER247, and LYS210 are depicted as atom type coloured CPK models. 
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    solomonsterol A (1)   solomonsterol B (2) 
position  δc, mult. δH (J in Hz)  δC, mult. δH (J in Hz) 
1α  38.8, CH2 1.40, ovl  38.8, CH2 1.40, ovl 
1β   2.10 br, dd (14.4, 2.9)   2.10, br dd (14.4, 2.9) 
2  76.1, CH 4.74, q (2.9)  76.0, CH 4.73, q (2.9) 
3  75.8, CH 4.70, q (2.9)  75.7, CH 4.70, q (2.9) 
4α  30.1, CH2 1.63, ovl  30.1, CH2 1.63, ovl 
4β   1.81, dt (13.0, 2.9)   1.80,dt (14.1, 2.9) 
5  39.9, CH 1.60, ovl  39.9, CH 1.60, ovl 
6α  28.8, CH2 1.27, m  28.9, CH2 1.25, m 
6β   1.29, m   1.29, ovl 
7α  32.9, CH2 1.68, m  32.9, CH2 1.68, m 
7β   0.95, m   0.94, m 
8  36.3, CH 1.44, ovl  35.9, CH 1.42, ovl 
9  56.2, CH 0.71, m  56.1, CH 0.72, m 
10  36.3, C -  36.1, C - 
11α  21.7, CH2 1.53, ovl  21.9, CH2 1.53, m 
11β   1.33, ovl   1.33, ovl 
12α  41.1, CH2 1.15, m  41.2, CH2 1.15, m 
12β   2.00, dt (12.6, 2.9)   2.01, dt (12.6, 3.2) 
13  43.5, C -  43.7, C - 
14  57.5, CH 1.04, m  57.6, CH 1.04, m 
15α  24.9, CH2 1.59, ovl  24.9, CH2 1.60, ovl 
15β   1.07, m   1.07, m 
16α  28.9, CH2 1.87, m  28.8, CH2 1.88, ovl 
16β   1.30, ovl   1.31, ovl 
17  57.3, CH 1.13, m  57.6, CH 1.13, m 
18  12.2, CH3 0.69, s  12.2, CH3 0.70, s 
19  14.1, CH3 1.00, s  14.2, CH3 1.00, s 
20  36.6, CH 1.43, ovl  33.9, CH 1.59, ovl 
21  18.7, CH3 0.95, d (6.5)  18.9, CH3 0.98, d (6.5) 
22  32.8, CH2 1.10, m 1.54, ovl  36.2, CH2 1.29, ovl 1.87, ovl 
23  26.9, CH2 1.55, ovl 1.75, m  66.9, CH2 4.00, m 4.05, m 
24   69.3, CH2 3.96, t (6.6)       
 
 
Table 5. 1H and 13C NMR spectroscopic data (700 MHz, CD3OD) for solomonsterols A and B. 
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 4.3 THE FAMILY OF PERTHAMIDES 
Pursuing the study of the polar n-BuOH extract of Theonella swinhoei some new 
cyclic peptides were isolated. They are 8-residue cyclic peptides related to 
perthamide B, a cytotoxic peptide isolated from an Australian collection of a 
Theonella swinhoei sponge,156 which we named perthamides C-K. Their structures 
were determined using extensive 2D NMR, ESI-MS/MS experiments; and 
stereochemical determination of conventional and unusual amino acid units was 
based on an integrated approach which combined NMR methods, stereoselective 
synthesis, chemical degradation and LC/MS analysis.  
Perthamide C is the major component of  the buthanol extract of the sponge, 
isolated on gram scale (1.2 g).157 From a chemical point of view, it is 
characterized by a 25-membered structure with several non conventional amino 
acids. The other perthamides isolated from this sponge are correlated to 
perthamide C and differ in the amino acid residues.  
 4.3.1 Perhamide C  
 
 
 
 
 
 
The HR-ESIMS spectrum of perthamide C (8) showed a pseudomolecular ion 
peak at m/z 1066.4106 [M-H]-, corresponding to a molecular formula of 
C44H65N11O18S; when we run the mass spectrum in positive ion mode we 
observed that the pseudomolecular ion peak was absent and the major observed 
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ion peak at m/z 945.4652 [M + H]+ was due to the loss, in source, of both the 
sulphate and the carbamoyl groups. 
The 1H NMR spectrum in DMSO-d6  showed signals ascribable to exchangeable 
NH protons from δH 6.00 to 9.02, a signal corresponding to a methyl amide at δH 
2.71 (3H, s), suggesting a peptidic structure for perthamide C, confirmed by the 
presence of acyl carbons (δC 167.1-172.5) in the 13C NMR spectrum.  
Extensive analysis of the 1H and 13C NMR data of perthamide C, including 1H-1H 
COSY, HSQC, HMBC spectra (Table 6), by comparison with those of perthamide 
B, established the presence of the 2-amino-2-butenoic acid (dAbu), O-
methylthreonine (ThrOMe), and γ-methylproline (γMePro), along with one N-
methylglycine and one asparagine residue (figure 21).  
 
 
 
 
 
 
 
 
The 1H NMR spectra also suggested the presence of a o-substituted phenolic ring, 
a downfield pair of doublets at δH 7.16 (1H, d, J = 7.4 Hz) and 6.88 (1H, d, J = 7.8 
Hz) together with a downfield pair of triplets at δH 7.11 (1H, t, J = 7.8 Hz) and 
6.80 (1H, t, J = 7.4 Hz), that on the basis of HMBC data was assigned to an o-
tyrosine subunit. In particular diagnostic HMBC correlations are from the α-
amino acyl proton at δH 4.12 (H-2o-Tyr) to the carbon resonances at δC 170.6 (C-1 
Figure 21. N-MeGly, Asn, dAbu, ThrOMe, γ-MePro units in perthamide C. 
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o-Tyr) and 124.0 (C-1' o-Tyr), and from the β-methylene protons at δH 2.95 and 
2.86 (H2-3 o-Tyr) to the carbon resonances at δC 170.6, 124.0, 154.4 (C-2' o-Tyr), 
and 130.3 (C-6' o-Tyr), and from the exchangeable proton OH at δH 10.2 to the C-
2’ o-Tyr and C-1’ o-Tyr (Figure 22).  
o-Tyrosine is well known as product of the oxidation of phenylalanine residue in 
proteins and is reported to be an endogenous biomarker of oxidative damage.158,159 
To the best of our knowledge this residue is unprecedented in marine natural 
products. 
 
 
 
 
 
A spin system was identified as the unusual amino acid 
residue 3-amino-2-hydroxy-6-methylheptanoic acid 
(AHMHA) which is also unprecedented in natural 
peptides. The complete spin system was easily inferred 
from COSY and TOCSY data. An acyl group was 
placed at C1 on the basis of HMBC cross peak between 
the hydroxymethine proton at C2 (δH 4.14) with a 
carbonyl at δ 169.7 ppm (Figure 23). 
The remaining spin system corresponded to a modified β-hydroxyasparagine (β-
OHAsn) unit (Figure 24). However this residue bore a sole downfield NH-4 
proton at δH 8.90 (1H, s) that suggested substitution of the Nδ atom. Although no 
HMBC correlations were observed for this exchangeable proton; correlations with 
Figure 22. Key HMBC correlations of o-Tyr unit of pethamide C. 
Figure 23. AHMHA 
residue in pethamide C. 
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an unassigned pair of NH2 protons at δ 7.51 (1H, br s) and 7.31 (1H, br s) were 
observed in TOCSY and ROESY experiments. Together with the loss of 59 Da in 
the MS/MS spectrum, these data supported addition of a carbamoyl moiety160 
linked to the δ-amide of β-OHAsn. Finally sulfation of the β-hydroxyl group was 
apparent from the downfield chemical shifts of the hydroxymethine signal (δH 
4.59, δC 74.9). This appears to be the first example where a β-OHAsn residue is 
further modified by an Nδ-carbamoyl moiety and O-sulfation (Nδ-c-β-OSO3Asn). 
 
 
 
 
 
The complete cyclic amino acid sequence of perthamide C was secured from the 
inter-residue NOE NH/CHα and NCH3/CHα interactions and HMBC correlations 
acquired in DMSO-d6 (Figure 25). Particularly long-range correlations between 
NH/NCH3 protons to carbonyl carbons of adjacent amino acids allowed us to 
establish the following sequences: AHMHA-Asn-oTyr-γMePro-ThrOMe-Nδ-c-β-
OSO3Asn and NMeGly-dAbu. Moreover, connectivity of the Nδ-c-β-OSO3Asn 
unit to NMeGly residue was indicated from an ROESY correlation between 
exchangeable amidic proton NHβ of Nδ-c-β-OSO3Asn (δH 7.18) and one of the 
γMePro-δ-methylene protons (δH 4.23). The ROESY cross peak between the NH 
at δH 8.65 of dAbu unit with the hydroxymethine proton at δH 4.14 of AHMHA 
suggested the connectivity of the dAbu residue to β-amino-α-hydroxy-amino acid 
unit. 
Figure 24. Nδ-c-β-OSO3Asn unit in perthamide C. 
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This sequence was consistent with the fragmentation pattern obtained from ESI-
MS/MS experiments. In addition to the major ion peak at m/z 945.81 [M + H]+, 
the ESI Q-TOF MS/MS spectrum provided several fragment ion peaks. The 
detailed interpretation of the fragmentation pattern confirmed the sequence of 
amino acids. In the first instance, the pseudomolecular ion lossed the sulphate 
group and the carbamoyl moiety.  The major peaks corresponded also to C-
terminus fragments derived from a homogeneous ring opening between the 
dehydrated threonine (dAbu) and the N-methylglicine residue. 
In particular, the signal at m/z 744.55 corresponding to the loss of 201.26 uma 
from the major ion was indicative of the presence of N-methylglicine and β-
hydroxy aspartic acid residues. Subsequently, the loss of 114.99 amu from the 
pseudo ion was attributed to the lack of ThrOMe (m/z at 629.56) residue, and the 
further losses of 111.30 from pseudo ion and 163.07 uma from pseudo ion were 
indicative of the presence of γ-methylproline and o-tyrosine. 
Besides, several internal fragments have been detected; the peak at 275.21 uma 
has been attributed to the dipeptide unit γ-methylproline/o-tyrosine; the fragment 
at 389.30 uma was ascribed to the tripeptide γMePrO-o-Tyr-Asn and the peak at 
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Figure 25. Inter residue ROESY (red) and HMBC (blue) correlations of perthamide C. 
Cpethamide C. 
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546.51 to the previous tripeptide increased by AHMHA unit. Finally, the peak at 
629.88 uma supported the presence of the dAbu residue. 
At this point it was evident that the amino acid sequence of perthamide C was 
related to that perthamide B. These two peptides differed by three residues, where 
perthamide B contained m-bromotyrosine, β-hydroxyasparagine, and 3-amino-2-
hydroxy-6-methyloctanoic acid residues, versus perthamide C that contained o-
Tyr, Nδ-c-β-OSO3Asn, and AHMHA residues.  
Once the planar structure was established, the next step was the determination of 
the configurations of the chiral  centers, that were secured through an integrated 
multiparametric  approach which combined NMR analysis, chemical degradation, 
stereoselective synthesis and LC/MS analysis. 
The absolute stereochemistry of the sole ribosomial amino acid residue (Asn) was 
determined by complete acid hydrolysis of perthamide C and Marfey’s analysis, 
establishing the presence of L-Asn.  
The Marfey’s method was used also to determinate the absolute stereochemistry 
of ThrOMe residue. The two possible diastereoisomeric ThrOMe standards have 
been already prepared in our laboratory by etherification of suitable protected L-
Thr and L-alloThr.161 The Marfey’s analysis revealed the L-configuration for 
ThrOMe. 
A NOE between the NH (δ 8.65) and vinyl methyl (δ 1.54) signals established a Z 
geometry for the dAbu residue (Figure 26).  
 
 
 
 Figure 26. NOE correlation in dAbu unit. 
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The relative configuration of γ-methylproline was determined on the isolated 
amino acid residue obtained by acidic hydrolysis of the parent peptide followed 
by HPLC separation.  
Recently a stereoselective access to all stereoisomers of γ-methylproline residue 
has been published together with relevant physical data.162 The two 
diastereoisomers can be differentiated on the basis of 1H NMR data in CD3OD. 
Particular diagnostic are the chemical shifts of H-3 diasterotopic methylene 
protons observed at δH 2.52 and 1.64 in the cis isomer and at δH 1.94 and 2.25-
2.38 in the trans isomer, and the coupling constant pattern of one of the H-5 
protons observed as a broad triplet (δH 2.87, J 10.6) in the cis isomer and as 
double doublet (δH 2.83, J 11.5 and 8.6 Hz) in the trans isomer (Figure 27).  
 
 
The 1H NMR spectral data of γ-methylproline isolated from parent perthamide C 
are consistent with the cis stereochemistry (Figure 28).  
 
 
Figure 27. 1H NMR (500 MHz, D2O) spectra of the two diastomeric 4-methylproline 
hydrochloride standards by synthesis. 
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The absolute configuration of the 
application of the advanced 
stereoisomers of γ-methylproline has been prepared and characterized, and it was 
found that they follow the usual elution order, namely 
derivative is eluted from a C
Thus a small sample of perthamide C was hydrolysed and derivatised with both 
enantiomers of the Marfey’s reagent. By monitoring for FDAA
m/z 382, the 2S configuration was assigned, therefore we assign the 
L-proline stereostucture to this subunit.
The absolute configuration of the new 
transformation of the residue, isolated from the acidic hydrolysis of perthamide C 
followed by HPLC separation, to aspartate by oz
work-up (Figure 29). The presence of a peak corresponding to L
by ion-selective monitoring for FDAA
L-configuration. 
 
 
Figure 28. 1H NMR (500 MHz, D
perthamide C. 
 
γ-methylproline residue was determined by 
Marfey’s method.27 The Marfey’s derivatives of all 
the L-amino acid FDAA 
-18 column before its corresponding D
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o-Tyr residue was assigned after 
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To determine the relative configuration of Nδ-c-β-OSO3Asn was used J-based 
NMR configurational analysis method (Figure 30). A small coupling constant 
between H-2 and H-3 (1.0 Hz) suggested that they were gauche. H-2 exhibited a 
small 3J coupling constant with C-4 and a small 2J coupling constant with C3, 
whereas H-3 displayed a large 2J coupling constant with C-2 supported an anti 
relative configuration. 
 
 
 
 
 
Because the acidic hydrolysis of perthamide C to obtain this residue afforded β-
hydroxy aspartate, to support the assignment of the relative configuration and to 
assign the absolute stereochemistry, all stereoisomers of β-hydroxy aspartate were 
prepared by ozonolysis of the corresponding β-hydroxy-phenylalanine 
stereoisomers (Figure 31).163 The so obtained β-hydroxy aspartatic acids were 
used as standards in the Marfey’s analysis, that evidenced the presence of (2R,3S)- 
Nδ-c-β-OSO3Asn residue in perthamide C. 
 
Figure 29. Determination of absolute stereochemistry of o-Tyr unit in perthamide C. 
NHCONH2
OSO3HO
HN
1 2 3 4
O
Figure 30. Relative configuration for  Nδ-c-β-OSO3Asn residues in perthamide C. 
3JH2-H3   1.0 Hz (small) 
3JH2-C4   1.0 Hz (small) 
2JH2-C3   -1.2 Hz (small) 
2JH3-C2  -4.0 Hz (large) 
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The remaining stereochemical uncertainty of perthamide C concerns the 
configuration of the two stereogenic centres in the AHMHA unit. We tentatively 
proposed a threo relative disposition of the hydroxyl and the amino group on the 
α and β-position, respectively, on the basis of the J coupling analysis. A small 
coupling constant between H-2 and H-3 (0.8 Hz) suggested that they were gauche. 
H-2 exhibited a small 3J coupling constant with C-4, and H-3 displayed a small 3J 
coupling constant with C-1, indicating that H-2/C-4 and H-3/C-1 were gauche, 
pointing for a threo configuration.  
The issue of stereochemistries of AHMHA residue was unambiguously solved in 
a parallel study by my research group.164 All steroisomers were prepared by 
asymmetric  synthesis, and the  (2R,3R) configuration for the AHMHA residue 
was established by comparison of spectral data and by pre-column derivatition 
method (Marfey’s analysis).  
 
Figure 31. Synthesis of  all steroisomers β-OHAsn and tR in LC/MS 
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4.3.2 Perthamide D  
 
 
 
 
 
 
The HR-ESIMS of perthamide D (9) showed a major ion peak at m/z 1050.4302 
[M-H]- corresponding to a molecular formula of C44H65N11O17S, that was 16 mass 
units (one oxygen atom) smaller than that of perthamide C (8). The 1H NMR 
spectrum is very similar to that of perthamide C, suggesting it is an analogue of 
the major cyclopeptide. This spectrum clearly evidenced the presence of a 
monosubstituted phenyl ring and the lack of a downfield exchangeable phenolyc 
proton, suggesting the replacement of o-tyrosine residue in perthamide D with a 
phenylalanine residue (Figure 32).  
Interpretation of 2D NMR data, including COSY, 
HSQC, HMBC and ROESY data led to the planar 
structure of perthamide D, that is almost 
superimposable with that of perthamide C. 
The complete agreement of chemical shifts and coupling constant patterns of γ-
methylproline and dAbu residues suggested the same relative configuration. 
Application of the Marfey’s method enable us to determine the chirality of the 
residue as L-Asn, L-Phe, L-ThrOMe and (2R,3S)- Nδ-c-β-OSO3Asn. 
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Figure 32. Phe unit in perthamide D. 
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4.3.3 Perthamide E and its analogue perthamide F  
 
 
 
 
 
 
The structural analysis of perthamide E (10) began with the HR-ESIMS m/z 
1080.4394 [M-H]- corresponding to a molecular formula of C45H67N11O18S. 
Compared with the molecular formula of perthamide C, there was the gain of 14 
u.m.a., as well as one additional methylene group. 1H NMR spectra indicated that 
perthamide E differed to perthamide C in the AHMHA unit. This spectrum 
showed the presence of two additional methylene proton signals at δH 1.03 and 
1.22 and the two methyl group were found slightly shifted at δH 0.76 and 0.74 
(0.77 and 0.78 in perthamide C). 
As inferred from a careful analysis of COSY, HSQC and HMBC spectra, the 
resonances relative to other portion of the molecule were almost superimposable 
with that found in the perthamide C (Table 6).  
As regards the modified residue, the analysis of 
bidimensional NMR experiments indicated that 
perthamide E possessed a residue of 3-hydroxy-3-amino-
6-methyloctanoic acid (HAMO) rather than AHMHA. 
The complete spin system of this residue was easily 
assigned by the analysis of the COSY, TOCSY and HMBC 
spectra (Figure 33).   
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Figure 33. HAMO  
unit in pethamide E. 
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The peptidic sequence of perthamide E and the placement of HAMO unit were 
assigned from the analysis of HMBC and ROESY correlations reported in Figure 
34 and was superimposable to perthamide C. 
 
 
 
 
 
 
 
The determination of stereochemistry of HAMO unit, that presents an additional 
chiral center compared to AHMHA unit in perthamide C, is currently in progress 
in our laboratory. The complete agreement of chemical shifts and coupling 
constant patterns of remaining amino acid residues suggest the same relative 
configurations than perthamide C.  
The molecular formula of perthamide F (11), C45H67N11O17S, was deduced by 
HR-ESIMS, m/z 1064.4473 [M-H]-. The NMR data suggested that this compound 
had the HAMO residue, like perthamide E; in fact, the spectra of perthamide F 
were almost superimposable with the corresponding signals in perthamide E, 
except for the aromatic ring. The mass data indicated that perthamide F was 16 
u.m.a. (one atom of oxygen) smaller than perthamide E.  The 1H NMR spectrum 
showed the presence of a monosubstituted phenyl ring, confirmed also by the lack 
of a downfield exchangeable phenolyc proton, suggesting the replacement of o-
tyrosine residue in perthamide F with a phenylalanine residue (Figure 35).  
 
Figure 34. Inter residue ROESY (red) and HMBC (blue) correlations of perthamide E. 
Cpethamide C. 
Chapter 4 – THEONELLA SWINHOEI 
 84 
 
 
 
 
 
 
 
 
 
 
 
4.3.4 Perthamide G  
 
 
 
 
 
 
 
The HR-ESIMS spectrum of perthamide G (12) showed a major ion peak at m/z 
1052.4237 [M-H]- corresponding to a molecular formula of C43H63N11O18S, that 
was 14 u.m.a. smaller than that of perthamide C (8). 
Figure 35. Comparison of 1H NMR spectra of perthamides E and F. 
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1H NMR spectrum suggested that perthamide I 
differed from perthamide C in the γ-MePro unit. 
This spectrum showed just few differecences, 
includig the absence of the methyl group at δΗ 1.04 
and the presence of two additional methylene proton 
signals at δH 1.84 and δH 1.93, suggesting the replacement of a γ-MePro unit with 
Pro unit (Figures 36 and 37).  
The peptidic sequence of perthamide E and placement of Pro residue were 
assigned from the analysis of HMBC and ROESY correlations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. 1H NMR spectra of perthamides C and G in DMSO-d6 at 700 MHz. 
NO
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Figure 36. Pro unit in 
perthamide G. 
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4.3.5 Perthamides H and I 
 
 
 
 
 
 
The HR-ESIMS of perthamide H (13) showed a major ion peak at m/z 986.4804 
[M-H]- corresponding to a molecular formula of C44H65N11O15, that was 80 mass 
units (a sulphate group) smaller than perthamide C (8), suggesting the lack of the 
sulphate group. The structure of the peptide H was performed through extensive 
application of NMR techniques and MS experiments. 
The perturbation in the Nδ-c-β-OSO3Asn residue was confirmed also by 1H NMR 
spectrum. In fact, the β-hydroxymethine proton of this residue was found slightly 
upfield shifted at δH 4.12 compared to the one in perthamide C (δH 4.59). The 1H 
NMR showed also the gain of an exchangeable OH proton at δ 6.16 and the 
downfield shift of the NHδ at 9.52, while the proton α was found slightly upfield 
at δ 4.82 vs 5.05 of major peptide (Figure 38). The remaining part of the molecule 
was almost superimposable with that of perthamides C. 
 
 
 
 
 
Perthamide H  (13)  R3=CH3   
Perthamide I    (14)  R3=CH2CH3 
Figure 38. Nδ-c-Asn residue in perthamide H and I. 
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The molecular formula of perthamides I (14), C45H67N11O15, deduced by HR-
ESIMS, was 14 u.m.a. larger than that of perthamide H, suggesting the gain of a 
methylene group. The comparison of the 1H NMR of the two peptides clearly 
showed that perthamide H and I differed each other in the portion reguarding the 
β-amino acid residue: in fact, while perthamide H had the AHMHA residue, 
perthamide I posseded the HAMO unit, like perthamide E.  
As inferred from a careful analysis of COSY, HSQC and HMBC spectra, the 
resonances relative to other portion of the molecula were almost superimposable 
with that found in the perthamide H.  
4.3.6 Perthamides J and K 
 
 
 
 
 
 
The HR-ESIMS spectrum of perthamide J (15) showed a pseudomolecular ion 
peak at m/z 970.4405 [M-H]-, corresponding to a molecular formula of 
C44H62N10O15, which is 97 u.m.a. less than the perthamide C. NMR data of 
perthamide J were almost superimposable to those of parent peptide, whereas only 
a perturbation in Nδ-c-β-OSO3Asn residue was observed.  
In particular in the 1H NMR the signals regarding the -NH2 group of the δ-
carbamoil moiety and the –OH exchangeable proton in position β were absent. 
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The downfield shift experienced by both proton and carbon in position β (at δH 
5.22 vs 4.59 in perthamide C; δC 79.0 vs 74.9) was indicative of an acylation shift. 
Also the signal of the  NHδ appeared downfield shifted at δH 12.2 vs 8.90 in 
perthamides C; this exanchageable proton, in the HMBC spectrum, correlated 
only with the C3 (δC 79.0) and C4 (δC 154.9) (Figure 39). Even if any long-range 
correlation could be traced from H-3 proton, mass data and chemical shift 
consideration clearly suggested a cyclization between the β-OH group and the 
carbamoil moiety to form a cyclic oxazolidin-2,4-dione.  
 
 
 
 
 
The peptidic sequence of perthamide L and placement of the modified β-OHAsn 
residue were assigned from the analysis of HMBC and ROESY correlations, 
affording the planar structure of the clyclic peptide. 
The molecular formula of perthamide K (16), C45H64N10O15, was deduced by HR-
ESIMS, m/z 984.4635 [M-H]-.  The NMR data suggested that perthamide K had 
the same perturbation in the Nδ-c-β-OSO3Asn residue like perthamide J, whereas 
differed in the portion reguarding the β-amino acid residue. The gain of 14 u.m.a. 
in mass spectrum, as well as one additional methylene group, together the 
comparison of NMR data, suggested the replacement in perthamide M of 
AHMHA unit with the HAMO residue. 
Figure 39. The modified β-OHAsn residue in perthamide J. 
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Interpretation of 2D NMR data, including COSY, HSQC, HMBC and ROESY 
data led to the planar structure of perthamide K, that is almost superimposable 
with that of perthamide J. 
4.3.7 Pharmaological activity of perthamide C  
Perthamides C and D did not show antiproliferative activity on KB cell line up to 
a dose of 10 µg/ml, in spite of the anti-KB activity showed by the crude extract. 
However, when tested in a well characterised model of inflammation in vivo i.e. 
mouse paw oedema,165 perthamide C significantly reduced carrageenan-induced 
paw oedema both in the early phase (0-6 h) and in the late phase (24-96 h) as 
shown in Figure 40. In particular perthamide C displayed a dose-dependent (0.1, 
0.3 and 1 mg/kg) anti inflammatory activity causing about 60% reduction of 
oedema in mice at the dose of 300 µg/kg (i.p.). Also perthamide D showed an anti 
inflammatory activity in both phases of oedema; however due to the scarcity of 
natural compound available, it was tested only in a single dose (0.3 mg/kg) where 
caused a 46% oedema inhibition. These data if compared with the ED50 of one of 
the most common NSAID sold in the market, e.g. naproxen (ED50 40 mg/kg) 
clearly indicate that perthamide C is about 100 times more potent. Furthermore 
the activity observed implies that the peptide is bioavailable and able to access the 
site of inflammation.  
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Figure 40. Dose-dependent inhibition on first (A) and second (B) phase of carrageenan-induced 
paw oedema by perthamide C (8). 
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Perthemide C showed also an immunosuppressive activity, this activity is shown 
by its ability to significantly reduce the Concanavalin A- induced proliferation of 
murine splenocytes obtained from mice injected with carrageenin into the paw and 
receiving perthamide intraperitoneally. The immunosuppressive activity of 
pertahmide is comparable with dexamethasone used as control (Figure 41). 
Anti inflammatory marine cyclic peptide are rare, with the exception of 
cyclomarins,1660 salinamides167,168 and halipeptins;169 the discovery that 
perthamides are potent and, in a way, unexpected anti-inflammatory agents 
deserves further investigations on the origin of their activity.  
 
 
 
 
 
 
 
 
Detailed pharmacological investigations to clarify the biomolecular target and 
therefore the mechanism of action at the molecular level are currently in progress 
in our laboratory. Target-discovery studies through chemical proteomics 
approaches will be performed, and it will try to identify the macromolecular 
partners of perthamide showing, in preliminary pharmacological assays 
immunoregulating and anti-inflammatory activities. Finally, global proteomics 
studies will be pursued in order to evaluate the quantitative modifications of cell 
proteomes when treated with perthamide. 
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Figure 41. Reduction of the Concanavalin A- induced proliferation of murine splenocytes by 
perthamide C (8). 
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Indeed the modular peptidic nature and the quite easily chemical access to 
perthamide C may open the possibility to investigate new pharmacophores useful 
in the identification of new leads for developing a new generation of anti-
inflammatory drugs.  
Moreover the isolation of small library of natural analogues will allowed for a 
detailed SAR study to determine the pharmacophores of the peptide. 
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 Perthamide C (8) Perthamide E (10) 
Position δH (J in Hz) δC  δH (J in Hz) δC 
ThrOMe     
1 - 171.0 - 171.2 
2 4.92 d (9.5) 55.3 4.91 d (9.5) 55.4 
3 4.16 m 72.8 4.16 m 72.9 
4 1.24 d (5.8) 14.3 1.23 d (5.9) 14.3 
OMe 3.27 s 54.7 3.26 s 54.7 
NH 9.05 d (8.8)  9.01 d (9.1)  
γMePro     
1 - 170.7 - 171.0 
2 3.90 dd (11.0, 6.7) 63.4 3.89 dd (11.1, 6.6) 63.4 
3 0.72 m, 2.09 m 36.1 0.71 m, 2.09 m 36.2 
4 2.25 m 33.2 2.25 m 33.2 
5 3.40 t (10.8) 
4.11 ovl 
53.0 3.39 ovl, 4.11 ovl 53.2 
6 1.04 d (6.1) 15.9 1.03 d (5.8) 15.8 
oTyr     
1 - 170.6 - 170.8 
2 4.12 ovl 56.3 4.11 ovl 56.4 
3 2.86 dd (13.2, 3.2), 
2.95 t (13.2) 
30.6 2.86 dd (13.2, 3.2), 
2.93 t (13.2) 
30.7 
1’ - 124.0 - 124.3 
2’ - 154.4 - 154.6 
3’ 6.88 d (7.8) 114.5 6.87 d (7.8) 114.5 
4’ 7.11 t (7.8) 127.9 7.10 t (7.8) 128.0 
5’ 6.80 t (7.4) 119.7 6.80 t (7.3) 119.9 
6’ 7.16 d (7.4) 130.3 7.16 ovl 130.5 
NH 7.19 ovl  7.20 ovl  
OH 10.2 s  10.1 s  
Asn     
1 - 170.3 - 170.5 
2 4.70 m 48.0 4.69 m 48.0 
3 2.41 dd (16.9, 2.2), 
3.15 d (16.9) 
36.9 2.41 d (16.3), 3.14 dd 
(16.3, 4.7) 
36.8 
4 - 172.5 - 172.6 
NH 7.18  7.19 ovl  
NH2 6.51 br s, 7.86 br s  6.52 br s, 7.83 br s  
AHMHA     
1 - 169.7 - 170.0 
2 4.14 br s 72.6 4.14 ovl 72.8 
3 4.00 t (9.9) 52.0 4.01 t (9.9) 51.9 
4 1.16 m, 1.41 m 24.1 1.44 m, 1.09 m 23.6 
5 0.95 m, 1.15 m 34.4 1.06 m 31.8 
6 1.41 m 27.2 1.17 m 33.4 
7 0.77 d (6.4) 21.9 1.03 m, 1.22 m 28.7 
8 0.78 d (6.4) 22.2 0.76 t (7.0) 11.0 
9   0.74 d (6.2) 18.5 
NH 6.38 d (9.1)  6.37 d (9.1)  
OH 
 
 
 
 
4.81 br s  4.81 br s  
Table 6. NMR Spectroscopic Data (700 MHz, DMSO-d6) for Perthamide C (8) and Perthamide E (10). 
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dAbu     
1 - 167.2 - 167.5 
2 - 132.1 - 132.3 
3 5.77 q (6.9) 126.4 5.77 q (6.8) 126.5 
4 1.54 d (6.9) 12.1 1.54 d (6.8) 12.0 
NH 8.65 s  8.62 s  
NMeGly     
1 - 167.1 - n.o 
2 3.31 d (17.9) 
4.21 d (17.9) 
51.4 3.31 d (17.5), 4.19 d 
(17.5) 
51.5 
NMe 2.70 s 34.4 2.70 s 34.6 
Nδ-c-β-OSO3Asn     
1 - 167.4 - 167.5 
2 5.05 t (7.4) 53.0 5.04 t (7.3) 53.0 
3 4.59 d (7.1) 74.9 4.59 d (7.1) 74.9 
4 - 170.5 - 172.7 
βNH 7.18 ovl  7.16 ovl  
NH 8.90 s  8.89 s  
CO - n.o - n.o 
NH2  7.31 br s, 7.51 br s   7.29 br s, 7.51 br s  
 
 
 
 
 
 
 
 
 
 
 
 
Ovl: overlapped; n.o: not observed. 
1H and 13C assignments aided by COSY, TOCSY, HSQC and HMBC experiments. 
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4.4 SOLOMONAMIDES 
Pursuing the chemical investigation of the polar extracts of the sponge Theonella 
we isolated two minor cyclopeptide derivatives unrelated to cyclopeptides 
previously described, which we named  solomonamides A and B, endowed of 
anti-inflammatory activity. 
4.4.1 Solomonamide A  
 
 
 
 
 
 
Solomonamide A (17) was isolated as minor peptide component as optical active 
amorphous solid. A molecular formula of C21H29N5O9 was established by high 
resolution ESIMS mass spectrometry.  
The 1H NMR spectrum contained four exchangeable amide NH protons between 
δΗ 11.5 and 7.49, disclosing the peptide nature of the compound, also 
corroborated by four 13C NMR resonances (δC 167.5, 169.2, 170.7 and 173.6) 
relative to the acyl carbonyls. 
The presence of three conventional amino acid residues, alanine, glycine, serine 
were easily deduced by interpretation of 2D NMR data obtained by 1H-1H COSY, 
HSQC, HMBC experiments (Figure 42, Table 7). A signal at δ 8.10, integrating 
for two protons, was assigned as α-amino group of the serine residue, indicating 
that the above residue is the N-terminus. 
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Two spin systems, one comprising a CH-CH3 group (δH 2.31, δC 44.4,C2; δH 0.94, 
δC 13.6, C7) and a sequential CH-OH (δH 3.13, δC 70.3, C3); and a second formed 
by a CH-NH (δH 4.51, δC 53.3, C4) and a sequential CH-OH (δH 4.72, δC 70.5, 
C5), were disclosed from COSY and HSQC data.  
Even if no COSY correlation was observed between the protons at δH 3.13 and δH 
4.51 the connection between C3 and C4 was deduced by HMBC data (Table 7, 
Figure 43). The linkage of an acyl carbonyl with the CH(2)-CH3 group at δH 2.31 
was deduced from the diagnostic heteronuclear long range correlations between 
the protons at C2; C3 and C7 with the carbon resonance at δC 173.6 (C1). 
Moreover a ketone carbonyl group was placed at C6 of the spin system on the 
basis of 3J heteronuclear coupling between CH(4)-NH (δH 4.54) with a carbonyl 
group at δC 201.2 (C6). 
In addition, the 1H NMR together with COSY, HSQC and HMBC data showed 
the presence of a 1,2,4 trisubstituted phenyl ring. The ketonic carbonyl at C6 of 
the abovementioned spin system was placed at C1’ of the phenyl ring on the basis 
of the HMBC cross peaks between the C6’ aromatic proton at δ 7.86 with the 
signal at δ 201.2.  
One phenolic hydroxy and one aromatic amido groups deduced by mass and 13C 
NMR data were also evidenced by two downfield signals, observed in the 1H 
Figure 42. Gly, Ser and Ala units in solomonamide A 
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NMR spectrum at δ 10.7 and 11.5 respectively, and in the 13C NMR spectrum at 
δ 162.7 and 141.7. The relative regiochemistry of oxygenated and nitrogen 
functionalities on the phenyl ring was secured by diagnostic long-range 
heteronuclear couplings showed in Figure 43.  
 
 
 
 
 
 
Therefore the new unit in solomonamide A was defined as 4-amino-(2’-amino-4’-
hydroxyphenyl)-3,5-dihydroxy-2-methyl-6-oxohexanoic acid (ADMOA), which 
is unprecedented in natural products. 
A plausible biogenetic origin of this unit could be drawn. 5-hydroxytryptophan 
could undergo to two well known processes of tryptophan catabolism, i.e β- 
hydroxylation170 and oxidative scission of the indole ring to afford a 
hydroxykynurenine unit.  
Reduction of the carboxy group to aldehyde, followed by a Claisen-type 
condensation with a propionate C3 unit (Scheme 7) would eventually afford the 4-
amino-3,5-dihydroxy-2-methyl-6-oxa-6-(2’-amino-4’-hydroxyphenyl)hexanoic 
acid residue. 
 
HN
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O
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1
Figure 43. New subunit of solomonamide A (17) with COSY/TOCSY connectivities (bold 
bonds) and key HMBC correlations (blue arrows). 
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The amino acid sequence of solomonamide A could be established from 
interpretation of the HMBC experiment where long-range correlations between 
protons on α-carbon and on α-amido groups and carbonyl carbons belonging to 
adjacent amino acids provided the partial sequence ADMOA-Gly-Ala (Table 1).  
Cyclization between the C-terminal alanine and the ADMOA 2’-amino group was 
apparent from HMBC correlations between 2’-amino proton of ADMOA (δH 11.5) 
and the carbonyl resonance at δ 170.7 (C-1 Ala). The linkage of γ-CHNH of 
ADMOHA residue to acyl group of N-terminal seine residue was determined by 
long-range correlations between protons at δ 7.89 (NH -4) and δ 4.54 (C4) to C1 
Ser (δC 167.5). Several inter-residue ROESY correlations confirmed the proposed 
sequence (Figure 44). 
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Figure 44. Inter residue ROESY (red) and HMBC (blue) correlations of solomoamide A. 
Cpethamide C. 
Scheme 7. Plausible biogenesis for ADMOHA unit in solomonamide A. 
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Definitive confirmation of the sample structure was derived from ESI MS/MS 
analysis. In addition to the pseudomolecular ion at m/z 496.2 [M + H]+, the ESI Q-
TOF MS/MS spectrum provided some fragment ion peaks, in agreement with the 
proposed sequence (Scheme 8). The major peak at m/z 374 corresponds to the 
simultaneous dehydratation at C2 and eliminative loss of terminal serine residue.   
Further MS3 fragmentation of the daughter ion at m/z 374 gave C-terminus ion 
fragments at m/z 303 [374 - Ala]+and  m/z 386 [374-Ala-Gly]+.  
 
 
 
 
 
 
 
 
 
 
 
 
The absolute stereochemistry of Ala and Ser residues was determined by complete 
acid hydrolysis of solomonamide A (6N HCl, 110°C, 12h) and Marfey’s analysis. 
The acid hydrolysate was derivatised with (1-fluoro-2,4-dinitrophenyl)-5-L-
alaninamide (L-FDAA), and then LC-MS comparison of the derivatives from 
parent peptide with the FDAA derivatives of appropriate standards established the 
presence of D-Ala and L-Ser.  
C21H29N5O9
495.19653
C18H20N3O6+
374.13466
C15H15N2O5+
303.09755
C13H12NO4+
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Scheme 8. Fragment ions in ESI Q-TOF MS/MS. 
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The configurational assignment of ADMOA residue was proved quite difficult. 
The fortuitous anti arrangement of H2/H3 and H4/5 and the absence of diagnostic 
ROE effects hampered the application of J-based analysis. Moreover 
solomonamide A showed an high instability towards chemical derivatization. The 
determination of the absolute stereochemistries of the ADMOA residue is in 
progress through the use of a computational method, relying on DFT calculation 
of 13C chemical shift values of all the possible stereoisomers. 
4.4.2 Solomonamide B  
 
 
 
 
 
 
Solomonamide B (18) was isolated as very minor peptide component as optical 
active white amorphous solid. The HR-ESIMS of solomonamide B showed a 
major ion peak at m/z 480.2094 [M + H]+ (C21H29N5O8, calcd for C21H30N5O8, 
480.2094), 16 mass units lower than that of solomonamide A. 
Comparison of 2D NMR data of solomonamide B with those of solomonamide A 
(Table 8) clearly evidenced a close analogy between two compounds and a 
perturbation in the ADMOA residue. The signal assigned to H-4 hydroxymethine 
of the above residue in solomonamide A was replaced by signals relative to a 
diasterotopic allyl methylene (δH = 3.34 and 2.87; δC 41.2) in solomonamde B. In 
this way it was easy establish the structure of  4-amino-6-(2’-amino-4’-
NH
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hydroxyphenyl)-3-hydroxy
instead of ADMOA residue
Interpretation of 2D NMR data, includin
data led to the planar structure of solomonamide B, that is almost superimposable 
with that of solomonamide A.
The presence of D-Ala and L
before. The determination of the 
residue is in progress through the use of a computational method.
4.4.3 Pharmacological activity of solomonamide A
Because the perthamides isolated from the same sponge showed a potent anti
inflammatory activity, we have investigated whether solomonamide A have the 
same property.  
Solomonamide A displayed a dose
about 60% reduction (Figure 4
The scarcity of the material humpered the evaluation of anti
for solomonamide B.  
In conclusion, solomonamide A is representative of a new class of 
inflammatory compounds. 
 
 
 
 
 
 
 
Figure 45. Dose-dependent inhibition on first (A) and second (B) phase of carrageenan
paw oedema by solomonamide A (
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 δCa δHb HMBCc ROESYd 
Gly   
1 169.2    
2a 42.6 3.90 dd (15.3, 6.6)  1, 1ADMOA  
2b  3.76 dd (15.3, 4.7) 1, 1ADMOA NHAla 
NH  7.49 br t (5.5) 2, 1ADMOA 2a e 2b, NHAla, 2ADMOA, 
3ADMOA, 4ADMOA, 7ADMOA 
Ala   
1 170.7    
2 49.1 4.41 quint (7.6) 1, 3, 1Gly NH-2’ADMOA 
3 15.5 1.31 d (7.0) 1, 2  
NH  8.77 d (7.9) 2, 3, 1Gly 2bGly, NHGly, NH-2’ADMOA 
Ser    
1 167.5    
2 54.2 4.02 m 1, 3 NH-4ADMOA 
3a 60.5 3.81 dd (11.4, 4.6)  1 NH-4ADMOA 
3b  3.68 dd (11.4, 6.9) 1, 2 NH-4ADMOA 
NH  8.10 br d (4.3) 1, 2, 3  
OH  5.39 br s   
ADMOA   
1 173.6    
2 44.3 2.34 m 1, 7, 3, 4 4, 5, NHGly, 
3 70.3 3.15 ovl 1, 2 4, 5, NHGly 
4 53.3 4.54 t (9.5) 2, 3, 6, 1Ser 2, 3, 6’, NHGly,  
5 70.4 4.75 d (9.5) 4 2, 3, NH-4, 6’ 
6 201.2    
7 13.7 0.98 d (7.1) 1, 2, 3 NHGly 
OH-3  5.26 br s  NH-4 
OH-5  5.53 br s   
NH-4  7.89 d (9.5) 1Ser, 3 5, 2Ser 
1’ 115.3    
2’ 141.8    
3’ 106.0 8.02 d (2.3) 1’, 2’, 4’, 5’ NH-2’, OH-4’ 
4’ 162.8 -   
5’ 109.6 6.57 dd (8.7, 2.3) 1’, 3’, 4’ OH-4’ 
6’ 133.4 7.86 d (8.7) 6
 ADMOA, 2’, 4’ 5 
OH  10.7 s 3’, 4’, 5’ 3’, 5’ 
NH-2’  11.5 s 1’, 3’, 1Ala 3’, 2Ala, NH-Ala 
Table 7. NMR Spectroscopic Data for Solomonamide A (17) (DMSO-d6, 700 MHz). 
aRecorded at 175 MHz; referenced to residual DMSO-d6 at δ 39.51 ppm. 
bRecorded at 700 MHz; referenced to residual DMSO-d6 at δ 2.50 ppm. 
cProton showing HMBC correlation to indicated carbon. 
dProton showing ROESY correlation to indicated proton. 
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 δCa δHb HMBCc 
Gly  
1 169.0   
2a 42.4 4.19 dd (15.7, 7.1)  1, 1AHMOA 
2b  3.78 dd (15.7, 3.4) 1, 1AHMOA 
NH  7.30 br dd (7.0, 3.4)  
Ala  
1 171.2   
2 49.7 4.29 quint (7.1) 1, 3, 1Gly 
Me-2 16.0 1.36 d (7.2) 1, 2 
NH  8.79 d (7.2) 2, 1Gly 
Ser  
1 166.7   
2 53.6 3.98 m  
3 60.3 3.69 br s  1 
NH2  8.08 br d (4.4) 1, 2, 3 
OH  5.46 br s  
AHMOA  
1 173.2   
2 45.4 2.35 m 1, 3 
3 72.2 3.39 ovl  
4 48.0 4.52 br dt (9.5, 1.7) 1Ser 
5a 41.2 3.34 ovl 3, 4, 6 
5b  2.87 br dd (17.6, 1.7) 3, 4, 6 
6 201.1   
7 13.6 1.08 d (7.2) 1, 2, 3 
OH-3  5.53 br d (5.3) 2 
NH-4  7.98 d (9.5) 1Ser 
1’ 115.8   
2’ 141.3   
3’ 106.1 7.92 d (2.1) 1’, 2’, 4’, 5’ 
4’ 162.9 -  
5’ 110.0 6.57 dd (8.8, 2.1) 1’, 3’ 
6’ 132.9 7.77 d (8.8) 2’, 4’, 6AHMOA 
OH  10.7 s 3’, 4’, 5’ 
NH-2’  11.5 s  
aRecorded at 175 MHz; referenced to residual DMSO-d6 at δ 39.51 ppm. 
bRecorded at 700 MHz; referenced to residual DMSO-d6 at δ 2.50 ppm. 
cProton showing HMBC correlation to indicated carbon. 
dProton showing ROESY correlation to indicated proton. 
 
Table 8. NMR Spectroscopic Data for Solomonamide B (18) (DMSO-d6, 700 MHz). 
Chapter 4 – THEONELLA SWINHOEI 
 103 
3.4 MACROLIDES FROM THEONELLA SWINHOEI 
 
 
 
 
 
 
 
 
 
 
The chloroform extract of Theonella sponge afforded to the isolation of a new 
dimeric macrolide (compound 19), togheter with the known major macrolide, 
swinholide A.  
Compound 19 showed a chemical lability in CDCl3; therefore all spectra were 
acquired in CD3OD. In order to compare the new macrolide with parent 
compound, all resonances of swinholide A were reassigned in CD3OD by careful 
analysis of 2D-NMR data and comparison of the data in CDCl3 reported in 
literature (Table 9).  
Compound 19 displayed a molecular formula of C79H134O20, 16 mass units higher 
than that of swinholide A.  
The 1H and 13C NMR spectra appeared more complicated than those of 
swinholide A, which suggested a dimeric structure comprising two non-identical 
units. In particular, the NMR data showed a perturbation in one of two dienone 
substructures in the dimeric molecule. The assignment of the complete structure, 
Swinholide A Compound 19 
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as well as the assignment of 1H and 13C NMR resonances, were supported by 
extensive study of  1H, 13C NMR, COSY, HSQC, HMBC spectra (Table 9). 
The 13C NMR spectrum of swinholide A showed six signals in the region between 
152.3 and 115.6 ppm, corresponding to six pair of equivalent carbons of C-2/C-2’ 
(δC 115.6, CH), C-3/C-3’ (δC 152.3, CH), C-4/C-4’ (δC 135.3, qC), C-5/C-5’ (δC 
140.5, CH), C10-C-10’ (δC 130.9, CH), and C-11/C-11’ (δC 124.9, CH), together 
with the lactone signal of C1/C1’ at δC 170.6. In comparison to swinholide A, the 
downfield region of 13C NMR spectrum of compound 19 showed 10 resonances 
for olefinic carbons in the region 152.5-115.9 ppm instead of six signals, together 
with two resonances at δC 170.2 and 168.7 for the lactone carbons C-1 and C-1’, 
respectively. The 1H NMR spectrum of compound 19 showed resonances for nine 
non-equivalent protons in the region 7.46-5.67 ppm, instead of resonances of five 
pairs of equivalent protons (H2/H2’, H-3/H-3’, H-5/H-5’, H-10/H-10’, H-11/H-
11’) between 7.43 and 5.65 ppm in swinholide A. Additionally, this spectrum, in 
contrast to that of swinholide A, displayed an additional resonance at δH 3.22, that 
in the HSQC experiment was correlated with a carbon at δH 64.4. On the basis of 
the COSY spectrum, this proton was assignable to an oxygen-bearing methine at 
C5’ and appeared upfield shifted compared to a hydroxymethine. This findings, 
together with the mass data and chemical shift consideretions, suggested the 
replacement of the C-4’/C-5’ double-bond moiety with an epoxy group in half of 
the molecule, causing twinning of most of the 1H and 13C NMR signals in this 
portion of the molecule. In particular, diagnostic chemical shift differences were 
observed for the signals due to methyl protons at δH 1.42 (1.77 in swinholide A) at 
C4’ and methylene protons at C6’ (δH 1.63 and 1.81 vs 2.40 in swinholide A).  
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The placement of the epoxy group was unambiguously supported from HMBC 
cross-peaks of H-5’/C4’, CH3-4’/C6’(Figure 46). 
The relative stereochemistry are proposed on the basis of the similarity of the JHH 
values between compound 19 and swinholide A.  
In conclution compound 19 was the first asymmetrical epoxidated version of 
swinholide A.  
Since swinholide A is a potent microfilament disrupting toxin and represents an 
useful tool in investigations of actin organization, dynamics and function;  
pharmacological activity of compound 19 will be valued. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. Key HMBC correlations in partial structure of compound 19. 
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 Swinholide A Compound 19 
position δH/δH’ (J in Hz) δC/δC’ δH/δH’ (J in Hz) δC/δC’ 
1/1’ - 170.6 - 170.2/168.7 
2/2’ 5.84 d (15.6) 115.6 5.88 d (15.6)/6.15 d (15.7) 115.9/122.1 
3/3’ 7.43 d (15.6) 152.3 7.46 d (15.6)/6.81 d (15.7) 152.0/152.5 
4/4’ - 135.3 - 135.5/59.7 
4/4’-Me 1.77 s 12.3 1.85 s/1.42 s 12.7/15.5 
5/5’ 6.14 t (7.2)  140.5 6.16 t (7.2)/3.22 m 140.6/64.6 
6/6’ 2.40 t (6.9) 38.8 2.44 m/1.81 m, 1.63 m 38.7/37.9 
7/7’ 4.02 m 68.0 3.99 ovl/4.12 m 68.2/66.4 
8/8’ 1.28 m, 1.75 m 41.0 1.87 m, 1.37 m/1.37 m, 1.78 m 41.8/41.6 
9/9’ 4.48 br d (10.3) 70.4 4.48 br d (10.2) 70.4 
10/10’ 5.65 dd (1.8, 10.3) 130.9 5.67 br d (10.3)  130.8 
11/11’ 5.82 m 124.9 5.83 m 124.8 
12/12’ 1.94 m 32.2 1.96 m 32.2 
13/13’ 3.49 m 65.3 3.54 m 65.4 
14/14’ 1.58 m, 1.77 m 37.2 1.58 m, 1.82 m 36.9 
15/15’ 3.76 m 78.2 3.76 m/3.83 m 78.4/77.9 
15/15’-OMe 3.32 s 56.8 3.34 s/3.35 s 56.9/57.2 
16/16’ 1.52 m 43.7 1.55 m 43.3 
16/16’-Me 0.82 d (6.9) 8.8 0.83 d (7.0)/ 0.84 d (7.0)  9.2 
17/17’ 3.61 73.2 3.60 m 73.2 
18/18’ 1.63 m, 1.74 m 39.0 1.61 m, 1.75 m 39.2 
19/19’ 3.97 ovl 70.1 3.97 ovl/3.88 m 69.9/70.1 
20/20’ 1.93 m 39.4 1.94 m 39.4 
20/20’-Me 0.90 d (7.0) 8.9 0.90 d (7.1)/0.91 d (7.1) 9.1 
21/21’ 5.47 d (10.5) 75.6 5.45 t (10.3) 75.7/76.3 
22/22’ 1.97 m 37.8 1.97 m 38.0 
22/22’-Me 0.93 d (6.9) 9.6 0.92 d (7.0)/0.93 d (7.0) 9.7 
23/23’ 3.11 dd (1.9, 9.7) 77.4 3.09 m 77.3 
24/24’ 1.70 m 34.4 1.70 m 34.5 
24/24’-Me 0.97 d (6.7) 17.7 0.97 d (6.7)/0.98 d (6.7) 17.9 
25/25’ 1.23 m, 1.42 m 25.1 1.23 m, 1.41 m 25.1 
26/26’ 1.27 m, 1.94 m 29.7 1.28 m, 1.94 m 29.8 
27/27’ 3.99 ovl 72.7 3.98 ovl 72.8 
8/28’ 1.52 m,  
1.87 br d (12.5) 
35.8 1.52 m, 
1.87 br d (12.5) 
35.8 
29/29’ 3.61 m 74.2 3.61 m 74.3 
29/29’-OMe 3.34 s 55.3 3.34 s 55.3 
30/30’ 1.09 dd (10.4, 12.6), 
2.02 br d (12.6) 
39.7 1.09 dd (10.4, 12.6), 
 2.02 br d 
39.7 
31/31’ 3.74 m 65.7 3.74 m 65.8 
31/31’-Me 1.19 d (6.2) 21.7 1.19 d (6.2) 21.8 
Table 9. NMR Spectroscopic Data (700 MHz, CD3OD) for Swinholide A and compound 19. 
1H and 13C assignments aided by COSY, TOCSY, HSQC and HMBC experiments. 
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CHAPTER 5 
PLANTS AS PHARMACY 
Man’s first interest in plants arose from  his search for food, for fuel, and for fibre. 
He soon discovered that many plants had marked effects on his physiological 
functions, and consequently, since prehistoric times, plants and their extracts have 
been used for their healing properties and have played a dominant role in the 
development of sophisticated traditional medicine systems. 
Some were successful. Ancient Egyptians, for example, chewed willow bark to 
relieve fever and headaches. Thousands of years later, scientists discovered that 
the bark contains salicylic acid, the active ingredient used to make aspirin.  
Some were not so successful. Medieval doctors believed that baldness could be 
cured by rubbing an onion on the scalp. 
Even today we are still using compounds derived from plants; so the plant 
kingdom represents an extraordinary reservoir of novel molecules.  
Of the estimated 400,000-500,000 plant species around the globe, only a small 
percentage has been investigated phytochemically and the fraction submitted to 
biological or pharmacological screening is even lower. There is currently a 
resurgence of interest in the vegetable kingdom as a possible source of new lead 
compounds for introduction into therapeutical screening programmes. For this 
reason plants are still contributing to medicine; plants and plant products have 
provided a definitive stimulus for the development of natural product chemistry. 
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CHAPTER 6 
CUCUMIS MELO 
 
 
 
 
 
 
 
Melon (Cucumis melo L. var. inodorus, Cucurbitaceae) is one of the important 
horticultural crops worldwide and plays an important role in international trade. 
Different forms of melon are known that are morphologically different and have 
different uses.  
Melons plants are procumbent vines that thrive on 
heat and sunshine and are grown in fields and 
gardens throughout the warmer and sunnier parts of 
the world. Melons rank high in economic value 
among vegetable crops. They are widely grown for their sweet, ripe fruits, which 
often fetch premium prices, but in some regions they are grown for the production 
of their immature fruits, which are reminiscent of cucumbers (C. sativus L.) in 
superficial appearance, taste, and usage. 
The center of origin of melons is considered to be the eastern tropical Africa, 
south of the Sahara. But wild types are commonly found in the Sudano-Sahelian 
Cucumis melo 
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area, while Asia from the Mediterranean to Japan is a secondary centre of 
diversity.  
Of the species of cucurbis, Cucumis melo was probably the most ancient in 
cultivation as a food plant around the Mediterranean Sea. This is not surprising, 
given the greater geographical proximity of the center of origin of this species to 
the Mediterranean Sea.  
The main plant organ used is the fruits, which are 
used both immature and mature as desserts and 
vegetables for salad. Fruits are usually consumed in 
the summer period and are popular because the pulp 
of the fruit is very refreshing and sweet, with pleasant aroma. Melon seeds may 
be eaten after being slightly roasted, or edible oil can be extracted from them.  
A number of studies have investigated the relationship between a range of 
physical and chemical parameters of melons and their sensory evaluation171,172 
and the compositional changes during ripening of fruits.173 
The seeds of Cucumis melo L. are used in Chinese folk medicine as antitussive, 
digestive, febrifuge and vermifuge174 and melon seeds extract can be used as an 
antidiabetic, and they are beneficial in chronic eczema.175,176 Many Cucurbitaceae 
seeds are rich in oil and protein. More recent studies were largely focused on fatty 
acids, tocopherols, sterols and phenolic profiles of seed oil177 and on 
physicochemical properties.178 As our current interest involves the chemistry of 
biologically active natural products, we investigated the chemical constituents of 
the seeds of C. melo L.  
 
 
Cucumis melo fruit 
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6.1 EXTRACTION AND ISOLATION 
Melon (C. melo var. inodorus) fruits were obtained from a local market in Napoli, 
Campania, Italy. The seeds were removed from their flesh and cleaned under 
running tap water. The whole seeds including the shell were finely ground using a 
blender. Fruits were identified in the Dipartimento di Scienze e Tecnologie per 
l’Ambiente e il Territorio (University of Molise) and a voucher specimen is 
deposited under N° ZZ-0743 in the Herbarium of University of Molise (Pesche, 
Isernia).  
The powdered seeds were extract with MeOH at room temperature. The MeOH 
extract of powdered seeds of Cucumis melo was subjected to Kupchan’s 
partitioning methodology to give four extracts: n-hexane, CHCl3, n-BuOH and the 
aqueous residue.2 The n-BuOH extract, after purification by droplet counter 
current chromatography (DCCC) and reversed phase HPLC, gave the new 
glycoside (20) and the known benzyl O-β-D-glucopyranoside (21). The CHCl3 
extract, purified by DCCC and HPLC, mainly contained multiflorane triterpene 
esters (22, 23).179 
4.2 STRUCTURAL CHARACTERIZATION OF COMPOUND 20 
 
 
 
 
ESI-MS of compound 20 exhibited a quasi-molecular ion at m/z 467 [M + Na]+, 
corresponding to a molecular formula C20H28O11. This molecular formula was 
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determined by HR-ESI-MS (C20H28O11) [M + Na]+ at m/z 467.1602, (calcd. for 
C20H28O11Na 467.1529) and confirmed by 1H and 13C NMR experiments. The 
structure of compound 20 was elucidated by detailed analyses of 1H and 13C NMR 
chemical shift, and by COSY, HSQC, and HMBC experiments (Table 10).  
The 1H NMR spectrum of compound  20 showed a carbinyl methylene group at 
δΗ 4.20 (2H, d, J = 5.9 Hz), two trans olefinic protons as ABX3 type signal [δΗ 
6.26 (1H, dq, J = 5.9, 16.3 Hz) and 6.55 (1H, d, J = 16.3 Hz)], aromatic protons as 
an A2B2 type pattern signals at δΗ 7.02 (2H, d, J = 8.7 Hz) and 7.35 (2H, d, J = 8.7 
Hz) and two anomeric protons [δΗ 4.96 (J = 7.4 Hz) and 5.47 (J = 1.4 Hz)].  
Inspection of COSY and TOCSY spectra allowed to detect fuor distinct spin 
systems: two of them belonging to the aglycon moiety, and the remaining two 
belonging to two sugar units.  
Concerning the aglycone moiety, the first spin system was ascrivable to a 1-4-
disubstituted aromatic ring, as suggested by 1H NMR; the second one 
corresponded to a chain including -CH=CH-CH2OH. 
Concerning the sugar portions of molecule, the first spin system started from the 
anomeric proton at δH 4.96 and arrived to the hydroxyl methylene at C-6’, 
identifying a hexopyranose unit. When the anomeric proton at δH 5.47 was used as 
a starting point, a sequence of only one oxymethine was identified.  
Acid hydrolysis of compound 20 afforded the two sugar units, which were 
identified as D-glucose and D-apiose by GC analysis.180 The chemical shift and 
coupling constants of H-1’ (δΗ 4.96 d, J = 7.4 Hz) and of H-1” (δΗ 5.47 d, J = 1.4 
Hz) and the chemical shift of C-1’ (δC 100.5) and C-1” (δC 110.4) supported a β-
configuration for the anomeric carbons.181 
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In the apiofuranoside ring when H-1’’ and H-2’’ are trans, 3J1,2 is usually close to 
1 Hz, indicating that both oxygen atoms take up quasi-axial positions. The 2D-
NOESY spectrum contains cross peaks between H-2’’ and the protons of the 
hydroxymethyl group (δH 3.54). Similar NOE cross peaks was observed between 
H2-5’’ (δH 3.54) and H-4’’b (δH 4.05) indicating that H-2’’, H2-5’’ and H-4’’b are 
found on the same face. 
By HSQC and HMBC experiments (Table 10) a total of 20 carbon signals were 
detected, 11 signals assignable to glucopyranosyl and apiofuranosyl moieties. The 
low-field chemical shift of glucose C-2’ (δC 78.2) suggests that the hydroxyl 
group at C-2 of glucose bears the apiose unit. The interglycosidic linkage was 
determined by the HMBC correlation evidenced between δH 3.64 (H-2’ Glc) and 
δC 110.4 (C-1” Api). H-1” (δΗ 5.47) also displayed cross peaks with C-3” (δC 
80.6) and C-4” (δC 75.2) by 3J correlations to reveal an apiofuranoside. The 
attachment of the sugar chain at C-4 of the aromatic ring was supported by the 
HMBC correlation observed between δΗ 4.96 (H-1’ Glc) and δC 157.4 (C-4) 
proving the C-4 glycosylation (Figure 47).  
On the other hand, the HMBC correlation of the olefinic proton at δH 6.55 with C1 
(δC 132.5) allowed to link the side chain to the aromatic ring (Figure 47). 
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Figure 47. Key HMBC cross peaks of compound 20. 
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E–geometry of C-7/C-8 double bond in the aglycone portion of the molecula was 
inferred by the J(H-7/H-8) value (16.3 Hz). Inspection of 1H NMR spectrum 
indicated that all signals relative to aglycone moiety were superimposable to that 
of (E)-4-hydroxycinnamyl alcohol 4-O-β-D-glucopyranoside isolated from the 
leaves of Lilium cordatum.182  
On the basis of the foregoing the structure of compound 20 was determined to be 
(E)-4-hydroxycinnamyl-4-O-(2’-O-β-D-apiofuranosyl)(1”→2’)-β-D-
glucopyranoside. 
 
6.3 STRUCTURAL CHARACTERIZATION OF COMPOUND 21 
 
 
 
The molecular formula of compound 21 was deduced from its positive ion FAB-
MS as C13H18O6 which showed a [M + Na]+ ion at m/z 293. The 1H NMR 
spectrum of compound 21, in addition to the signals due to the β-glucopyranosyl 
moiety (anomeric signals: δC 102.1 and δH 4.36, J = 7.7 Hz), showed a set of 
monosubstituted aromatic proton signals at δΗ 7.42, 7.33, 7.28 and a 
hydroxymethyl signal at δΗ 4.93 suggesting the presence of a benzyl alcohol 
moiety. The significant downfield shift of the H2-7 (δH 4.93 and 4.67, each d, J = 
11.9 Hz) and C-7 (δC 70.5) signals of compound 21 supported the location of 
glucosyl linkage also confirmed by the HMBC data. HMBC correlations were 
observed for H-7 (δH 4.93)/C-1’ (δC 102.1 Glc), H-7/C-1 (δC 138.0), H-7/C-2(6) 
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(δC 128.0), proving that the glucose unit was linked to the benzyl carbon (Figure 
48).  
Thus the structure was defined as benzyl O-β-D-glucopyranoside. This compound 
was previously identified in Vitis vinifera grapes and has been described as the 
corresponding peracetylated derivative.183 
 
 
 
 
6.4 OTHER METABOLITES ISOLATED 
Compounds 22 and 23 were found to be known multiflorane triterpene esters. By 
spectroscopic analysis the structures of the two compounds were determined to be 
3,29-O-dibenzoylmultiflor-8-en-3α,7β,29-triol (22) previously isolated from the 
seeds of Trichosanthes kirilowii184 and 3-O-p-amino-benzoyl-29-O-
benzoylmultiflor-8-en-3α,7β,29-triol (23) identified only from the seeds of 
pumpkin185 and seeds of zucchini.186  
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Figure 48. Key HMBC cross peaks of compound 21. 
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position δHa (J in Hz)  δCa HMBCb 
1 - 132.5  
2,6 7.35 d (8.7) 128.3 4, 7, 
3,5 7.02 d (8.7) 117.3 4, 1 
4 - 157.4  
7 6.55 d (16.3) 130.9 2, 9 
8 6.26 dq (5.9, 16.3) 128.3 1, 9 
9 4.20 d (5.9) 63.4 7, 8 
Glc    
1’ 4.96 d (7.4) 100.5 4 
2’ 3.64 dd (7.4, 9.2) 78.2 1’, 1’’ 
3’ 3.59 t (9.1) 78.4  
4’ 3.39 71.1  
5’ 3.43 m 77.7  
6’ 3.69 dd (5.4, 11.9),  62.4  
Api    
1’’ 5.47 d (1.4) 110.4 3’’, 5’’ 
2’’ 3.95 d (1.4) 77.8  
3’’ - 80.6  
4’’ 4.05 d (9.5), 75.2  
5’’ 3.54 s 65.8  
Table 10. 1H and 13C NMR (CD3OD, 500 MHz) of compound 20. 
a 1H and 13C assignments aided by COSY, TOCSY, HSQC and HMBC experiments. 
b HMBC correlations, optimized for 8 Hz, are from proton(s) stated to the indicated carbon. 
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CHAPTER 7 
BORRAGO OFFICINALIS 
 
 
 
 
 
 
 
 
 
 
Borage, also known as a starflower, is an annual herb originating in Syria, but 
naturalized throughout the Mediterranean region, as well as Asia Minor, Europe, 
North Africa, and South America.  
The name borage can, by way of French and Spanish, be traced back to Medieval 
Latin borrago. The latter name is generally accepted to have Arabic origin; it has 
been proposed to derive it from Andalusian Arabic abu buraq “father of sweat” 
(standard Arabic abu araq) or from abu huras 
“father of roughness”. In the first case, the 
motive would be the use of borage leaves in 
diaphoretic medicines, in the second case the 
rough leaf surface.  Borrago officinalis 
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It grows to a height of 60–100 cm (2.0–3.3 ft), and is 
bristly or hairy all over the stems and leaves; the 
leaves are alternate, simple, and 5–15 cm (2.0–5.9 in) 
long. The flowers are complete, perfect with five 
narrow, triangular-pointed petals. Flowers are most often blue in color, although 
pink flowers are sometimes observed. White flowered types are also cultivated. 
The flowers arise along scorpiod cymes to form large floral displays with multiple 
flowers blooming simultaneously, suggesting that borage has a high degree of 
geitonogamy. It has an indeterminate growth habit which may lead to prolific 
spreading. In milder climates, borage will bloom continuously for most of the 
year.  
Traditionally borage was cultivated for culinary and medicinal uses, although 
today commercial cultivation is mainly as an oilseed. The seed oil is desired as 
source of γ-linolenic acid (GLA, 18:3, cis 6,9,12-octadecatrienoic acid), for which 
borage is the highest known plant-based source (17-28%).187 This fatty acid is an 
intermediate of indispensable compounds in the body, such as prostaglandin E1 
and its derivatives.188 The seed oil content is between 26-38% and in addition to 
GLA contains the fatty acids palmitic acid (10-11%), stearic acid (3.5-4.5%), oleic 
acid (16-20%), linoleic acid (35-38%), eicosenoic acid (3.5-5.5%), erucic acid 
(1.5-3.5%), and nervonic acid (1.5%). The oil is often marketed as "starflower oil" 
or "borage oil" for uses as a GLA supplement, although healthy adults will 
typically produce ample GLA through dietary linoleic acid. The main constituents 
of the oil are vitamin C, saponins, tannins and minerals. 
Borage production does include use as either a fresh vegetable or a dried herb. As 
a fresh vegetable, borage, with a cucumber like taste, is often used in salads or as 
Borrago officinalis flower 
Chapter 7 – BORRAGO OFFICINALIS 
 119 
a garnish. The flower, which contains the non-toxic pyrrolizidine alkaloid 
thesinine,189 has a sweet honey-like taste and as one of the few truly blue-colored 
edible things, is often used to decorate dessert.  
It is notable that the leaves have been found to contain small amounts 
pyrrolizidine alkaloids: intermedine, lycopsamine, amabiline and supinine.190,191 
Pyrrolizidine alkaloids, which are extremely common in the Boraginaceae family, 
are powerful hepatotoxins that cause severe liver damage on chronic ingestion, 
often with lethal outcome. Although the total concentration in borage is extremely 
small (around 10 ppm in the dried herb), it has been argued that borage is an 
unsafe herb when used in folk medicine; the risks associated with casual culinary 
usage are probably negligible.  
Borage is also traditionally used for its cosmetic properties, as cleanser and 
emollient mash and as a facial scrub. 
Naturopathic practitioners use borage for regulation of metabolism and the 
hormonal system, and consider it to be a good remedy for premestrual syndrome 
and menopause symptoms, such as the hot flash. Borage is sometimes indicated to 
alleviate and heal colds, bronchitis, and respiratory infections, and in general for 
its anti-inflammatory, depurative, diuretic, purifier, regenerative, sudorific and 
balsamic properties. The flowers can be prepared in infusion to take advantage of 
its medicinal properties. The oleic and palmitic acid of borage may also confer a 
hypocholesterolemic effect. 
In the book History of Plants, published in 1597, John Gerad quoted as “an old 
verse” the following sentence: “Ego Borago gaudia simper ago” (I, Borage, bring 
always courage), confirming the old bielef in the properties of the leaves and 
flowers of borage to take away sorrow and melanchony.192 
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7.1 EXTRACTION AND ISOLATION 
The plants of Borrago officinalis were collected from natural population growing 
in the mountain areas of Avellino (Italy) in October 2008. 
The flowers, deprived of stems, were crushed and subsequently extract with 
MeOH (1.5 L) at room temperature. The methanol extracts were then subjected to 
Kupchan’s partitioning methodology to give four extracts. The butanol-soluble 
portions were separated by sequential chromatographic techniques, affording, as 
major metabolite, a new glucoside (compound 24).  
 
7.2 STRUCTURAL ELUCIDATION OF COMPOUND 24 
 
 
 
 
The molecular formula of compound 24 was determined as C19H26O10 by HR-ESI 
[M+H]+ (m/z 415.1534, calcd. 415.1526), which was consistent with 13C NMR 
and HSQC data. The structure of compound 24 was elucidated by detailed 
analyses of 1H and 13C NMR chemical shift, and by COSY, HSQC, and HMBC 
experiments (Table 11).  
The 1H NMR spectrum clearly showed the presence of a methyl group at δH 1.35; 
an anomeric proton at δH 4.36 (d, J=7.8 MHz), with a large 3JH1,H2 coupling 
constant indicating the β-anomeric configuration of the monosaccharide residue; a 
set of monosubstituted aromatic proton signals at δH 7.26 (t, J=7.2 Hz), 7.32 (t, 
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J=7.2 Hz), 7.40 (d, J=7.7 Hz) and hydroxymethylene signals at δH 4.63 and 4.88 
suggesting the presence of a benzyl alcohol moiety. 
 The H2-7 (δH 4.88 and 4.63) and C-7 (δC 71.6) signals of the benzyl alcohol 
residue appeared downfield shifted and suggested the position of a 
monosaccharide unit. HMBC correlations were observed for H-7/C-1’ (δC 103.1), 
H-7/C-1 (δC 138.6), H-7/C-2(6) (δC 128.9), indicating that the monosaccaride  unit 
was linked to the benzyl carbon C-7 (Figure 49).  
 
 
 
 
Starting from the anomeric proton signal, the proton resonances of sugar moiety 
were assigned as reported in Table 11, by 1H-1H COSY and TOCSY experiments. 
The acid hydrolysis of compound 24 afforded D-glucose, which was identified 
after derivatization with L-cysteine methyl ester hydrochloride, followed by 
trimethylsilylation and GC analysis.193,194 
The chemical shift and coupling constants of H-1’ (δΗ 4.36 d, J = 7.4 Hz) and the 
chemical shift of C-1’ (δC 100.5) supported a β-configuration for the anomeric 
carbon. The low-field chemical shift of H2-6 (δΗ 3.84 dd and 4.06 dd) in the 1H 
NMR spectrum, indicated that the hydroxyl group at C-6 of glucose was linked 
with a second residue.  
The 13C NMR data disclosed the presence of two downfield signals at δC 172.2 
and 180.5, respectively assignable to an ester and a carboxylic function, a 
quaternary carbon at δC 70.9, two methylene carbon and a methyl group.  
Figure 49. HMBC cross peaks of compound 24. 
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The HMBC correlations showed the presence of 3-hydroxy-3-methylglutaric acid 
(HMGA) chain (Figure 50).  
 
 
 
 
The connection of the 3-hydroxy-3-methylglutaric acid with the sugar residue was 
supported from the HMBC correlation observed between the protons at δΗ 4.47 
and 4.22 (H2-6’ Glc) and the carbon at  δC 172.2 (Cα). This data were indicative 
of an ester function formed between the hydroxyl group in 6’ of glucose and the 
carboxylic group of 3-hydroxy-3-methilglutaric acid (Figure 51). 
 
 
 
 
 
Thus the structure of this compound was defined as a benzyl O-β-D-
glucopyranoside ester-linked with a chain of 3-hydroxy-3-methylglutaric acid 
(HMGA). This compound was unprecedented in natural products. 
There are few examples of natural compounds linked with HMGA. In flaxseed 
hulls the hydroxy-methyl-glutaric acid is the linker-molecule that connettes a 
glucosidated lignin with a second monosaccharide derivative to form 
macromolecules or oligomers.195,196  
 
 
Figure 50. HMBC cross peaks of HMGA in compound 24. 
Figure 51. HMBC cross peaks of compound 24. 
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Position  δHa (J in Hz) δC HMBCb (H→C) 
1 - 138.6  
2,6 7.40 d (7.7) 128.9 C4, C7 
3,5 7.32 t (7.2) 128.9 C1 
4 7.26 t (7.2) 128.5 C2,6 
7 4.88 ovl, 4.63 d (11.8) 71.6 C1, C2,6, C1’ 
Glc    
1’ 4.36 d (7.8) 103.1 C7 
2’ 3.26 74.9 C1’, C3’ 
3’ 3.35 77.7  
4’ 3.35 71.4 C3’ 
5’ 3.46 75.1 C4’ 
6’ 4.47 dd (11.8,2.0) 4.22 dd (11.8, 5.6) 64.3 Cα, C4, C5 
HMGA    
α - 172.2  
β 2.63, s 46.8 Cγ, Cα, Cω, Cδ 
γ - 70.9  
δ 2.55 d (15.3) 47.5 Cε, Cγ, Cω, Cβ 
δ 2.38 d (15.3)   
ε - 180.5  
ω 1.35 s 27.5 Cγ, Cβ, Cδ 
 
 
 
 
 
Table 11. 1H and 13C NMR (CD3OD, 500 MHz) of compound 24. 
a  1H and 13C assignments aided by COSY, TOCSY, HSQC and HMBC experiments. 
b HMBC correlations, optimized for 8 Hz, are from proton(s) stated to the indicated carbon. 
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CHAPTER 8 
RUSCUS ACULEATUS 
 
 
 
 
 
 
 
 
 
Ruscus aculeatus, Ruscaceae, (formerly in Liliaceae) is a low evergreen shrub that 
is native to the Mediterannean regions, but grows throughout Europe and 
elsewhere in woods and waste places. 
Tough, green, erect, striated stems, which are destitute of bark, have in the upper 
part many short branches, plentifully furnished with very rigid leaves known as 
cladodes, which are really a mere expansion of the stem, and terminate each in a 
single sharp spine (Figure 52). The plant’s true leaves are very small and appear at 
the center of cladodes. They are triangular or lanceolate, and are only a few 
millimeters long. The plant’s greenish-white flowers are placed singly in the 
center of the cladodes (along with the true leaves), they have a casing made up of 
6 petals and blossom in the early spring. The fertile flowers are succeeded by 
scarlet berries as large as cherries, containing 1-2 seeds, which are ripe in 
September, and remain attached to the plant all the winter and cause it often to be 
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picked for room decoration. The root or rhizome is thick, striking deep into the 
ground, that has no odour, but its taste is sweetish at first and then slightly acrid.  
 
Ruscus aculeatus is known with various names. The common name, Knee Holly, 
is derived from the fact that it rises to a height of a man's knee.  The name, 
Butcher's Broom, is derived from the fact that the dried plant was actually used as 
a broom (until the twentieth century!) throughout Europe, mostly by butchers who 
used it to whisk scraps from their cutting blocks.  
The aerial parts and roots are used in herbal medicine. Ancient Mediterranean 
healers utilized the root for circulatory and inflammatory disorders, and Greek 
doctors reported curing swelling with its use, referring to Butcher's Broom as "the 
miracle herb."  The first-century Roman scholar, Pliny, described its use as a cure 
for varicose veins in the first century, while Dioscorides highly recommended it as 
a diuretic and aperient (mild laxative), as well as a remedy for kidney stones and 
dropsy (edema). The herb was used regularly for many years to treat jaundice, 
gout and kidney and bladder stones.  
Today, it is used in Europe for disorders involving the venous system, including 
venous fragility or varicose veins, and clinical data also revealed positive effects 
on circulation. In particular, the extracts of rhizomes are used in the prevention 
and treatment of venous insufficiency.197-199 Moreover, because of their 
antielastase activity, they are components of drugs administered as 
Figure 52. Ruscus aculeautus plant, leaves, flowers and barriers. 
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antiinflammatory and vasoconstrictor agents.200 Their antiedematous effects have 
been also demonstrated.201,202 
 
8.1 EXTRACTION AND ISOLATION 
The plants of Ruscus aculeatus were collected from natural population growing in 
the hill areas of Pisa (Italy) in May 2009. The rhizomes were cleaned and  kept 
frozen at -20°C until analyzed. 
Rhizomes of Ruscus aculeatus were shaved and exhaustively extracted with 
MeOH. The MeOH  extracts were partitioned according the modified Kupchan 
partitioning procedure, obtaining four extracts.2 
The butanol-soluble portions were separated by sequential chromatographic 
techniques, affording, as major metabolites, three new furostanol saponins 
(compounds 25, 26 and 27).  
 
8.2 SAPONINS 
Saponins are terpenoid glycosides distributed widely in the plant kingdom. 
Saponins can be broadly divided into two groups based on whether the aglycone 
is of a triterpene or steroidal type. Triterpene saponins are the more widespread 
class, while steroidal saponins are mainly found in families of monocotyledons. 
Many medicinally important species are rich in these compounds; plant-derived 
saponins present a broad spectrum of biological uses, such as anti-cancer, anti-
inflammatory, ion channel blocking, immune stimulating, antifungal, 
antitrombotic, and hypocholesterolemic properties.203,204 
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Rhizomes of Ruscus aculeatus are rich in saponins, that are considered to be the 
active principles of the extract since they induce a beneficial effect on venous 
insufficiency, especially in the haemorroidal crisis.205-208 
Steroidal saponins isolated from Ruscus species are spirostane prosapogenins 
bearing a sugar chain linked to C-1 and furostanols carrying a sugar chain at C-1 
and a D-glucose residue at C-26.209-211  
 
8.3 STRUCTURAL CHARACTERIZATION OF COMPOUND 25 
 
 
 
 
 
Compound 25 showed in the HR-ESIMS spectrum a pseudomelecular ion peak at 
m/z  703.3447 [M-Na]- corresponding to the molecular formula C34H55NaO13S.  
The 1H NMR spectrum (Table 12) exhibited the signals of four distinct methyl 
groups (two singlets at δH 0.84 and 1.10 and two doublets at δH 0.95 and 0.99), a 
methoxyl signal at δH 3.14, an anomeric proton at δH 4.23 (d, J=7.7 MHz), a  
signal at δH 5.59 (br d, J=5.3 MHz), that was ascribable to a proton on sp2 carbon, 
and a further signal at δH 4.01, that in the HSQC experiment was correlated to the 
carbon at δC 85.6, that was attributed to a proton on  oxygenated bearing carbon 
esterificated with a sulfate group. This pattern of proton chemical shifts led us to 
initially suppose the glycoterpene nature of the compound. This was further 
corroborated by the 13C NMR spectrum, which showed the resonance of an 
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anomeric carbon (δC 104.3); the presence of the semiketal carbon signal at δC 
113.9, together with the carbinol at δC 82.2, suggested the furostanol nature of the 
aglycon. All the proton resonances were unambiguously associated with the 
relevant carbon atoms by using the HSQC spectrum. 
Insepction of COSY and TOCSY spectra allowed us to detect four distinct spin 
systems: three of them belonging to the aglycon moiety and the remaining one 
belonging to a monosaccharide unit (Figure 53).  
 
 
 
 
 
Concerning the aglycon moiety, the first spin system possessed two substituents at 
position 1 and 3, respectively a sulfated and an hydroxyl group; this spin system 
connected the sulfated carbon C-1 (δH 4.01, δC 85.6) with C-4, while the second 
one, starting from the sp2 C-6 (δH 5.60, δC 126.4) and encompassing all the 
protonated carbons of rings B, C and D ran out with C-21. The last spin system of 
the aglycon was constituted by protons of the side chain, from C-23 to the 
oxygen-bearing C-26 (δH 3.38-3.73, δC 75.6), including CH2-CH2-CH(CH3)-
CH2O-. 
Concerning the sugar portion of the molecule, the last spin system started from the 
anomeric proton and arrived to the hydroxymethylene at C-6’, identifying a 
hexopyranose unit. Comparing the 1H and 13C NMR values of this 
monosaccharide unit with the data reported in literature, a glucose was identified. 
O
OCH3
HO
NaO3SO O O
HO OH
OH
OH
Figure 53. Four distinct spin systems deduced from COSY spectrum. 
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The chemical shift and the coupling constants of H-1’ (δH 4.23, d, J=7.7 MHz) 
and the chemical shift of C-1’ (δC 104.3) supported a β-configuration for the 
anomeric proton. To confirm the nature of the sugar and to determine its absolute 
configuration, compound 25 was subjected to acid hydrolysis (HCl 1N). The 
hydrolyzed was reacted with L-cysteine methyl ester hydrochloride; followed by 
trimethylsilylation and GC analysis in comparison with D- and L- glucose.193 By 
this procedure the sugar was identified as D-glucose. 
Data arising from HMBC experiment were used to interconnect the spatial 
structures (Figure 54). The following HMBC cross-peaks were particularly 
diagnostic to assemble the above structures: H3-19 (δH 1.10) with C-1 (δC 85.6), 
C-5 (δC 138.7), C-9 (δC 50.7), and C-10 (δC 43.7); H3-18 (δH 0.84) with C-12 (δC 
40.8), C-13 (δC 41.4), C-14 (δC 57.5) and C-17 (δC 65.0); H3-21 (δH 1.72) with C-
17, C-20 (δC 41.0) and the ketal carbon C-22 (δC 113.9), and the methoxyl protons 
(δH 3.14) with C-22. So the three methyl groups were placed in positions 10, 13 
and 20; and the methoxyl group was placed on the ketal carbon at C-22. The side 
chain was linked to C-22, because the presence of HMBC cross-peaks between 
H2-23 (δH 1.72-1.63) and C-20 and C-22. A further methyl group was placed on 
the side chain at C-25 for the presence of the HMBC correlations of H3-27 with C-
24 (δC 28.7), C-25 (δC 34.7) and C-26 (δC 75.6). The total of this evidence allowed 
us to identify the aglycon moiety as a ∆5-furostan-1,3,22,26-tetraol.  
The β-D-glucose unit was placed at C-26 by interpretation of the key HMBC 
correlation peak between H-1’ (δH 4.23) and C-26 (δH 75.6). 
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The presence of the sulfate group was confirmed after solvolysis in a dioxane-
pyridine mixture, that afforded a less polar desulfated derivative, which gave a 
pseudomolecular ion at m/z 623.5 [M-H]-. The upfield shift of the H-1 signal from 
δH 4.01 to 3.34 ppm in the desulfate derivative established the location of the 
sulfate residue at C-1 of the aglycon. This placement was confirmed by 13C NMR, 
in which the signal of C-1 was upfield shifted from δC 85.6 to 78.6 ppm. 
The ROESY experiment allowed us to determinate the ring-junctions (Figure 55). 
In particular, the ROESY correlations H-11/H3-19, H-11/H3-18, H-9/H-14, H-
14/H-16, H-16/H-17 and H-17/H3-21 completed the relative stereochemistry of 
the saponin with the usual B/C trans, C/D trans, D/E cis, and C-20α 
stereochemistries.212,213 The ROE effect between H-1 and H-3 indicated the cis 
orientation of the two  substituents of ring A.  
 
 
 
 
 
 
 
Figure 54. Key HMBC correlations of compound 25. 
Figure 55. ROE correlations supporting the relative configuration of compound 25. 
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The last step was the determination of the stereochemistries at C-22 and C-25. 
We have assigned the 22β orientation on the basis of the chemical shift value of 
H-16. In fact when the methoxyl group is α, the signal of  H-16 was downfield 
shifted, due to the deshielding effect of the cis-oriented OCH3 group (H-16 δH 
4.60  instead of 4.35).214,215 
The 25R stereochemistry of the side chain was tentatively assigned by the 
resonances of the protons and carbons at C-25, C-26 and C-27 and by the vicinal 
couplings between H-25 and the two H-26, in comparison with the literature 
data.216 To confirm this stereochemistry, we will derivatize with a chiral agent 
(MPTA, the Mosher reagent). This method allows determination of the absolute 
configuration of primary carbinols with a chiral center at C-2 by comparing 1H-
NMR spectra with those of 25-(R)- and 25-(S)-MPTA esters of model 
compounds. 
 
8.4 STRUCTURAL CHARACTERIZATION OF COMPOUND 26 
 
 
 
 
Compound 26 showed a pseudomolecular ion peak at m/z 701.4326 [M-Na]-, 
corresponding to the molecular formula C34H53NaO13S, indicating, as in compound 
25, the presence of a sulfate function. The 1H NMR spectrum was very similar to 
that of compound 25, concerning  the steroidal portion, but it differs only for the 
side chain (Table 12). In particular the 1H NMR spectrum clearly showed the loss 
O
OCH3
HO
NaO3SO O
26
O
HO OH
OH
OH
1
3
6
19
18
21
16
22
25
27
1' 6'
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of the methyl group at C-25 and the gain of two signals [δH 5.10 and 4.94 (br s)], 
ascribable to protons on sp2 carbon, suggesting the replacement of a methyl group 
with an exomethylene group. This function was placed in the side chain at C-25 for 
the presence of diagnostic HMBC cross-peaks between the two vynil portons with 
the C-24 (δC 28.5), C-25 (δC 147.0), and C-26 (δC 72.5) (Figure 56). 
 
 
The steroidal saponin skeleton was considered to adopt the usual B/C trans, C/D 
trans, D/E cis arrangement, and the two substituents of ring A was considered to 
adopt a cis orientation as evidenced by ROESY analysis. The stereochemistry at 
C-22 and C-25 were established similarly to compound 25. 
Saponins containing sulphated sugar residues have frequently been 
identified,217,218 but direct esterification of the aglycone by a sulphate function is 
much less common.219 
 
 
 
 
 
 
Figure 56. Key HMBC correlations of the side chain of compound 26. 
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8.5 STRUCTURAL CHARACTERIZATION OF COMPOUND 27 
 
 
 
 
 
Compound 27 showed a pseudomolecular ion peak at m/z 929.5682 [M-H]-, 
corresponding to the molecular formula C46H74O19. The 1H NMR spectrum of 
compound 27 was very similar to that of compound 26 concerning the side chain 
(Table 13 Hz). This spectrum clearly evidenced the gain of a methyl group at δH 
1.24 (d, J=6.6); the loss of the proton at δH 4.03, suggesting the absence of the 
sulfate group, also confirmed by mass data; and a number of overlapped signals 
between δH 3.16 and 5.30, attributable to protons on oxygen-bearing carbons, 
indicating the presence of some sugar units. In particular there were three 
anomeric protons at δH 4.27 (d, J=7.5), 4.28 (d, J=7.6) and 5.29 (br s), indicating 
the presence of three sugar units. This was further corroborated by the 13C NMR 
which showed the resonances of three anomeric carbons at δC 101.0, 101.6, 103.3. 
The interpretation of bidimentional NMR data showed that the aglycone moiety of 
compound 27 was superimposable to that of compound 26, except for the 
replacement of the sulfate group at C-1 with a sugar moiety. In fact, the H-1 
proton was upfield shifted from δH 4.03 to 3.37 ppm. 
Analysis of homonuclear COSY and TOCSY experiments allowed the 
assignements of all the proton resonances of the three sugar moieties, whereas 
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evaluation of the coupling constants was used to elucidate the monosaccaride 
relative stereochemistry.  
Hence, when the anomeric proton at δH 4.27 (H-1’’) was used as a starting point, a 
sequence of only two oxymethines was identified from the TOCSY spectrum. The 
large coupling constants observed for H-1”/H-2” and H-2”/H-3” vicinal 
couplings, and the relatively small coupling constants of H-3”/H-4” and H-4”/H-
5”, indicated the β-galactopyranose nature of this sugar. The pattern of 13C NMR 
resonances confirmed this assignment. The galactopyranose residue was linked to 
the C-1 of the aglycon, as indicated by the HMBC correlation peak between the 
anomeric proton H-1” at δH  4.27 to the C-1  at δC 84.2 (Figure 56).  
The spin system starting with the anomeric proton at δH 5.29 (H-1’’’), extended to 
four oxymethine and one methyl group. This sugar moiety was identified as a 
rhamnopyranose. The chemical shift of C-3’’’ (δC  72.1) and C-5’’’ (δC 69.7) 
indicated the α-anomeric configuration of this sugar, in accordance with data 
reported in literature.220 The linkage of this monosaccharide at C-2” of the 
galactose unit was inferred on the basis of the HMBC cross-peaks between H-1’’’ 
(δH 5.29) and C2” (δC 75.6) (Figure 57).  
On the other hand, the HMBC cross-peaks of H-1’ (δH 4.28)  with the C-26 (δC 
72.5) allowed to identify this carbon as a further glycosidic linkage site. Starting 
from the H-1’ (δH 4.28), we identified a sequence of four oxymethine and one 
oxymethylene protons. These data led to the assignment of this sugar as a β-
glucopyranose linked at C-26 like in compound 26.  
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The stereochemical series of the sugar units were defined as D for glucose and 
galactose and L for rhamnose, assuming that these monosaccharides belong to the 
most commonly found stereochemical series. 
 
 
ROESY experiment showed the usual B/C trans, C/D trans, D/E cis arrangement, 
C-20α stereochemistry, and a cis orientation for the two substituents of ring A, 
similarly to compound 26.  
However, this compound differed from compound 26 in the stereochemistry of C-
22. In fact 1H and 13C NMR spectra of these two compounds appeared to differ 
considerably in the resonances of atoms located close to C-22. We had tentatively 
assigned the 22α orientation to compound 27 on the basis of the 1H NMR 
resonance of H-16, slightly downfield shifted (at δH 4.57 instead of 4.39) 
compared to compound 26, suggesting that it was deshielded by the cis-
orientation of the methoxyl group at C-22.  
 
 
 
 
 
Figure 57. HMBC cross-peaks of the sugar units. 
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 Compound 25 Compound 26 
Position δH (J in Hz) δC δH (J in Hz) δC 
1 4.01 (dd, 11.7, 3.9) 85.6 4.03 (dd, 11.7, 3.89 84.6 
2a 
2b 
2.55 a 
1.67 a 
38.8 2.58 a 
1.72 a 
38.8 
3 3.42 a 68.7 3.46 a 68.6 
4a 
4b 
2.21 a 
 
42.8 2.26 a 42.7 
5 - 138.7 - 137.9 
6 5.60 (br d, 5.3) 126.4 5.61 (br d, 5.4) 126.5 
7a 
7b 
1.95 a 
1.54 a 
32.7 1.99 a 
1.51 a 
32.6 
8 1.54 a 33.7 1.58 a 33.8 
9 1.35a 50.7 1.38 a 50.8 
10 - 43.7 - 43.7 
11a 
11b 
2.36a 
 
24.0 2.39 a 
1.55 a 
23.8 
12a 
12b 
1.70a 
1.25a 
40.8 1.74 a 
1.29 a 
40.9 
13 - 41.4 - 41.4 
14 1.13a 57.5 1.19 a 57.4 
15a 
15b 
1.95a 
1.25a 
32.6 2.00 a 
1.32 a 
32.7 
16 4.35 (m) 82.2 4.39 (m) 82.3 
17 1.71a 65.0 1.75 a 65.0 
18 0.84 s 16.7 0.87 s 16.7 
19 1.10 s 14.5 1.13 s 14.5 
20 2.17 a 41.0 2.23 a 41.1 
21 0.99 (d, 6.8) 16.1 1.04 (d, 6.7) 15.9 
22 - 113.9 - 112.7 
23a 
23b 
1.72 a 
1.63 a 
 1.58 a 31.8 
24a 
24b 
1.57 a 
1.12 a 
28.7 2.22 a 
1.87 a 
28.5 
25 1.72 a 34.7 - 147.0 
26a 
26b 
3.73 a 
3.38 a 
75.6 4.36 
4.12 
72.5 
27 0.95 (d, 6.6)  17.1 5.10 (br s) 
4.94 (br s) 
111.9 
OCH3 3.14 s 47.4   
Glucose     
1’ 4.23 (d, 7.7) 104.3 4.27 (d, 7.7) 103.0 
2’ 
3’ 
3.18 a 
3.35 a 
74.9 
77.9 
3.23 a 
3.35 a 
74.8 
77.8 
4’ 3.25 a 71.5 3.20 a 71.4 
5’ 3.26 a 77.9 3.26 a 77.6 
6’ 3.84 (br d, 11.7) 
3.64 (dd, 11.7, 5.1) 
62.6 3.88 (br d, 11.8) 
3.69 (dd, 11.8, 5.2) 
62.5 
Table 12. 1H and 13C NMR (CD3OD, 500 MHz) of compounds 25 and 26. 
a
 Overlapped with other signals 
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Position δH (J in Hz) δC  
1 3.37 a 84.2 
2a 
2b 
2.09 a 
1.68 a 
36.9 
3 3.34 a 68.9 
4a 
4b 
2.26 a 
2.22 a 
43.1 
5 - 141.1 
6 5.56 (br d, 5.3) 125.6 
7a 
7b 
1.97 a 
1.56 a 
32.7 
8 1.55 a 33.7 
9 1.24 a 51.1 
10 - 43.1 
11a 
11b 
2.56 a 
1.44 a 
24.5 
12a 
12b 
1.69 a 
1.21 a 
40.9 
13 - 41.2 
14 1.44 a 57.5 
15a 
15b 
1.97 a 
1.28 a 
32.4 
16 4.57 (m) 82.1 
17 1.77 a 63.9 
18 0.85 s 16.9 
19 1.10 s 14.9 
20 2.14 a 40.6 
21 1.02 (d, 6.6) 15.7 
22 - 111.1 
23a 
23b 
1.85 a 37.6 
24a 
24b 
2.28 a 28.2 
25 - 147.0 
26a 
26b 
4.34 
4.12 
72.5 
27 5.08 (br s) 
4.93 (br s) 
111.9 
OCH3 3.16 s 47.4 
Glucose   
1’ 4.28 (d, 7.6) 103.3 
2’ 
3’ 
3.20 a 
3.35 a 
75.2 
78.1 
4’ 3.28 a 71.7 
5’ 3.26 a 77.9 
6’ 3.88 a 
3.65 a 
62.8 
Galactose   
1’’ 4.27 (d, 7.5) 101.0 
2’’ 3.69 a 75.6 
3’’ 3.67 a 72.2 
4’’ 3.63 a 76.0 
5’’ 3.73 a 70.9 
6’’ 3.85 (br d, 11.5) 
3.48 (br d, 11.5) 
67.4 
Rhamnose   
1’’’ 5.29 (br s) 101.6 
2’’’ 3.88 a 72.4 
3’’’ 3.69 a 72.1 
4’’’ 3.39 a 74.2 
5’’’ 4.08 a 69.7 
6’’’ 1.24 (d, 6.6) 18.4 
Position δH (J in Hz) δC  
Table 13. 1H and 13C NMR (CD3OD, 500 MHz) of compounds 27. 
a
 Overlapped with other signals 
a
 Overlapped with other signals 
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CONCLUSIONS 
In conclusion, natural products have proven to be the most prolific source of new 
and effective drugs, and they have also provided insight into new mechanisms of 
action. Medicine would be immeasurably poorer without the insights and the 
compounds provided from Nature. 
It is thus instructive to ask why it is that natural products have proved to be such a 
prolific source of bioactive agents. There are several reasons, but certainly one of 
the most important is that plants and marine organisms produce many biologically 
active substances for defense and other purposes, and so these substances are 
uniquely tailored to fit into a biological receptor of some kind. Natural products 
are often large molecules with built-in chirality and are thus uniquely suited to 
bind to complex proteins and other biological receptors. As a result of these 
considerations, there is a high correlation between the properties of drugs and 
those of natural products. 
The focus of this phD Thesis was the investigation of bioactive secondary 
metabolites from different natural sources (plants and marine sponges) that has 
been successful in the discovery of new chemistry with potential pharmaceutical 
and biochemical applications. This thesis underlines that the marine sponges are a 
cornucopia of new bioactive compounds, and plants are still contributing to 
medicine. The interest in these compounds is first of all due to their strong 
biological activity. This aspect has also inspired synthetic study to develop several 
synthetic methodologies and strategies for new drugs. 
In summary, the misconception that natural products research has not produced 
many drugs is laid: the future of natural products research remains bright. 
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EXPERIMENTAL SECTION 
 
I. General Experimental Procedures.  
Optical rotations (CHCl3 or MeOH) were measured at 589 nm on a JASCO P-
2000. High-resolution ESI-MS spectra were performed with a Micromass Q-TOF 
mass spectrometer. ESIMS experiments were performed on an Applied Biosystem 
API 2000 triple–quadrupole mass spectrometer. 1H (500 and 700 MHz) and 13C 
(125 and 175 MHz) NMR spectra were measured on Varian INOVA 
spectrometers. Chemical shifts were referenced to the residual solvent signal 
(CHCl3: δH 7.26, δC 77.0; CD2HOD: δH 3.30, δC 49.0; CD2HSOCD3: δH 2.50, δC 
39.5). Homonuclear 1H connectivities were determined by the COSY experiment; 
one-bond heteronuclear 1H-13C connectivities by the HSQC experiment; two- and 
three-bond 1H-13C connectivities by gradient-HMBC experiments optimized for a 
2,3J of 8 Hz . 
DCCC was performed using a DCC-A (Rakakikai Co. Di Tokio) equipped with 
250 columns (internal diameter 3 mm). 
Medium pressure liquid chromatography was performed on a Büchi apparatus 
using a silica gel (230-400 mesh) column. 
HPLC was performed using a Waters Model 510 pump equipped with Rheodine 
injector and a differential refractometer, Waters model 401. 
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II. Experimental Section of Coscinoderma mathewsi 
 
Sponge material and separation of individual sesterpenoids. Coscinoderma 
mathewsi Lendenfield (order Dictyoceratida, family Spongiidae) was collected on 
the barrier reef of Vangunu Island, Solomon Islands, in July 2004. The samples 
were frozen immediately after collection and lyophilized to yield 322 g of dry 
mass. The sponge was identified by Dr John Hooper, Queensland Museum, 
Brisbane, Australia, where a voucher specimen is deposited  under the accessing 
number G322695. 
The lyophilized material (322 g) was extracted with methanol (3×3 L) at room 
temperature and the crude methanolic extract (72.6 g) was subjected to a modified 
Kupchan's partitioning procedure as follows. The methanol extract was dissolved 
in a mixture of MeOH/H2O containing 10% H2O and partitioned against n-
hexane. The water content (% v/v) of the MeOH extract was adjusted to 30% and 
partitioned against CHCl3. The aqueous phase was concentrated to remove MeOH 
and then extracted with n-BuOH. The hexane, chloroform and butanol extracts 
were tested against PLA2 at 400 mg/mL dose showing 94, 93 and 59% inhibition, 
respectively. 
The n-BuOH extract (4 g) was chromatographed in four runs by DCCC 
(CHCl3/MeOH/H2O, 7:13:8, ascending mode) and fractions of 6 mL were 
collected and combined on the basis of their similar TLC retention factors.  
Fraction 7 (28.4 mg) was purified by HPLC on a Nucleodur C18 column (3?m, 
150×4.60 mm, flow rate 1.0 mL/min) with 45% MeOH/H2O as eluent to give 3.1 
mg of coscinolactam A (1) (tR=10 min) and 1.9 mg of coscinolactam B (2) (tR=11 
min).  
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The chloroform-soluble material (1.5 g), mainly containing suvanine, was 
chromatographed by DCCC using CHCl3/MeOH/H2O (7:13:8) in the ascending 
mode (the lower phase was the stationary phase); the flow rate was 18 mL/h; 6 mL 
fractions were collected and combined on the basis of their similar TLC retention 
factors. 
Fraction 2 (262 mg) was purified by HPLC on a µ-Bondapack C18 column (10?m, 
300×7.8 mm, flow rate 4.0 mL/min) with 65% MeOH/H2O as eluent to give 240 
mg of suvanine (tR=8 min). 
Characteristic data for each compound 
Coscinolactam A: white amorphous solid; [α]D25 +25.7 (c 0.07, methanol); 1H and 
13C NMR data in CD3OD given in Table 1; ESI-MS: m/z 522.3 [M-H]-. HRMS 
(ESI): calcd. for C27H40NO7S: 522.2525; found 522.2547 [M-H]-. 
Coscinolactam B: white amorphous solid; [α]D25 +8.57 (c 0.07, methanol); 1H and 
13C NMR data in CD3OD given in Table 1; ESI-MS: m/z 522.3 [M-H]-. HRMS 
(ESI): calcd. for C27H40NO7S: 522.2525; found 522.2509  [M-H]-. 
Suvanine: white amorphous solid; [α]D25 +12.2 (c 0.4, methanol); ESI-MS: m/z 
522.3 [M-H]-. HRMS (ESI): calcd. for C25H37O5S: 449.2362; found 449.2387 [M-
H]-. 
Synthetic Procedures  
Aldehyde 4 
A solution of suvanine 3 (15 mg, 0.033 mmol) in pyridine (0.5 ml) and dioxane 
(0.5 ml) was heated at 150°C for 2.5 h in a stoppered reaction vial. After the 
solution was cooled, the mixture was evaporated to dryness and then purified by 
HPLC on a µ-Bondapak C18 column (30 cm x 3.9 mm i.d.) with MeOH/H2O 
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80:20, to give aldehyde 4 as a 9:1 mixture of two diasteroisomers (9.2 mg, 80%). 
ESIMS: 371.30 [M+H]+; selected 1H-NMR (500 MHz, CDCl3) for major 
diasteroisomer: 9.48 (1H, s, -CHO), 7.39 (1H, s), 7.28 (1H, s), 6.33 (CH-18, s), 
1.04 (3H, s), 0.87 (3H, s), 0.86 (3H, s), 0.84 (3H, s),. 
Alcohol 5 
NaBH4 was added in one portion to a stirred solution of 4 (5.2 mg, 0.014 mmol) in 
MeOH at room temperature. The mixture was stirred for 1 h and then was 
concentrated in vacuo and then diluted with NH4Cl and ethyl acetate. The aqueous 
phase was extracted with ethyl acetate and then the combined organic extracts 
were washed with brine, dried (Na2SO4) and concentrated in vacuo to yield alcohol 
5 as a 9:1 mixture of two diasteroisomers (4.7 mg, 90%). ESIMS: 373.40 [M+H]+; 
selected 1H-NMR (500 MHz, CDCl3) for major diasteroisomer: 7.39 (1H, s), 7.28 
(1H, s), 6.33 (1H, s), 3.71 (d, J=11.3 Hz, H-24), 3.43 (dd, J=11.3, 4.5 Hz, H-24), 
1.13 (3H, s), 0.90 (3H, s), 0.86 (6H, s). 
Anti-inflammatory assays. 
Materials. [5,6,8,11,12,14,15(n)-3H] PGE2 and [9,10-3H]oleic acid were purchased 
from Amersham Biosciences (Barcelona, Spain). Inducible NO synthase specific 
polyclonal antiserum was purchased from Cayman Chem. (MI, USA). The 
peroxidase-conjugated goat anti-rabbit Immunoglobulin G (IgG) was purchased 
from Dako (Copenhagen, Denmark). The rest of reagents were from Sigma (MO, 
USA) 
Assay of sPLA2. sPLA2 activity was assayed using [3H]-oleate labeled 
membranes of Escherichia coli, following a modification of the method of 
Franson et al.221,222 E. coli strain CECT 101 was grown for 6 to 8 h at 37 ºC in the 
presence of 5 µCi/mL [3H]-oleic acid (specific activity 10 Ci/mmol) until the end 
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of the logarithmic phase. After centrifugation at 1,800 g for 10 min at 4 ºC, the 
membranes were washed, resuspended in PBS and autoclaved for 30 to 45 min. 
At least 95% of the radioactivity was incorporated into the phospholipid fraction. 
Naja naja venom (Group IA sPLA2), porcine pancreatic (Group IB sPLA2), 
human recombinant synovial (Group IIA sPLA2), and bee venom (Group III 
sPLA2) enzymes were used as sources of sPLA2. Enzymes were diluted in 10 µL 
of 100 mM Tris-HCl, 1 mM CaCl2 buffer pH 7.5, and preincubated at 37 ºC for 5 
min with test compound or vehicle in a final volume of 250 µL. Incubation 
proceeded for 15 min in the presence of 20 µL of [3H]oleic-Escherichia coli 
membranes and was terminated by addition of 100 µL ice-cold solution of 0.25% 
BSA in saline to a final concentration of 0.07% w/v. After centrifugation at 2,500 
x g for 10 min at 4 ºC, the radioactivity in the supernatants was determined by 
liquid scintillation counting. 
Culture of murine macrophage RAW 264.7. The mouse macrophage cell line 
RAW 264.7 (Cell Collection, Department of Animal Cell Culture, C.S.I.C., 
Madrid, Spain) was cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin and 
10% foetal bovine serum. Cultures were maintained at 37 ºC in 5% CO2 (air: 
CO2, 95:5) humidified incubator. Cells were resuspended at a concentration of 
1.5x106 cells/mL.  
Nitric oxide and PGE2 production in RAW 264.7 macrophages. RAW 264.7 
macrophages (1.5x106 cells/mL) were co-incubated in 96-well culture plate (200 
µL) with 1 µg/mL of Escherichia coli [serotype 0111:B4] lipopolysaccharide 
(LPS) at 37 ºC for 20 h in the presence of test compounds or vehicle. Nitrite 
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concentration as reflection of NO release was assayed fluorometrically.223 PGE2 
levels were determined in culture supernatants by radioimmunoassay.224 The 
mitochondrial-dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to formazan,225 was used to assess the 
possible cytotoxic effects of compounds (100% viability = 0.533 ± 0.010 at 492 
nm). 
Western blot assay of iNOS. Cellular lysates from RAW 264.7 (murine 
macrophages 1.5x106 cell/mL) incubated for 18 h with LPS (1 µg/mL) were 
obtained with lysis buffer A (10 mM HEPES, pH 8.0, 1 mM EDTA, 1mM EGTA, 
10 mM KCl, 1 mM dithiothreitol, 5mM NaF, 1 mM Na3VO4, 10mM Na2MoO4, 1 
µg/mL leupeptin, 0.1 µg/mL aprotinin and 0.5 mM phenylmethyl sulfonyl 
fluoride). Following centrifugation (10,000 x g/15 min/4 ºC), supernatant protein 
was determined by the Bradford method226 using bovine serum albumin (BSA) as 
standard. iNOS protein expression was studied in the total fraction Equal amounts 
of protein (25 µg) were loaded on 15% SDS-PAGE and transferred onto 
polyvinylidene difluoride membranes for 90 min at 125 mA. Membranes were 
blocked in PBS (0.02M pH 7.0)-Tween 20 (0.1%), containing 3% w/v unfatted 
milk and incubated with specific polyclonal antibody against iNOS (1/1,000). 
Finally, membranes were incubated with peroxidase-conjugated goat anti-rabbit 
IgG (1/10,000). The immunoreactive bands were visualized using an enhanced 
chemiluminescence system (Amersham Biosciences, Barcelona, Spain). 
Statistical analysis. The results are presented as mean ± SEM represents the 
number of experiments. Inhibitory concentration 50% (IC50) values were 
calculated from at least 4 significant concentrations (n=6). The level of statistical 
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significance was determined by analysis of variance (ANOVA) followed by 
Dunnett's t-test for multiple comparisons.227 
Spectroscopic Data of Coscinolactams A and B 
 
 
 
 
COSY spectrum of Coscinolactam A in CD3OD at 700 MHz. 
1H NMR spectrum of coscinolactam A  in CD3OD at 700 MHz. 
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TOCSY spectrum of coscinolactam A  in CD3OD at 700 MHz. 
HSQC spectrum of Coscinolactam A in CD3OD at 700 MHz. 
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1H NMR spectrum of coscinolactam B  in CD3OD at 700 MHz. 
HMBC spectrum of Coscinolactam A in CD3OD at 700 MHz. 
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HMBC spectrum of coscinolactam B  in CD3OD at 700 MHz. 
HSQC spectrum of coscinolactam B  in CD3OD at 700 MHz. 
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III. Experimental section of Theonella swinhoei 
Sponge material and separation of individual. Theonella swinhoei (order 
Lithistida, family Theonellidae) was collected on the barrier reef of Vangunu 
Island, Solomon Islands, in July 2004. The samples were frozen immediately after 
collection and lyophilized to yield 207 g of dry mass. Taxonomic identification 
was performed by Prof. John Hooper of Queensland Museum, Brisbane, Australia, 
and reference specimens are on file (R3170) at the ORSTOM Centre of Noumea. 
The lyophilized material (207 g) was extracted with methanol (3×1.7 L) at room 
temperature and the crude methanolic extract was subjected to a modified 
Kupchan's partitioning procedure as follows. The methanol extract was dissolved 
in a mixture of MeOH/H2O containing 10% H2O and partitioned against n-hexane. 
The water content (% v/v) of the MeOH extract was adjusted to 30% and 
partitioned against CHCl3. The aqueous phase was concentrated to remove MeOH 
and then extracted with n-BuOH.  
The n-BuOH extract (4 g) was chromatographed in two runs by DCCC using n-
BuOH/Me2CO/H2O (3:1:5) in the descending mode (the upper phase was the 
stationary phase), flow rate 8 mL/min; 4 mL fractions were collected and 
combined on the basis of their similar TLC retention factors.  
Fractions 2 and 3 (45.4 mg) were purified by HPLC on a C-18 column Macherey-
Nagel Nucleodur 100-5 (5µ, 250 x 4.6 mm, 1.0 mL/min) using 32% MeOH/H2O 
(isocratic mode) as eluent to give solomosterols A and B. 
Fractions 8-13 (560 mg) were purified by HPLC on a reverse phase C-12 Jupiter 
Proteo C12 (Phenomenex, 4µ, 250 x 4.6 mm, 1.0 mL/min) eluting in isocratic 
mode with 59% MeOH/H2O + 0.1% TFA to afford perthamides C-K. 
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Fractions 15-23 (256.6 mg) were purified by HPLC on a C-12 Jupiter Proteo 
column (Phenomenex, 4µ, 250 x 4.6 mm, 1.0 mL/min) with 20% MeOH/H2O + 
0.1% of TFA as eluent to give 44.3 mg of solomonamide A and B. 
The chloroform-soluble material (5.83 g) was chromatographated by silica gel MPLC 
(Macherey-Nagel 200-400 mesh, eluting with CH2Cl2-MeOH 0-100%), the fractions 
were collected on the basis of their TLC retention times. Fraction 2 (88 mg) was 
purified by HPLC on a Nucleodur C18
 
column (5µ, Makerey Nagel, 250 x 7.8mm, 1.0 
mL/min) with 95% MeOH/H2O as eluent to give swinholide A (24.2 mg) and its 
structural analogue (compound 19, 1.6 mg). 
Characteristic data for Solomonsterols A and B 
Characteristic data for each compound. Solomonsterol A (6): white amorphous 
solid; [α]D25 +4.6 (c 0.8, methanol); 1H and 13C NMR data in CD3OH given in 
Table 5; ESIMS: m/z 661.2 [M-Na]-, 308.3 [M-2Na]2-. HR ESIMS: calcd for 
C24H39Na2O12S3: 661.1399; found 661.1415 [M-Na]-. 
Solomonsterol B (7): white amorphous solid; [α]D25 +3.3 (c 0.1, methanol); 1H and 
13C NMR data in CD3OH given in Table 5 ESIMS: m/z 647.3 [M-2Na]-, 301.2 [M-
2Na]2-. HR ESIMS: calcd for C23H37Na2O12S3: 647.1243; found 647.1298 [M-Na]-. 
Quantitative Real-Time PCR. RAW264.7 macrophages and HepG2 cells were 
cultured as previously described. Cells were incubated with 10 and 50 µM of 
solomonsterols A and B for 24 hours. At the end of incubation cells were 
harvested and lysed with 1 mL TRIZOL reagent for RNA extraction (Invitrogen). 
Fifty ng template was added to the PCR mixture (final volume 25 µL) containing 
the following reagents: 0.2 µM of each primer and 12.5 µL of 2X SYBR Green 
qPCR master mix (Invitrogen, Milan, Italy). All reactions were performed in 
triplicate and the thermal cycling conditions were: 2 minutes at 95 °C, followed 
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by 40 cycles of 95 °C for 20 seconds, 55 °C for 20 seconds and 72 °C for 30 
seconds in iCycler iQ instrument (Biorad, Hercules, CA). The mean value of the 
replicates for each sample was calculated and expressed as cycle threshold (CT: 
cycle number at which each PCR reaction reaches a predetermined fluorescence 
threshold, set within the linear range of all reactions). The amount of gene 
expression was then calculated as the difference (∆CT) between the CT value of 
the sample for the target gene and the mean CT value of that sample for the 
endogenous control (GAPDH). Relative expression was calculated as 2-∆∆CT. All 
PCR primers were designed with PRIMER3-OUTPUT software using published 
sequence data from the NCBI database.152 
Cell Based Luciferase Assay. To investigate their PXR-activating properties, 
solomonsterols A and B were tested in a cell based luciferase assay. Since PXR 
functions as an heterodimer with the retinoid-X-receptor (RXR), HepG2 cells 
were transfected with a PXR and RXR expressing vectors (pSG5-PXR and pSG5-
RXR), with a reporter vector containing the PXR target gene promoter (CYP3A4 
gene promoter) cloned upstream of the luciferase gene (pCYP3A4promoter-
TKLuc) and with a β-galactosidase expressing vector as internal control of 
transfection efficiency (pCMV-β-gal). 24 hours post transfection the cells were 
stimulated 18 hours with the PXR ligand rifaximin 10 ?M (as positive internal 
control) and with 50 ?M of solomonsterols A and B. 5 ?L of cell lysate was 
incubated with a substrate of luciferase gene (luciferase assay substrate - 
Promega) and the Relative Luciferase Units (RLU) were measured with the 
Glomax 20/20 luminometer (Promega). Luciferase activities were normalized for 
transfection efficiencies by dividing the relative light units by β-galactosidase 
activity expressed from cotransfected pCMV-βgal plasmid (RLU/β-gal). 
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Computational Details. To allow full exploration of the conformational space of 
solomonsterol A, molecular dynamics (MD) calculations were performed at 300K 
for 50ns using the AMBER force field (MacroModel software package)228 to give 
100 structures, each of which was minimized using the Polak-Ribier Conjugate 
Gradient algorithm (PRCG, 1000 steps, maximum derivative less than 0.05 
kcal/mol). These calculations provided the lowest energy minimum conformer for 
solomonsterol A. 
Docking of the minimized energy structure of solomonsterol A to the crystal 
structure of the human pregame-X-receptor in complex with hyperforin, pdb 
accession code 1M13) was carried out with the program Autodock Vina 1.0.3. 
Blind docking was carried out with an exhaustiveness value of 256. The binding 
affinities of the 9 output structures ranged from -10.0 kcal/mol to -8.7 kcal/mol. 
 
Spectroscopic Data of Solomonsterols A and B 
 
 
1H NMR spectrum of solomonsterol A  in CD3OD at 700 MHz. 
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HSQC spectrum of solomonsterol A  in CD3OD at 700 MHz. 
COSY spectrum of solomonsterol A  in CD3OD at 700 MHz. 
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ROESY spectrum of solomonsterol A  in CD3OD at 700 MHz (200 msec). 
HMBC spectrum of solomonsterol A  in CD3OD at 700 MHz. 
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1H NMR spectrum of solomonsterol B  in CD3OD at 700 MHz. 
ROESY spectrum of solomonsterol A  in CD3OD at 700 MHz (400 msec). 
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HSQC spectrum of solomonsterol B in CD3OD at 700 MHz. 
COSY spectrum of solomonsterol B in CD3OD at 700 MHz. 
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HMBC spectrum of solomonsterol B in CD3OD at 700 MHz. 
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Characteristic data for Perthamides C
Perthamide C (8): white amorphous solid; 
13C NMR data in DMSO
C44H65N11O18S: 1066.4242; found 
Perthamide D (9): White amorphous solid; [
(ESI): calcd for C44H65N11O
Perthamide E (10): white amporphous solid; 
given in Table 6; HR-ESIMS: calcd for C
1080.4394 [M-H]-. 
Perthamide F (11): white amporphous solid; 
C45H67N11O17S m/z 1064.4437; found 106
Perthamide G (12): white amporphous solid; HR
C43H63N11O18S m/z 1052.4146; found 105
Perthamide H (13): white amporphous solid; 
C44H65N11O15 m/z 986.4662; found 988.4
Perthamide I (14): white amporphous solid; 
C45H67N11O15 m/z 1000.4823
Perthamide J (15): white amporphous solid; 
C44H62N10O15 m/z 970.4396; found 97
Perthamide K (16): white amporphous solid; 
C45H64N10O15 m/z 984.4553; found 98
Amino Acid Analysis of perthamide C
sample of perthamide C dissolved in 6N HCl (3 mL) and heated at 130 
h. The crude residue was fractionated by HPLC on the reversed
Phenomenex Hydro (4µ, 250 x 4.6 mm) column eluting with MeOH:H
-K 
[α]D25 -6.3 (c 2.8, chloroform); 
-d6 given in Table 6; HRMS (ESI): calcd for 
1066.4106 [M-H]-. 
α]D25 −4.1 (c 0.1, chloroform); HRMS 
17S: 1050.4353; found 1050.4302 [M-H]-. 
1H and 13C NMR data in DMSO
45H67N11O18S m/z 1080.4386; found 
1H; HR-ESIMS: calcd for 
4.4473 [M-H]-. 
-ESIMS: calcd for 
2.4237 [M-H]-. 
1H; HR-ESIMS: calcd for 
804 [M-H]-. 
1H; HR-ESIMS: calcd for 
; found 1000.5003 [M-H]-. 
1H; HR-ESIMS: calcd for 
0.4405 [M-H]-. 
1H; HR-ESIMS: calcd for 
4.4635 [M-H]-. 
 (8). For a large scale hydrolysis, a 12 mg 
1H and 
-d6 
C for 12 
-phase 
2O 2:98, 
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(flow rate 0.5 mL/min) to give: NMeGly (tr=4.8 min), ThrOMe (tr=6.4 min), γ-
MePro (tr=7.6 min), o-Tyr (tr=24.6 min).  
γ-MePro: 1H NMR (500 MHz, D2O) δ 4.10 (1H, dd, J = 6.7, 5.1 Hz, H-2), 3.44 
(1H, dd, J = 10.5, 7.6 Hz, H-5a), 2.90 (1H, t, J = 10.5 Hz, H-5b), 2.51 (1H, dt, J = 
13.0, 7.0 Hz, H-3a), 1.60 (1H, dt, J = 13.0, 9.4 Hz, H-3b), 1.04 (3H, d, J = 6.6 Hz, 
Me-4).  
Determination of the Absolute Configuration of Perthamide C and D.  
Peptide Hydrolysis. Peptide samples (200 µg) were dissolved in degassed 6 M 
HCl (0.5 mL) in an evacuated glass tube and heated at 160 °C for 16 h. The solvent 
was removed in vacuo  and the resulting material was subjected to further 
derivatisation. 
LC-MS Analysis of Marfey’s (FDAA) Derivatives. A portion of the hydrolysate 
mixture (800 µg) or the amino acid standard (500 µg) was dissolved in 80 µL of a 
2:3 solution of TEA:MeCN and this solution was then treated with 75 µL of 1% 1-
fluoro-2,4-dinitrophenyl-5-L-alaninamide (FDAA) in 1:2 MeCN:acetone. The 
vials were heated at 70 °C for 1 h, and the contents were neutralised with 0.2N HCl 
(50 µL) after cooling to room temperature. An aliquot of the L-FDAA derivative 
was dried under vacuum, diluted with MeCN-5% HCOOH in H2O (1:1), and 
separated on a Proteo C18 (25 x 1.8 mm i.d.) column by means a linear gradient 
from 10% to 50% aqueous acetonitrile containing 5% formic acid and 0.05% 
trifluoroacetic acid, over 45 min at 0.15 mL/min. The RP-HPLC system was 
connected to the electrospray ion source by inserting a splitter valve and the flow 
going into the mass spectrometer source was set at a value of 100 µL/min. Mass 
spectra were acquired in positive ion detection mode (m/z interval of 320-900) and 
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the data were analysed using the suite of programs Xcalibur; all masses were 
reported as average values. Capillary temperature was set at 280 °C, capillary 
voltage at 37 V, tube lens offset at 50 V and ion spray voltage at 5 V.  
Retention times (min) of FDAA-amino acids are given in parentheses: D-Asp 
(26.5), L-Asp (25.2), D-alloThrOMe (37.3), L-alloThrOMe (32.5), D-ThrOMe 
(39.8), L-ThrOMe (34.5) (2S,3R)-βOHAsp (24.0), (2R,3S)-βOHAsp (21.8), 
(2S,3S)-βOHAsp (18.0), (2R,3R)-βOHAsp (16.9), L-Phe (45.0), D-Phe (49.2). 
The hydrolysate of perthamide C (8) contained: L-Asp (25.4), L-ThrOMe (34.5), 
(2R,3S)-βOHAsp (21.9). 
The hydrolysate of perthamide D (9) contained: L-Asp (25.4), L-ThrOMe (34.5), 
(2R,3S)-βOHAsp (21.9), L-Phe (45.0). 
To determine the absolute configuration of γ-MePro two aliquots of the 
hydrolysate mixture were derivatised with L- and D-FDAA, respectively and then 
they were subjected to LC-MS as described above. Retention times (min): L-
FDAA- γ-MePro (37.7), D-FDAA- γ-MePro (39.8).  
To determine the absolute configuration of o-Tyr in perthamide C, a stream of 
ozone in O2 was bubbled through cooled solutions of pure amino acid residue (0.1 
mg) in MeOH (0.5 mL) at -78 °C for 1 h. Hydrogen peroxide (35%, 10 drops) was 
added to the reaction mixture which was then allowed to stand at room temperature 
overnight. The solvent was removed under a stream of N2 and the ozonolysis 
product was subjected to Marfey’s derivatisation with L- FDAA and LC–MS 
analysis to obtain L-Asp (25.4 min). 
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Pharmacological Assays.  
Mouse Paw Oedema. Male Swiss (CD-1; Harlan, Italy) weighing 28-30g were 
divided into groups (n=6 each group) and lightly anaesthetized with isoflurane. 
Each group of animals received subplantar injection of 50µl of carrageenan 1% 
(w/v) or 50µl of saline in the left hind paw. Paw volume was measured by using an 
hydropletismometer specially modified for small volumes (Ugo Basile, Comerio, 
Italy) immediately before the subplantar injection and 2, 4, 6, 24, 48, 72 and 96h 
thereafter. The same operator always performed the double-blind assessment of 
paw volume. The increase in paw volume was calculated as the difference between 
the paw volume measured at each time point and the basal paw oedema. Each 
group of animals received intraperitoneal administration of Perthamide C (0.1, 0.3, 
1 mg/kg), Perthamide D (0.3 mg/kg) or vehicle (PEG). All drugs were 
administrated immediately before the injection of carrageenan and 24h thereafter.  
Statistical analysis. Results were expressed as mean ± s.e.m. Statistical analysis 
was determined by one way ANOVA followed by Dunnett’s test for multiple 
comparisons, using GraphPad Prism software (GraphPad Software Inc., San Diego, 
CA). Differences were considered statistically significant when p< 0.05. 
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Spectroscopic Data of Perthamide C-K 
 
 
 
 
 
COSY spectrum of Perthamide C (8) in DMSO-d6 at 700 MHz. 
1H NMR spectrum of Perthamide C (8)  in DMSO-d6 at 700 MHz. 
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HMBC spectrum of Perthamide C (8) in DMSO-d6 at 700 MHz. 
HSQC spectrum of Perthamide C (8) in DMSO-d6 at 700 MHz. 
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1H NMR spectrum of Perthamide D (9) in DMSO-d6 at 700 MHz. 
ROESY spectrum of Perthamide C (8) in DMSO-d6 at 700 MHz (100 ms). 
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COSY spectrum of Perthamide E (10) in DMSO-d6 at 700 MHz. 
1H NMR spectrum of Perthamide E (10) in DMSO-d6 at 700 MHz. 
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HMBC spectrum of Perthamide E (10) in DMSO-d6 at 700 MHz. 
HSQC spectrum of Perthamide E (10) in DMSO-d6 at 700 MHz. 
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1H NMR spectrum of Perthamide F (11) in DMSO-d6 at 700 MHz. 
TOCSY spectrum of Perthamide E (10) in DMSO-d6 at 700 MHz. 
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COSY spectrum of Perthamide G (12) in DMSO-d6 at 700 MHz. 
1H NMR spectrum of Perthamide G (12) in DMSO-d6 at 700 MHz. 
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HMBC spectrum of Perthamide G (12) in DMSO-d6 at 700 MHz. 
HSQC spectrum of Perthamide G (12) in DMSO-d6 at 700 MHz. 
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TOCSY spectrum of Perthamide H (13) in DMSO-d6 at 700 MHz. 
1H NMR spectrum of Perthamide H (13) in DMSO-d6 at 700 MHz. 
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HSQC spectrum of Perthamide H (13) in DMSO-d6 at 700 MHz. 
HMBCspectrum of Perthamide H (13) in DMSO-d6 at 700 MHz. 
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1H spectrum of Perthamide I (14) in DMSO-d6 at 700 MHz. 
HMBC spectrum of Perthamide H (13) in DMSO-d6 at 700 MHz. 
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COSY spectrum of Perthamide J (15) in DMSO-d6 at 700 MHz. 
1H NMR spectrum of Perthamide J (15) in DMSO-d6 at 700 MHz. 
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HMBC spectrum of Perthamide J (15) in DMSO-d6 at 700 MHz. 
HSQC spectrum of Perthamide J (15) in DMSO-d6 at 700 MHz. 
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TOCSY spectrum of Perthamide J (15) in DMSO-d6 at 700 MHz. 
ROESY spectrum of Perthamide J (15) in DMSO-d6 at 700 MHz. 
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Characteristic data for Solomonamide A and B 
Solomonamide A (17): white amorphous solid; [α]25D +2.3° (c 0.17, CH3OH); 1H 
NMR and 13C NMR data in DMSO-d6 given in Table 7; positive HR ESIMS m/z 
496.2018 [M + H]+ (calcd for C21H30N5O9, 496.2044). 
Solomonamide B (18): white amorphous solid; [α]D25 +4.8 (c 0.28, CH3OH); 1H 
and 13C NMR data in DMSO-d6 given in Table 8; positive HR ESIMS m/z 
480.2067 [M + H]+ (calcd for C21H30N5O8, 480.2094). 
LC–MS analysis of Marfey’s (FDAA) derivatives. The hydrolysate mixture or 
the amino acid standards (100 µg) was dissolved in 80 µL of a 2:3 solution of 
TEA:MeCN and this solution was then treated with 75 µL of 1% 1-fluoro-2,4-
dinitrophenyl-5-L-alaninamide (L-FDAA) in 1:2 MeCN:acetone. The vials were 
heated at 45 °C for 1 h, and the contents were neutralised with 0.2 N HCl (50 µL) 
after cooling to room temperature. An aliquot of the L-FDAA derivative was dried 
1H spectrum of Perthamide K (16) in DMSO-d6 at 700 MHz. 
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under vacuum, diluted with MeCN-5% HCOOH in H2O (1:1), and separated on a 
Proteo C18 (25x1.8 mm i.d.) column by means a linear gradient from 10% - 50% 
aqueous acetonitrile containing 5% formic acid and 0.05% trifluoroacetic acid, 
over 45 min at 0.15 mL/min. The RP-HPLC system was connected to the 
electrospray ion source by inserting a splitter valve and the flowgoing into the 
mass spectrometer source was set at a value of 100 µL/min. Mass spectra were 
acquired in positive ion detection mode (m/z interval of 320–900) and the data 
were analysed using the suite of programs Xcalibur; all masses were reported as 
average values. Capillary temperature was set at 280 °C, capillary voltage at 37 V, 
tube lens offset at 50 V and ion spray voltage at 5 V. Retention times (min) of 
FDAA-amino acids are given in parentheses: D-Ala (29.53), L-Ala (24.97), D-Ser 
(25.02), L-Ser (22.18)  
The hydrolysate of solomonamide A contained: L-Ser (22.13) and D-Ala (29.68).  
The hydrolysate of solomonamide B contained: L-Ser (22.2) and D-Ala (29.64).  
Biological activity. Male Swiss (CD-1; Harlan, Italy) weighing 28–30 g were 
divided into groups (n¼6 each group) and lightly anaesthetized with isoflurane. 
Each group of animals received subplantar injection of 50 µL of carrageenan 1% 
(w/v) or 50 µL of saline in the left hind paw. Paw volume was measured by using 
an hydropletismometer specially modified for small volumes (Ugo Basile, 
Comerio, Italy) immediately before the subplantar injection and 2, 4, 6, 24, 48, 72 
and 96 h thereafter. The same operator always performed the double-blind 
assessment of paw volume. The increase in paw volume was calculated as the 
difference between the paw volume measured at each time point and the basal 
paw oedema. Each group of animals received intraperitoneal administration of 
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solomonamide A (0.03, 0.1, 0.3 mg/kg) or vehicle (PEG). All drugs were 
administrated immediately before the injection of carrageenan and 24 h thereafter.  
Statistical analysis. Results were expressed as mean_s.e.m. Statistical analysis 
was determined by one way ANOVA followed by Dunnett’s test for multiple 
comparisons, using GraphPad Prism software (GraphPad Software Inc., San Diego, 
CA). Differences were considered statistically significant when p<0.05.  
 
Spectroscopic Data of SolomonamideA and B 
 
 
 
1H spectrum of Solomonamide A (17) in DMSO-d6 at 700 MHz. 
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HSQC spectrum of Solomonamide A (17) in DMSO-d6 at 700 MHz. 
COSY spectrum of Solomonamide A (17) in DMSO-d6 at 700 MHz. 
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ROESY spectrum of Solomonamide A (17) in DMSO-d6 at 700 MHz (200ms). 
HMBC spectrum of Solomonamide A (17) in DMSO-d6 at 700 MHz. 
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1H spectrum of Solomonamide A (17) in DMSO-d6 at 700 MHz. 
ROESY spectrum of Solomonamide A (17) in DMSO-d6 at 700 MHz (500 ms). 
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HSQC of Solomonamide B (18) in DMSO-d6 at 700 MHz. 
COSY of Solomonamide B (18) in DMSO-d6 at 700 MHz. 
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Characteristic data for swinholide A and Compound 19 
Swinholide A: light yellow solid; 1H NMR and 13C NMR data in CD3OD  given in 
Table 9; positive ESIMS m/z 1408.9 [M + Na]+. 
Compound 19: light yellow solid; 1H NMR and 13C NMR data in CD3OD given in 
Table 9; positive HR ESIMS m/z 1424.9 [M+Na]+. 
 
 
 
 
 
 
 
 
HMBC of Solomonamide B (18) in DMSO-d6 at 700 MHz. 
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Spectroscopic Data of Swinholide A and Compound 19 
 
 
 
 
 
COSY spectrum of Swinholide A in CD3OD at 700 MHz. 
1H spectrum of Swinholide A in CD3OD at 700 MHz. 
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HMBC spectrum of Swinholide A in CD3OD at 700 MHz. 
HSQC spectrum of Swinholide A in CD3OD at 700 MHz. 
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HSQC spectrum of Compound 19 in CD3OD at 700 MHz. 
1H spectrum of Compound 19 in CD3OD at 700 MHz. 
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HMBC spectrum of Compound 19 in CD3OD at 700 MHz. 
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IV. Experimental section of Cucumis melo 
Extraction and isolation. The powdered seeds (230 g) were extract with MeOH 
(1.5 L) at room temperature. The methanol extracts (4 g) were then subjected to 
Kupchan’s partitioning methodology to give four extracts: n-hexane (910 mg), 
CHCl3 (312 mg), n-BuOH (372 mg) and an aqueous residue (3.65 g). The n-
BuOH extract was chromatographed by DCCC using n-BuOH-Me2CO-H2O 
(3:1:5) in the descending mode (the upper phase was the stationary phase), flow 
rate 8 ml min-1; 4 ml fractions were collected and monitored by thin layer 
chromatography (TLC) on silica gel with n-BuOH-HOAc-H2O (12:3:5) and 
CHCl3-MeOH-H2O (80:18:2). These fractions were then separated by reversed-
phase HPLC (C18 µ-Bondapak 30 cm × 3.9 mm i.d.) with MeOH-H2O (15:85) as 
eluent, to give pure compound 20 (1.4 mg), Tryptophan and Inosine. The 
purification by HPLC with MeOH-H2O (1:9) as eluent, gave pure compound 21 
(2 mg). 
The CHCl3 extract was chromatographed by DCCC using CHCl3-MeOH-H2O 
(7:13:8) in the ascending mode (the lower phase was the stationary phase), flow 
rate 8 ml min-1; 4 ml fractions were collected and monitored by thin layer 
chromatography (TLC) on silica gel with CHCl3-MeOH-H2O (80:18:2). These 
fractions were then separated by reversed-phase HPLC (C18 µ-Bondapak 30 cm × 
3.9 mm i.d.) with MeOH-H2O (85:15) as eluent, to give pure compound 22 (2.3 
mg) and with MeOH-H2O (9:1) as eluent, to give pure compound 23 (1.5 mg) and 
unsaturated fatty acids. 
Acid hydrolysis and sugars analysis. Compound 20 and apiin (0.5 mg each) 
were hydrolyzed with 2N CF3CO2H (2 ml) at 110° in a sealed tube for 8 h. After 
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cooling, the solution was diluted with H2O (5 ml) and extracted with AcOEt (3 x 2 
ml). The aqueous layer was evaporated to dryness under reduced pressure and the 
residue was reacted with 0.1 M L-cysteine methyl ester hydrochloride in 
anhydrous pyridine (200 µl) for 2 h at 80°.193 1-(Trimethylsilyl)imidazole in 
pyridine was added and the thiazolidine derivatives analyzed by GC.194  D-apiose 
and D-glucose were confirmed in 20 by comparison of the retention time of their 
derivatives with those of apiine hydrolysate prepared in a similar way [D-apiose 
(tR 5.22 min) and D-glucose (tR 12.10 min)]. 
Characteristic data  
Compound 20: (E)-4-hydroxycinnamyl alcohol 4-O-(2’-O-β-D-apiofuranosyl) 
(1’’→2’)-β-D-glucopyranoside. [α]25D -6.0 (c 0.14, MeOH); 1H and 13C NMR 
data (Table 10); HRESIMS (C20H28O11) m/z 467.1602 (M + Na)+ [calcd. for 
C20H28O11Na 467.1529] 
Compound 21: Benzyl O-β-D-glucopyranoside. FAB-MS (positive ion) m/z 293 
[M + Na]+ ;1H NMR (500 MHz, CD3OD): 7.42 (d, J = 7.5 Hz, H-2 and H-6), 7.33 
(t, J = 7.5 Hz, H-3 and H-5), 7.28 (d, J = 7.5 Hz, H-4), 4.93 (d, J = 11.9 Hz, H-7), 
4.67 (d, J = 11.9 Hz, H-7), 4.36 (d, J = 7.7 Hz, H-1’), 3.91 (dd, J = 11.9, 1.9 Hz, 
H-6’), 3.70 (dd, J = 11.9, 5.7 Hz, H-6’), 3.25-3.33 (H-2’-H5’). 13C NMR (500 
MHz, CD3OD): 138.0 (C-1), 128.2 (C-3, C-5), 128.0 (C-2, C-6), 127.8 (C-4), 
102.1 (C-1’), 77.7 (C-5’), 78.1 (C-3’), 74.9 (C-2’), 71.5 (C-4’), 70.5 (C-7), 61.7 
(C-6’). 
Compound 22: 3,29-O-dibenzoylmultiflor-8-en-3α,7β,29-triol. 1H NMR (500 
MHz, CD3OD): 8.00 (d, J = 7.5 Hz, H-3’’ and H-7’’), 7.95 (d, J = 7.5 Hz, H-3’ 
and H-7’), 7.62 (t, J = 7.6 Hz, H-5’’), 7.60 (t, J = 7.6 Hz, H-5’), 7.48 (t, J = 7.6 
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Hz, H-4’’ and H-6’’), 7.46 (t, J = 7.6 Hz, H-4’ and H-6’), 4.85 (br s, H-3), 4.39 (t, 
J = 6.0 Hz, H-7), 4.11 (d, J = 10.5 Hz, H2-29), 1.32 (s, CH3-26), 1.18 (s, CH3-28), 
1.16 (s, CH3-25), 1.14 (s, CH3-30), 1.04 (s, CH3-24), 1.01 (s, CH3-27), 0.94 (s, 
CH3-23). 13C NMR (500 MHz, CD3OD): 167.3 (C-29a), 166.3 (C-3a), 138.3 (C-
8), 140.3 (C-9), 134.0 (C-4’/C-4’’), 129.4 (C-3’/C-5’, C-3’’/C-5’’), 130.0 (C-
2’/C-6’, C-2’’/C-6’’), 131.6 (C-1’, C-1’’), 78.8 (C-3), 73.7 (C-29), 70.6 (C-7), 
45.2 (C-5), 43.8 (C-18),41.3 (C-14), 38.7 (C-10), 38.4 (C-13), 37.0 (C-4), 36.8 
(C-16), 36.7 (C-22), 32.4 (C-20), 31.3 (C-6), 31.4 (C-17), 31.1 (C-28), 31.0 (C-
12), 30.9 (C-1), 29.6 (C-19), 29.3 (C-30), 28.6 (C-21), 27.3 (C-26), 27.2 (C-23), 
26.3 (C-15), 23.4 (C-2), 21.3 (C-24), 20.3 (C-25), 19.9 (C-11), 18.2 (C-27). 
Compound 23: 3-O-p-amino-benzoyl-29-O-benzoylmultiflor-8-en-3α,7β,29-
triol. 1H NMR (500 MHz, CD3OD): 8.01 (OPABA, H-3’’ and H-7’’), 7.90 (d, J = 
7.5 Hz, H-3’ and H-7’), 7.64 (t, J = 7.6 Hz, H-5’), 7.46 (t, J = 7.6 Hz, H-4’ and H-
6’), 6.64 (OPABA, H-4’’ and H-6’’), 4.85 br s (H-3), 4.39 (t, J = 6.0 Hz, H-7), 
4.13 (d, J = 10.5 Hz, H2-29), 1.32(s, CH3-26), 1.18 (s, CH3-28), 1.15 (s, CH3-25), 
1.14 (s, CH3-30), 1.03 (s, CH3-24), 1.01 (s, CH3-27), 0.92 (s, CH3-23). 
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Spectroscopic Data of Compound 20 
 
 
 
 
COSY spectrum of Compound 20 in CD3OD at 700 MHz. 
1H NMR spectrum of Compound 20 in CD3OD at 700 MHz. 
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HMBC spectrum of Compound 20 in CD3OD at 700 MHz. 
HSQC spectrum of Compound 20 in CD3OD at 700 MHz. 
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V. Experimental section of Borrago officinalis 
Extraction and isolation. The flowers (300 g), deprived of stem, were crushed 
and subsequently extract with MeOH (1.5 L) at room temperature. The methanol 
extracts (10.8 g) were then subjected to Kupchan’s partitioning methodology to 
give four extracts: n-hexane (760 mg), CHCl3 (1.32 g), n-BuOH (1.71 g) and an 
aqueous residue (4.1 g). The n-BuOH extract was chromatographed by DCCC 
using n-BuOH-Me2CO-H2O (3:1:5) in the descending mode (the upper phase was 
the stationary phase), flow rate 8 ml min-1; 4 ml fractions were collected and 
monitored by thin layer chromatography (TLC) on silica gel with n-BuOH-
HOAc-H2O (12:3:5). The fraction 8 was then separated by reversed-phase HPLC 
(C18 µ-Bondapak 30 cm × 3.9 mm i.d.) with MeOH-H2O (1:9) as eluent, to give 
pure compound 24 (3.6 mg). 
Acid hydrolysis and sugar analysis. Compound 24 (0.5 mg) was hydrolyzed 
with 2N CF3CO2H (2 mL) at 110° in a sealed tube for 8 h. After cooling, the 
solution was diluted with H2O (5mL) and extracted with AcOEt (3 x 2 mL). The 
aqueous layer was evaporated to dryness under reduced pressure and the residue 
was reacted with 0.1M L-cysteine methyl ester hydrochloride in anhydrous 
pyridine (200 µL) for 1 h at 60°. 1-(Trimethylsilyl)imidazole in pyridine was 
added and the thiazolidine derivatives analyzed by GC.193 The D configuration of 
glucose was confirmed by comparison of the retention time of D- and L- glucose 
derivatives with the hydrolysate prepared in a similar way (tR 12.10 min).  
Characteristic data of Compound 24: white amorphous solid; 1H and 13C NMR 
data in CD3OD given in Table 11; HR-ESIMS m/z 415.1534 [M]+ (calcd. for 
C19H26O10 415.1526). 
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Spectroscopic Data of Compound 24 
 
 
 
 
 
COSY of Compound 24 in CD3OD at 500 MHz. 
1H spectrum of Compound 24 in CD3OD at 500 MHz. 
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HMBC of Compound 24 in CD3OD at 500 MHz. 
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VI. Experimental section of Ruscus aculeatus 
Extraction and isolation. Rhizomes (243.5 g) of Ruscus aculeatus were shaved 
and exhaustively extracted with MeOH (1.5 L) at room temperature. The 
methanol extracts (56 g) were then subjected to Kupchan’s partitioning 
methodology to give four extracts: n-hexane (483.8 mg), CHCl3 (3.7 g), n-BuOH 
(9.1 g) and an aqueous residue (36.2 g). The n-BuOH extract was 
chromatographed by DCCC using n-BuOH-Me2CO-H2O (3:1:5) in the descending 
mode (the upper phase was the stationary phase), flow rate 8 ml min-1; 4 ml 
fractions were collected and monitored by thin layer chromatography (TLC) on 
silica gel with n-BuOH-HOAc-H2O (12:3:5). The fractionas 8-11 were then 
separated by reversed-phase HPLC (Luna C18 Phenomenex, 5µ,  250 × 4.6 mm)  
with MeOH-H2O (48:52) as eluent, to give pure compound 25 (4.3 mg, tR=25.5 
min), compound 26 (4.1 mg, tR=25.5 min). The fractions 16-18 were purified in 
the same conditions to give compound 27 (16.6 mg, tR=23 min). 
Determination of the sugar absolute configuration of glucose. A solution of 
each isolated compounds 25 and 26 (1 mg) in 1N HCl (0.25 mL) was stirred at 
80° C for 4 h. The hydrolysed was reacted with 0.1M L-cysteine methyl ester 
hydrochloride in anhydrous pyridine (200 µl) for 1 h at 60°. 1-
(Trimethylsilyl)imidazole in pyridine was added and the thiazolidine derivatives 
analyzed by GC.193  
Solvolysis of Compound 25. A solution (1 mg) of the compound 25 in a mixture 
of pyridine (125 mL) and dioxane (125 mL) was heated at 150° C for 3 h in a 
stoppered reaction vial. The residue was evaporated to dryness and purified by 
HPLC [Luna C18 (Phenomenex, 5µ,  250 × 4.6 mm)] with MeOH-H2O (80%) as 
eluent. 
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Characteristic data  
Compound 25: white amorphous solid; 1H and 13C NMR data in CD3OD given in 
Table 12; HR-ESIMS m/z 703.5130 [M-Na]-. 
Compound 26: white amorphous solid; 1H and 13C NMR data in CD3OD given in 
Table 12; HR-ESIMS m/z 701.4326 [M-Na]-. 
Compound 27: white amorphous solid; 1H and 13C NMR data in CD3OD given in 
Table 13; HR-ESIMS m/z 929.5682 [M-H]-.  
 
Spectroscopic Data of Compound 25 and 26 
 
 
 
 
1H NMR spectrum of Compound 25 in CD3OD at 500 MHz. 
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HSQC spectrum of Compound 25 in CD3OD at 500 MHz. 
COSY spectrum of Compound 25 in CD3OD at 500 MHz. 
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1H NMR spectrum of Compound 26 in CD3OD at 500 MHz. 
HMBC spectrum of Compound 25 in CD3OD at 500 MHz. 
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HSQC spectrum of Compound 26 in CD3OD at 500 MHz. 
COSY spectrum of Compound 26 in CD3OD at 500 MHz. 
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TOCSY spectrum of Compound 26 in CD3OD at 500 MHz. 
HMBC spectrum of Compound 26 in CD3OD at 500 MHz. 
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13C NMR of Compound 27 in CD3OD at 500 MHz. 
1H NMR of Compound 27 in CD3OD at 500 MHz. 
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HSQC of Compound 27 in CD3OD at 500 MHz. 
COSY of Compound 27 in CD3OD at 500 MHz. 
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HMBC of Compound 27 in CD3OD at 500 MHz. 
HSQC-TOCSY of Compound 27 in CD3OD at 500 MHz. 
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ROESY of Compound 27 in CD3OD at 500 MHz. 
TOCSY of Compound 27 in CD3OD at 500 MHz. 
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